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A CLINICAL STUDY EXPLORING OSTEOARTHRITIS PAIN USING 
CEREBROSPINAL FLUID 
Background: Osteoarthritis (OA) reduces quality of life and affects more than 40% of older 
adults but the molecular mediation of OA pain in the dorsal horn is yet to be explored 
clinically. Sufferers may experience central sensitisation and some may have an increased 
risk of persistent post-arthroplasty pain.     
The study explored two hypotheses. 
1. There would be significant differences in pro-inflammatory cytokines (interleukin 
[IL]-1β IL-2, IL-6, IL-7, IL-8, IL-12, interferon [IFN]-γ and tumour necrosis factor 
[TNF]-α), excitatory amino acids (glutamate, aspartate, arginine, citrulline, serine and 
glutamine), anti-inflammatory cytokines (IL-4, IL-5, IL-10 and IL-13) and inhibitory 
amino acids (glycine and gamma-amino-butyric acid [GABA]) when participants 
with OA were compared with pain free controls after adjustment is made for the 
influence of age, gender and psychological distress (total Hospital Anxiety and 
Depression [HAD] score).  
2. Concentrations of these amino acids and cytokines would differ significantly when a 
group of OA participants who have no pain at rest (0PAR) were compared with a 
group who did have pain at rest (PAR) after adjustment for age, gender and total 
HAD score (HADS-T).  
Method: After ethical approval people having elective primary hip or knee arthroplasty (OA 
group) or urological surgery (pain-free controls) were recruited on the day of surgery.  Pain 
at rest (PAR), pain on movement (POM) (0-10 numerical rating scale), and HADS data was 
collected pre-operatively.  A 2ml sample of cerebrospinal fluid (CSF) was aspirated by an 
independent anaesthetist prior to spinal anaesthesia.  Filtered CSF was snap frozen and then 
stored at -80 C.  Samples thawed on ice were then subjected to High Pressure Liquid 
Chromatography for assay in duplicate of amino acids and high-sensitivity multiplex bead 
array assay in duplicate for the cytokines.    
Differences in amino acids and cytokines between the groups were explored using 
ANCOVA adjusting for age, gender and total HAD score (HADS-T).  Where residuals were 
not normally distributed a boot-strapping technique was used.   
Binary logistic regression was conducting using a forward step-wise approach with age, 
gender and HADS-T as part of the initial model.  The regression analyses explored the 
predictor variables for membership of the OA group, membership of the PAR group, and 
having psychological distress (HADS-T≥12). A multiple linear regression was conducted to 
determine the predictor variables that influenced HADS-T.   
 Results: A total of 21 control (75% male) and 59 OA (46% male) participants were eligible 
for the statistical analysis. Median pain on movement in the OA group was 6 and 59% of this 
group had pain at rest (PAR≥1).  57% (n=34) of the OA group had psychological distress 
(HADS-T ≥12) compared with 19% (n=4) of the pain free group (Fischer’s exact test 
p=0.006).  
   
Serine, leucine, valine, and TNFα were significantly higher in the OA group (p<0.05) than 
the control group. IL-12 was significantly lower in the OA group (p<0.05).  Aspartate and 
IFNγ were both significantly lower in the PAR group than the 0PAR group (p<0.05). 
Membership of the OA group was predicted by being male, increasing HADS-T, serine and 
leucine and decreasing GABA.  Membership of the PAR group was predicted by decreases 
in aspartate and IFNγ.  Having psychological distress (HADS-T≥12) was predicted by 
increasing POM and decreasing serine.    
Discussion: Significant differences were identified for serine and TNFα in the CSF of the 
OA/control therefore the null hypotheses was rejected.  Although there were significant 
differences between the 0PAR and PAR groups these were not in the direction expected and 
not in keeping with the hypothesis therefore the null hypothesis was retained.   
The findings in this study indicate an unexpected role for IL-12 and IFNγ; it is possible that 
these cytokines have an anti-inflammatory influence centrally in OA pain.  
This study offers support to the theory that central sensitisation is part of OA pain signalling 
at the level of the dorsal horn.  Further, psychological distress is an integral part of the OA 
experience. The findings are in agreement with other published studies which model a three-
way influence between peripheral disease activity, depression and pain.   
The study provides a preliminary but broad over-view of the pain of OA in the clinical 
setting.  It demonstrates the complexity and utility of this kind of study and provides a 
platform for further work. 
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GLOSSARY 
  
Aδ fibre Relatively large myelinated fast pain fibre 
Acute pain pain of a short duration related to damaged tissues 
 
Aggrecan A large proteoglycan: in aggregated form along with 
type II collagen provides structure to cartilage and gives 
it strength 
Agonism Ligand binding to a receptor that leads to activity 
Algesic Endogenous substance capable of producing pain 
Allodynia1 Pain due to a stimulus that does not normally evoke 
pain 
Angiogenesis The growth of new blood vessels from old 
Anhedonia The inability to experience pleasure 
Antagonism Ligand binding to a receptor that prevents activity 
Anxiety2 A negative mood state characterised by bodily 
symptoms of physical tension and apprehension about 
the future 
Astrocytes Non-neuronal cells whose chief function is the support 
of neuronal cells and maintenance of homeostasis in the 
CNS. 
Box rating scale A visual pain rating scale that presents 0-10 range of 
numbers to the patient in a horizontal table. 0 denotes 
no pain and 10 the most pain the person can imagine. 
C-fibre Unmyelinated, small and slow conducting pain fibres 
C-reactive protein A protein found in the blood whose levels increase in 
response to inflammation 
Catastrophisation The tendency to focus on, and even exaggerate the 
negative threat value of a painful stimulus or experience 
Central sensitisation3 The increased synaptic efficacy established in 
somatosensory neurons in the dorsal horn of the spinal 
cord following intense peripheral noxious stimuli, tissue 
injury or nerve damage. This heightened synaptic 
transmission leads to a reduction in pain threshold, an 
amplification of pain responses and a spread of pain 
sensitivity to non-injured areas 
                                                
1 International Association for the Study of Pain ( 1994)  
2 Barlow and Durand ( 2009) 
3 Ji et al. (2003) 
   
Chemokine Small cytokine proteins that function as 
chemoattractants.  
Chondrocytes Cartilage cells 
Chondropathy A disease of the cartilage often graded 0-5 
Clinical Studies Research studies involving human participants as 
distinct from animal studies 
Crepitus A feeling or sound of grating, crackling or popping often 
experienced by people with OA 
Cytokine A protein whose primary function is inter and 
intracellular signalling 
Depression4 Depression is a common mental disorder that presents 
with depressed mood, loss of interest or pleasure, 
feelings of guilt or low self-worth, disturbed sleep or 
appetite, low energy, and poor concentration. 
Dorsal horn The posterior portion of the spinal cord that contains 
grey matter 
Dorsal root ganglion A collection of cell bodies of primary afferent (sensory) 
fibres that lies just outside the dorsal horn 
Erythrocyte sedimentation rate The speed with which red blood cells settle in a sample 
of blood left to stand. An indicator of inflammation with 
faster speeds indicating greater inflammation 
Glia Non-neuronal cells that have homeostatic function.  
Include astrocytes, microglia and oligodendrocytes 
Hypoalgesia1 Diminished pain in response to a normally painful 
stimulus 
Hyperalgesia1 An increased response to a stimulus which is normally 
painful 
Incidence The frequency that new cases appear over a period of 
time.  Expressed as the number of new cases as the 
numerator and the population at risk as the 
denominator. 
Interneuron A local cell found within the spine forming connections 
with a high number of other cells but with not 
projection to the brain, also called a relay neuron 
Large neutral amino acids Amino acids that compete with tryptophan to cross the 
blood brain barrier (leucine, isoleucine, valine, tyrosine 
and phenylalanine) 
                                                
4 World Health Organisation ( 2010) 
   
Matrix metalloprotease (MMP) Enzymes that are involved in degradation of 
extracellular matrices, cleavage of membrane-bound 
receptors and induction of cytokines 
Neuron An electrically excitable cell that transmits information 
electrically and communicates with other cells 
chemically 
Neuropathic pain1 Pain initiated or caused by a primary lesion or 
dysfunction in the nervous system 
Neuropathy1 A disturbance of function or pathological change in a 
nerve: in one nerve, mononeuropathy; in several nerves, 
mononeuropathy multiplex; if diffuse and bilateral, 
polyneuropathy 
Neurotoxicity Damage to neurons (in this context this is often being 
caused by over-stimulation with glutamate) 
Nociception The sensory process that translates noxious stimuli into 
signals that will ultimately be interpreted by the brain as 
the perception of pain 
Nociceptor1 A receptor preferentially sensitive to a noxious stimulus 
or to a stimulus which would become noxious if 
prolonged 
Noradrenergic Pertaining to the activity of noradrenalin 
Noxious stimulus1 A noxious stimulus is one which is damaging to normal 
tissues 
Number needed to treat A measure of the effectiveness of an intervention.  In 
analgesia studies it is common to see this expressed as 
the number of people who need to be treated before 1 
person will achieve at least 50% pain relief.  An NNT of 1 
means everyone will get 50% pain relief, an NNT of 10 
means that 1 in 10 people treated will achieve 50% or 
better pain relief, everyone else will achieve less than 
this 
Osteophytes Bony projections that form along a joint space as a 
result of damage to the joint’s surface 
Pain1 An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage or 
described in terms of such damage 
Pain threshold1 The least experience of pain which a subject can 
recognise 
Pain tolerance1 The greatest level of pain which a subject is prepared to 
tolerate 
Pathological pain Pain that does not serve a protective function 
Physiological pain Pain that serves a protective function 
Prevalence The amount of a disease in a population at a given time 
   
Projection neuron A neuron that projects an axon from the spinal cord to 
the brain/brainstem 
Proteases Enzyme that breaks down proteins 
Self-efficacy Self-belief relating to the ability to perform a specified 
function 
Serotonergic Pertaining to the activity of 5-HT 
Subchondral bone The layer of bone just below the cartilage 
Subchondral bone sclerosis Increased density of thickening of the subchondral bone 
Synovitis Inflammation of the synovial membrane  
Thermal threshold Temperature required to evoke pain 
Wide dynamic range neuron/cell Cells that respond to a wide range of stimuli and alter 
their output according to the frequency of the input 
Wind-up Repeated stimulation of C-fibres leads to summation of 
potentials in wide dynamic range neurons and this 
translates to sensitisation causing hyperalgesia and 
allodynia that reverts to normal over a relatively short 
period of time once the stimulus is removed 
 
 
 
  
   
ABBREVIATIONS 
 
5-HIAA 5-hydroxyindole acetic acid 
5-HT  5-hydroxytryptamine also known as serotonin 
5-HTT  5-HT transporter 
ACTH  adrenocorticotrophic hormone 
AIDS  Acquired Immune Deficiency Syndrome 
AMPA(R) α-amino-hydroxy-5-methyl-4-isoxazoleproprionic acid (receptor) 
ANOVA Analysis of variance 
ANCOVA Analysis of covariance 
ATP  Adenosine triphosophate 
BDNF  Brain derived neurotrophic factor 
Ca+  calcium ion 
CaM  Calmodulin 
Ca+CaM Calcium calmodulin 
CFA  Complete Freund’s Adjuvant 
CCL2  a chemokine also known as monocyte chemoattractant protein 1   
  (MCP-1) 
CCR2  the receptor for CCL2/MCP-1 
cGMP  Cyclic guanosine 3,5-monophosphate 
CGRP  Calcitonin gene related peptide 
CNS  Central nervous system 
COX-1/2 Cyclo-oxygenase enzyme 1 or 2 
CRP  C-reactive protein 
CSF  Cerebrospinal fluid 
DLPT  dorsolateral pontine tegmentum 
EAAT  Excitatory amino acid transporter 
ECF  Extracellular fluid 
ELISA  Enzyme Linked Immunosorbent Assay 
EP2R  Prostaglandin E2 receptor 
ESR  Erythrocyte Sedimentation Rate 
GABA  Gamma amino butyric acid 
GFAP  Glial fibrillary acidic protein 
H+  Hydrogen ion 
HADS  Hospital Anxiety and Depression Scale 
HPA  hypothalamic-pituitary-adrenal (axis) 
HPLC  High pressure liquid chromatography 
HIV  Human Immunodeficiency Virus 
IASP  International Association for the Study of Pain 
ICD-10 International Classification of Diseases -10 (1990, World Health   
  Organisation) 
K+  Potassium ion 
KCC2  Potassium and chloride ion transporter 
HRQoL Health related quality of life 
MANOVA Multivariate analysis of variance 
MCP-1 Monocyte chemoattractant protein-1, a chemokine also known as   
  CCL2 
   
mRNA  memory ribonucleic acid 
NA  noradrenalin 
Na+  sodium ion 
NK-1  Neurokinin-1 receptor, ligand = Substance P 
NMDA(R) N-methyl-D-aspartate (receptor) 
NNT  Number needed to treat 
NRM  Nucleus Raphe Magnus 
NSAIDs Non-steroidal anti-inflammatory drugs 
NO  Nitric oxide 
NOS  Nitric oxide synthase 
OA  Osteoarthritis 
OPA/3-MPA ortho-phthaldiahyde/3-mercaptoproprionic acid 
PAF  Primary afferent fibre 
PAG  Periaqueductal grey 
PGE2  Prostaglandin E2 
QA  Quinolinic acid 
RA  Rheumatoid Arthritis 
RVM  Rostroventromedial medulla 
SD  Standard deviation 
sGC  soluble guanylyl cyclase 
SP  Substance P 
SPSS  Statistical Package for Social Sciences 
TENS  Transcutaneous Electrical Nerve Stimulation 
UK  United Kingdom 
US  United States of America 
VAS  Visual Analogue Scale 
VGLUT Glutamate transporter 
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Chapter 1  
1.1 Introduction   
Osteoarthritis is a prevalent chronic joint condition that affects synovial joints and can lead to 
pain, functional limitation and reduced quality of life.  It affects joints with weight-bearing 
cartilage, sites where trauma has occurred and also the smaller joints including fingers, toes 
and ankles (NICE 2008; Badley and Tennant 1992: 494; Felson et al. 1987).   
OA is thought to affect approximately 41% of those aged over 65 years in the United 
Kingdom (UK) (Dawson et al. 2004).  Approximately 25-37% of those diagnosed with OA 
describe their condition as mild, 47-56% as moderate and 16-19% as severe (Bushmakin et al. 
2011; Sadosky et al. 2010).  The subjective severity level of the OA correlates with self-
reported pain severity and functional impairment and demonstrates that within the cohort of 
people diagnosed with OA there is a wide variation in severity and impact.  Much of the 
research in OA focuses on those at the more severe end of the spectrum and this may lead to 
over-statement of the impact of the condition generally.  However, people with this disease 
often experience poor quality of life (Hirvonen et al. 2006) and many with more severe forms 
suffer from co-morbid depression (Rosemann et al. 2007b).   
The pain of OA is assumed to be predominantly nociceptive, meaning that noxious 
stimulation created within the joint results in perception of pain.  The pain may be partially 
managed using a combination of paracetamol, anti-inflammatory and weak opioid medication.  
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In addition to medication, pain relief and improved function can be facilitated by exercise, 
physiotherapy, acupuncture, Transcutaneous Nerve Stimulation (TENS), heat or cold and 
natraceuticals. Some, whose disease affects the larger joints such as shoulder, elbow, knee or 
hip, who do not find sufficient relief in this medical management approach will undergo joint 
replacement surgery, which can help to alleviate pain and improve function. However, a 
number of people continue to suffer an unacceptable level of pain for months or years after 
surgery (Wylde et al. 2011a; Puolakka et al. 2010; Lundblad et al. 2008; Singh et al. 2008; 
Hawker et al. 1998; Bourne et al. 1994).  The reasons for this continued pain following 
surgery include intra-operative nerve damage (Brown et al. 2008), malalignment of the 
implant (Thompson et al. 2011; Czurda et al. 2010), heterotopic bone formation (Neal 2003), 
and infection (Parvizi et al. 2010).  In addition to these factors it has been hypothesised 
recently that some cases of long-term post-operative pain are related to persistent central 
sensitisation (Wylde et al. 2011a).   
Central sensitisation describes a form of synaptic plasticity where specific patterns of pain 
signals (nociceptive inputs) reduce the threshold of secondary dorsal horn neurons and alter 
their relationship with non-nociceptive sensory fibres.  This leads to a situation where sub-
threshold stimuli of a noxious type and non-noxious sensory signals create action potentials 
that are read as pain.  The relationship of this phenomenon and persistent pain in the post-
operative arthroplasty patient has been suggested by Lundblad et al. (2008) who found that 
the presence of pre-operative rest pain and lower pre-operative pressure-pain thresholds was 
associated with an increased risk of persistent post-operative pain.  Wylde et al. (2011a) 
suggest that increased risk of persistent post-operative pain following arthroplasty is related to 
an increased ‘vulnerability’ to pain, i.e. sensitisation.  This is based on their findings that 
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persistent pain is associated with the presence of pains elsewhere in the body in addition to 
the joint pain. Pain severity in the replaced joint was observed to increase with the number of 
pain sites elsewhere. There is also evidence of the presence of central sensitisation in OA 
from experimental studies on human participants (Arendt-Nielsen et al. 2010; Imamura et al. 
2008; Lundblad et al. 2008; Bajaj et al. 2001), the pain sufferers’ use of neuropathic pain 
descriptors (Hochman et al. 2010) and the efficacy of centrally acting pain relievers 
(Duloxetine) in OA (Chappell et al. 2009) .  This has implications for the management of pre-
operative OA pain but also for the risk and management of some forms of persistent post-
surgical pain.   
A number of studies exploring persistent post-surgical pain have identified depression as a 
risk factor (Hinrichs-Rocker et al. 2009).  This finding extends to OA joint replacement pain.  
Wylde  et al. (2011a) found that patients with major depression were 1.3 times more likely to 
suffer worse persistent post-arthroplasty pain. The reported lack of correlation between 
reported pain and radiographic severity of OA (Bedson and Croft 2008) may be partially 
explained by depression given some of the neurobiological interactions between pain and 
depression. Kim et al (2011a) identify an increased likelihood of moderate grade OA changes 
causing pain when depression is also present.  This and the increased prevalence of depression 
in the OA population compared with the general population (Axford et al. 2010; Rosemann et 
al. 2007b) suggests that depression is an important covariate for pain in OA and perhaps a risk 
factor for persistent post-surgical pain in this group. 
The clinical study of OA pain has focused on the peripheral joint.  In order to fully explore 
central sensitisation as a factor in OA pain it is necessary to consider the transmission of pain 
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signals at the level of the dorsal horn, the seat of central sensitisation.  Animal models of OA 
pain have been used to demonstrate the likelihood of central sensitisation at the level of the 
spinal cord in OA (Im et al. 2010; Schaible et al. 2009) but there are very few clinical studies 
of pain at this level.  Lundborg et al ( 2010) found that interleukin 1-beta (IL-1β), IL-8 and 
Glial cell-line Derived Neurotrophic Factor (GDNF) were higher in the cerebrospinal fluid 
(CSF) of OA participants than controls in their study.  Buvanendran et al (2006) found that 
IL-6 was upregulated in the CSF following arthroplasty surgery.  These studies demonstrate 
that pro-inflammatory responses can be detected in the CSF of OA patients. 
The present study aims to explore a number of amino acid and cytokine transmitters 
putatively involved in the dorsal horn transmission of osteoarthritis (OA) pain with 
consideration given to anxiety and depression.  It will be the first time that OA pain has been 
characterised using CSF in a clinical study and will provide important insight into the 
mechanism of this pain. 
 
1.2 Epidemiology, diagnosis and impact of osteoarthritis 
The National Collaborating Centre for Chronic Conditions (2008: 3), in their guidance for the 
National Institute for Health and Clinical Excellence (NICE) define OA as: 
… ‘ a metabolically active, dynamic process that involves all joint tissues (cartilage, bone, 
synovium/capsule, ligaments and muscle). Key pathological changes include localised loss of articular 
(hyaline) cartilage and remodelling of adjacent bone with new bone formation (osteophyte) at the joint 
margins. This combination of tissue loss and new tissue synthesis supports the view of osteoarthritis as the 
repair process of synovial joints’. 
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OA is a common condition that can be disabling.  Much of the published research focuses on 
those people with OA who have sought medical help and it is therefore unclear whether the 
global impact of OA is as great as this data suggests.  However, what is apparent is that for 
many, OA is a painful and disabling condition that has an impact on the ability to live a full 
and satisfying life.   
1.2.1 Diagnosis of OA 
The reported prevalence of hip and knee OA varies according to the criteria used to diagnose 
it.  It is difficult to compare prevalence between populations and across studies because the 
diagnostic and sampling criteria vary broadly.  A recent EULAR systematic review (Zhang et 
al. 2010a) states knee OA can be diagnosed with confidence using a detailed clinical 
interview and physical assessment of the sufferer (Figure 1-1).  The population prevalence 
and personal risk factors (see 1.4) are taken into account along with symptoms of persistent 
pain, stiffness and functional limitation and physical signs such as crepitus, bony enlargement 
and restricted movement.  
Radiographic evidence is often used in addition to the clinical interview as part of the 
diagnostic process and as a means of grading the severity of OA. One of the most commonly 
used grading tools for radiographic changes is the Kellgren-Lawrence (K-L) scale (Box 1-1). 
Changes can be graded from 0 (no radiographic evidence of OA) to 4 (severe OA) (Figure 
1-2).  A cut-off point of grade 2 - definitely present but of minimal severity (Kellgren and 
Lawrence 1957) is often used to define cases.  Other criteria including pain and joint space 
width are also used in studies and this can lead to differences in the rates of diagnosis.   
6 
 
Figure 1-1: Diagnosis of knee OA (EULAR) 
 
Box 1-1: The Kellgren-Lawrence Scale: joint changes that can be observed in OA (Kellgren and Lawrence 1957: 494)  
Osteophytes on the joint margins or tibial spines; 
Periarticular ossicles (mainly seen in fingers);  
Narrowing of the joint cartilage associated with sclerosis of subchondral bone;  
Small pseudocystic areas with sclerotic walls usually situated in the subchondral bone 
Altered shape of bone ends, particularly the head of the femur. 
 
Figure 1-2: Kellgren Lawrence radiographic grading of hip and knee OA 
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1.2.1.1 Discrepancy between pain and radiographic observations of joint structures 
There are a small number of studies that have identified associations between self-reported 
OA symptoms such as pain and radiographic changes such as joint space width and 
osteophyte development (Fukui et al. 2010; Neogi et al. 2009b; Cicuttini et al. 1996).  
However, a far greater number of studies report poor or no correlation between the severity of 
OA changes seen on X-ray and OA symptoms (Astephen Wilson et al. 2011; Bedson and 
Croft 2008; Dieppe et al. 2005; Hannan et al. 2000; Dieppe et al. 1997; Claessens et al. 1990).    
There are a number of reasons reported for the discrepancies between x-ray findings and 
symptom reports.  First is the view of the knee used in the diagnosis.  The sensitivity of 
radiologic OA detection can be improved to 70% or more by using views of the three 
different knee compartments (Peat et al. 2007; McAlindon et al. 1992) but many studies do 
not include the patello-femoral joint view (Bedson and Croft 2008).   
Varying definitions of pain are used in different studies.  One may define OA pain as ‘ever 
having an episode of pain lasting 15 day’ while another uses ‘any knee pain in the last 
month’.   Studies also differ in their definition of OA, which might or might not include 
functional difficulty or disability as well as pain.  Different K-L grades are also used to define 
OA in different studies.  Finally study samples vary in terms of age range, ethnicity and other 
confounding factors (Bedson and Croft 2008).  Neogi et al. (2009b) have addressed a number 
of these discrepancies by comparing pain and structural changes in the same person and 
therefore removing a great deal of the confounding noise typical of many of the previous 
studies.  Overall they find that more significant x-ray changes are associated with symptoms 
of OA but the relationship is less strong in early OA. 
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A further reason for the discrepancy between radiographic findings and OA symptoms is that 
the x-rays provide only limited information. Pain and dysfunction from the OA joint is not 
only related to those structures that can be directly or indirectly assessed by x-ray.  The use of 
magnetic resonance imaging (MRI) has enabled closer examination of a number of joint 
structures thought to be responsible for pain.  In a systematic review of 5 cohort studies and 
17 cross-sectional studies Yusuf et al. (2011) found a moderate level of evidence that bone 
marrow lesions and effusions/synovitis are associated with pain.  There was limited evidence 
that ligamentous abnormalities were associated with pain, conflicting evidence that cartilage 
defects, meniscal tears and bone attrition were associated with pain and limited evidence that 
osteophytes and subchondral cysts were not associated with pain.  
The part played by other physical, social and psychological factors in the experience of pain 
for the individual also has an influence over the apparently disproportionate amount of pain 
and disability experienced by some people with relatively minor observable OA changes.  As 
will be seen in the next section a number of different factors, biological, social and 
psychological, influence the development and the impact of OA.  Additionally, this study 
aims to explore the mechanism of pain in this disease and will demonstrate that central 
sensitisation plays an important role.  Central sensitisation has the potential to cause a 
disconnection between the painful stimulus and the degree of pain experienced by the 
individual and this will be more fully explored in both Chapter 3 and the discussion. 
1.3 Prevalence of OA 
 A systematic review of hip OA (Dagenais et al. 2009) examined 23 studies from Europe 
(n=25), North America (n=6), Asia (n=4), Africa (n=2), the Caribbean (n=1) and the Middle 
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East (n=1).   They report mean prevalence ranging from 1.4% in Asia to 10% in Europe.  
Knee OA is thought to be more highly prevalent but perhaps due to the variety of aetiologies 
systematic reviews are lacking.  A large cohort study in Holland that excluded people with 
developmental dysplasia, previous knee surgery and  knee replacement, or amputation found 
that 12.1% of men and 142% of women had radiographic OA (≥K-L 2) (Laxafoss et al. 2010).  
Prevalence of OA increases linearly with age in both genders (Kopec et al. 2007; Hart et al. 
2002; Zhang et al. 2001a) with peak prevalence for women in their 60s and in men in their 
70s (Rossignol et al. 2003).  A Dutch study of a random sample of adults found a prevalence 
of knee OA to be approximately 11-12% in the 50-59 age group rising to more than 20% in 
those aged over 70 years (van Saase et al. 1989). 
When women are compared to men OA of most joints is more prevalent in men under 50 
years of age, but after the age of fifty the prevalence is greater in women than men for most 
joints (Jordan et al. 2007; Kopec et al. 2007; Jacobsen et al. 2004; Felson et al. 1987).   Van 
Saase et al. (1989) did not see a gender difference in OA of most joints except for the hip and 
knee in those aged more than 65 years when the prevalence in women exceeded that in men. 
In addition to the personal burden that OA causes, which will be explored in more depth 
below, this disease has an impact on the economy and health expenditure, which creates a 
further imperative to develop the most effective and efficient management strategies possible.  
The amount of years of productive life lost as a result of osteoarthritis in the year 2000 was 
3,048, 000 years in the western and developing world (Reginster and Khaltaev 2002). To 
place this in context, this compares to a figure of 2,690,000 years for HIV and AIDS and 9 
042 000 years for ischaemic heart disease.  In 1997 an economic evaluation of five 
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industrialised nations (UK, US, Canada, Australia and France) estimated that between 1 and 
2.5% of the gross national product was being spent on OA management (March and 
Bachmeier 1997).  The use of ‘managed care’ in the US allows examination of a breakdown 
of that expenditure and shows that approximately one third is used for medication 
management, primarily pain-relieving drugs, and one half of the total is used to service the 
5% of the US OA population who require arthroplasty (Bitton 2009).   
1.4 Risk factors for symptomatic OA 
There are a number of factors that increase the likelihood of developing symptomatic OA.  
Non-modifiable factors include age, gender and ethnicity, while others such as obesity, 
activity level and employment are modifiable.  
1.4.1 Age as a risk factor for OA 
The prevalence of OA increases with age because exposure to other factors has a cumulative 
effect and because changes associated with ageing increase the impact of factors such as load-
bearing and obesity.  One of the main characteristics of OA is deterioration in the cartilage of 
the joint; the health of the cartilage depends on the function of cartilage cells (chondrocytes) 
which deteriorates with ageing leading to a loss of ability of the cartilage to maintain and 
repair itself (Grogan and D'Lima 2010; Loeser 2009).  This deterioration is observable in 
most people over 50 years of age, but it is far more pronounced in people with OA (Yamada 
et al. 2002).   
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1.4.2 Gender as a risk factor for OA 
Differences in prevalence according to gender are due to a number of factors including 
differences in cartilage health (Hanna et al. 2009), a tendency for misalignment of the joint 
(varus-valgus laxity) (van der Esch et al. 2007) and congenital or developmental deformities 
(Barros et al. 2010; Doherty et al. 2008; Ganz et al. 2008; Jacobsen 2006; Jacobsen and 
Sonne-Holm 2005).  Some of these skeletal malformations are associated with genetic 
mutations (Li et al. 2007).   Genetic polymorphisms can also increase risk of OA via 
abnormalities in pathways involved in joint health such as apoptosis, inflammation and bone 
morphogenetic protein signalling (Valdes and Spector 2010) and a number of studies have 
established that there is a clear degree of heritability involved in the development of 
symptomatic and radiographic OA (Zhai et al. 2007; Neame et al. 2004; Page et al. 2003). 
1.4.3 Ethnicity as a risk factor for OA 
There are ethnic variations in prevalence of OA with Asians, African-Americans, American 
Indian women and non-white Hispanic women reported to have higher rates of knee OA and 
lower rates of hip OA than Caucasians in the US population (Wright et al. 2008; Jordan et al. 
2007; Zhang et al. 2001a; Hoaglund et al. 1995).  Some of the ethnic variation is related to 
genetic polymorphisms (Nakamura et al. 2007) but many of the studies suggesting a genetic 
cause for these differences are underpowered (Zintzaras et al. 2010).  The research in this area 
will require large sample sizes because there is a great deal of interaction between ethnicity 
and other risk factors such as obesity, education, and socioeconomic status. 
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1.4.4 Occupation as a risk factor for OA 
The risk of both hip and knee OA is increased by a number of occupational factors including 
for knee OA kneeling, lifting, crawling and heavy work while standing, and for hip OA 
bending, twisting and reaching even after joint injury has been controlled for (Allen et al. 
2010; Rytter et al. 2009).  It is possible that these factors contribute to the gender differences 
in prevalence of knee and hip OA due to differences in gender bias for load-bearing and 
heavy manual work, lorry driving and agricultural work, all associated with increased risk of 
OA (Rossignol et al. 2003).   
1.4.5 Injury as a risk factor for OA 
Knee injury is also associated with a much greater risk of developing knee OA at an earlier 
age.  People who have experienced anterior cruciate ligament injury or a meniscal tear are 
much more likely to develop symptomatic and radiographic OA than their peers (Roos 2005; 
Lohmander et al. 2004; Gelber et al. 2000).   
1.4.6 Obesity as a risk factor for OA 
Obesity is a major risk factor for development of OA and is associated with higher incidence 
of OA requiring joint replacement (Turley et al. 2006; Flugsrud et al. 2006; Holmberg et al. 
2005; Oliveria et al. 1999).  Obesity increases the load managed by the weight-bearing joints 
(Messier et al. 2005), which leads to the development of abnormalities in the regeneration and 
structure of the cartilage (Gosset et al. 2006) and increased bone density (Nunez et al. 2007; 
Taguchi et al. 2007) leading to a higher rate of cartilage breakdown.  Obesity is also 
associated with increased OA in small non-load-bearing joints like the fingers (Kalichman 
and Kobyliansky 2009; Grotle et al. 2008).  This suggests that obesity also influences OA 
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humorally and there is growing evidence that leptin, an adipokine produced by white 
adipocyte fat cells, is involved (Vuolteenaho et al. 2009; Zhang et al. 1994).  The link 
between obesity and OA appears to be established in early life (Karlson et al. 2003) and the 
increased prevalence of childhood obesity as well as that in the older population suggests that 
the personal and economic burden of OA will increase.   
1.4.7 Socioeconomic status as a risk factor for OA 
Lower socioeconomic status has been associated with increased risk of radiographic OA 
(Callahan et al. 2010; Hannan et al. 1992) and symptomatic OA (Odutola and Ward 2005; 
Thumboo et al. 2002) and this is likely to be mediated via other factors associated with poor 
socioeconomic status including obesity, occupation, physical activity, and in women access to 
hormone replacement therapy (Roskam et al. 2010; Seppanen-Nuijten et al. 2009; Wardle et 
al. 2002; Hannan et al. 1992).   
1.5 The effect of OA on the individual 
Many OA sufferers cope well with their condition and require little medical or emotional 
support.  Approximately 25-37% of people describe their condition as mild but 16-19% 
describe it as severe (Bushmakin et al. 2011; Sadosky et al. 2010).  It is likely that the latter 
group are the people whom the majority of research exploring the effects of the condition 
focuses upon.   
1.5.1 OA is associated with poorer quality of life 
One of the main ways in which the impact of a condition is measured and communicated is 
through evaluations of health-related quality of life (HRQoL).  A number of tools are 
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available which attempt to quantify the effects of a disorder on an individual’s satisfaction 
with life.   The tools often include component measures of general health, physical function 
and symptoms, role function, mental well-being, emotional functioning, cognitive functioning 
and pain (Fayers and Machin 2007).  It is reported that the HRQoL  of people with moderate 
to severe OA is poorer than healthy normal controls (Rabenda et al. 2007; Cook et al. 2007; 
Lastowiecka et al. 2006; Jakobsson and Hallberg 2006; Hirvonen et al. 2006; Salaffi et al. 
2005; Ackerman et al. 2005).  In other words OA leads to a variety of effects that make their 
life less enjoyable and more challenging.  These effects could be broadly divided into 
physical, social and psychological and are observable from the time that the person first 
presents to their general practitioner (Rosemann et al. 2007c; Roux et al. 2005; Birrell et al. 
2000).   
1.5.2 OA is associated with pain and stiffness 
One of the most commonly reported physical symptoms of OA is joint pain, which tends to be 
localised to the affected joint sometimes radiating to the nearby tissues.  Pain may be 
accompanied by swelling, stiffness, and loss of mobility (Martel-Pelletier 2004).   Stiffness, 
which adds greatly to discomfort and disability, usually follows a period of inactivity and as 
such can be particularly troublesome on wakening when the normal activities of bathing and 
dressing can be significantly disrupted.   
1.5.3 OA is associated with functional limitation 
OA is often associated with functional limitation (Ling et al. 2003; Guccione et al. 1994) and 
together with pain this is one of the major factors that determine the likelihood of joint 
replacement being offered (Gossec et al. 2011).  The relationship between functional 
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restriction and objective indicators of OA is weak because it is mediated by the working 
model that the sufferer builds about their condition.  Perceptions and cognitions about cause, 
likely duration and outcome all influence current behaviour and treatment outcomes so that a 
person who believes their OA to have more serious consequences is likely to be less 
functionally active (Orbell et al. 1998; Hampson et al. 1994).  A person’s function will also be 
influenced by a number of psychological factors such as learned helplessness, self-efficacy 
and mood (Botha-Scheepers et al. 2006).   Function is itself a construct composed of a 
number of different components including activity, participation and health.  In terms of 
health, people with hip OA have been demonstrated to have lower scores on the physical 
functioning and role functioning sub-scales of the SF36, lower range of movement of the 
joint, lower knee muscle extensor strength and shorter 6 minute walking distance than 
matched controls (Rydevik et al. 2010).    Similarly people with knee OA have been found to 
have reduced muscle strength, reduced flexibility and functional restrictions (Swank et al. 
2011).   
1.5.4 OA is associated with increased risk of falls 
Muscle weakness and joint instability in people with lower limb OA increases the risk of falls 
(Yakhdani et al. 2010).  A Canadian study of community-dwelling older adults who had more 
than 6 month history of OA found that approximately 45% of them had experienced a fall and 
77% occasional or frequent near-falls (Arnold and Faulkner 2007).  Concern or fear about 
falling is a significant risk factor that predicts balance and number of falls even when other 
factors such as medication use, use of walking aids and other factors are controlled for 
(Delbaere et al. 2009; Arnold and Faulkner 2007).  Fear of falling, or catastrophic thoughts 
about the consequences of falling leads to a loss of mobility (Delbaere et al. 2009; 
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Bialoszewski et al. 2008).  This is of concern generally and in particularly for people who 
suffer from OA where this will further decrease lower limb strength. 
1.5.5 OA is associated with fatigue 
People with OA also have a higher than normal incidence of fatigue, in fact a similar 
incidence to that seen in Rheumatoid Arthritis (RA) (Wolfe and Michaud 2004; Currey et al. 
2003; Wolfe et al. 1996).  Fatigue in people with OA tends to escalate during the day and can 
have more of a negative impact on physical activity than pain (Murphy et al. 2008). OA 
sufferers who complain of fatigue suggest it is like ‘coming up against a brick wall’ (Power et 
al. 2008: 4).  The factors that have a reciprocal relationship with fatigue include sleep, 
depression, stressful events, older age, pain, pain medication, disability, physical function and 
social interactions (Murphy and Smith 2010; Stebbings et al. 2010; Murphy et al. 2008; 
Currey et al. 2003; Wolfe et al. 1996).  
1.5.6 OA is associated with lower levels of social participation 
Despite pain fatigue and functional restrictions knee and  hip OA does not appear to lead 
directly to work loss through sick leave or early retirement in those of working age  
(Bieleman et al. 2011).  However, OA does lead to difficulty achieving satisfactory 
participation in a variety of social roles, and this causes people with OA upset and 
dissatisfaction  (Wilkie and Peat 2008; Gignac et al. 2008).   
1.5.7 OA is associated with increased risk of depression 
The prevalence of depression among patients who seek help with their OA is relatively high 
with approximately twenty per cent of people with OA in the primary care setting having 
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moderate to severe depression (e.g. Rosemann et al. 2007a) in comparison to a rate in the 
general population of approximately three per cent (Singleton 2001; Jenkins et al. 1997).  One 
of the factors that influence people with OA to seek medical help is co-morbid depression 
(Dexter and Brandt 1994).  Variance in depression among those with OA is explained largely 
by the level of perceived pain, social isolation, and physical limitation and these factors in 
turn relate to other risk factors for symptomatic OA including a high body mass index 
(Rosemann et al. 2008).    
Depression is linked with reduced functional ability and activity in people with pain.  The 
more physically disabled a person is by their pain the more likely they are to suffer from 
concurrent depression (McIlvane et al. 2007; Chou 2007; Mossey and Gallagher 2004; 
Williamson and Schulz 1992). The relationship between depression and functional ability is 
bidirectional: treatment of depression has been shown to reduce disability in pain patients (Lin 
et al. 2006; Lin et al. 2003) and improving activity levels through exercise programmes has 
improved the patients mood as well their pain (Lim et al. 2005).  
There has been a long-standing observation that certain disorders involving inflammation 
have a tendency to be associated with depression, for example cardiovascular disease (Lippi 
et al. 2009; Halaris 2009; Panagiotakos et al. 2004), type 2 diabetes (Pickup 2004) and 
rheumatoid arthritis (Kojima et al. 2009).  They share symptoms including sleep disruption, 
low mood, fatigue, and appetite changes and there is a high level of co-morbidity between 
painful disorders and depression.  The relationship can be partially but not fully explained by 
the psychological burden of living with the disease or disorder (Pollak and Yirmiya 2002).  
There is a great deal of compelling evidence that shared neurochemistry is equally 
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responsible.  The degree of inflammation in most OA cases is thought to be minor but 
evidence that some people have a greater inflammatory involvement may increase the 
likelihood of co-morbid depression. 
1.5.8 OA is not associated with increased risk of anxiety 
There is a positive correlation between anxiety and pain (Loncar et al. 2006; Velikova et al. 
1995; Smedstad et al. 1995; Casten et al. 1995; Walsh 1993; Linton and Gotestam 1985) but 
anxiety is no more prevalent in the OA population than the general population (approximately 
24%) (Kessler et al. 2003; Memel et al. 2000; Regier et al. 1988). One recent study of 54 
consecutive OA patients attending a rheumatology clinic identified a prevalence of 31% using 
psychiatric diagnostic criteria (Axford et al. 2010), which suggests that anxiety is not a 
particular problem in this cohort as those attending such a clinic are likely to represent the 
more severely affected.   
Anxiety in OA is associated with poorer function (Scopaz et al. 2009), which is mediated by 
fear-avoidance behaviour.  Fear-avoidance behaviour describes how the fear of pain leads to 
the avoidance of activities or behaviours that the person believes will trigger pain.  It was first 
described in the 1980s (Lethem et al. 1983) and is known to be associated with disuse, 
disability and hypervigilance (Lethem et al. 1983; Slade et al. 1983).  Trait anxiety and 
anxiety-sensitivity (a heightened fear of anxiety-related symptoms) are both associated with 
pain-avoidance behaviour (Ocanez et al. 2010; Newcomer et al. 2010).  This behaviour 
accounts for up to 40% of the variance in functional level in people with OA (Heuts et al. 
2004). 
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Chapter 2 The pathophysiology and pain of OA 
 
The traditional view of OA has been that it is a disease of wear and tear and in comparison to 
other forms of arthritis the degree of inflammation is thought to be low.   
The focus for OA pathophysiology has been the cartilage but it is now clear that the whole 
joint is involved in the development and progression of OA.  The pain of OA is initiated as a 
consequence of the production of a number of inflammatory mediators generated as a result of 
the changes within the joint.   
2.1 Bone, cartilage and synovium as major components of the OA joint 
2.1.1 Subchondral bone in the pathophysiology of OA 
There is debate about whether bone changes lead to or are caused by changes to the cartilage 
(Martel-Pelletier et al. 2007)  and although the debate continues there is evidence that  
subchondral bone attrition occurs  before cartilage loss in the same sub-region (Roemer et al. 
2009; Neogi et al. 2009a).   Bone changes occur early in the development of OA before they 
can be detected radiographically (Hutton et al. 1986) and include increased thickness of the 
subchondral bone plate, alterations in the structure of the trabecular bone, and the 
development of osteophytes and cysts (Goldring and Goldring 2010a). 
Bone is continually remodelled via the activities of osteoblasts, which construct new bone 
matrix and osteoclasts, which degrade it. Alterations in the structure of subchondral bone vary 
according to the stage of OA and the site of the bone (Goldring and Goldring 2010b).  In early 
OA it is reported that an increased rate of resorption leads to a reduction of trabecular 
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thickness and an increase in the size of the trabecular spaces (Martel-Pelletier et al. 2007).  
The hardness of trabecular bone, one of its key qualities, is reduced in severe OA (Dall'Ara et 
al. 2011) and this likely results from alterations in its architecture and also its composition, 
with a reduced mineral content and an increased water content (Lories and Luyten 2011).    
Bright areas visualised on MRI scans of subchondral bone represent a variety of alterations in 
the bone marrow including oedema, fibrosis and necrosis (Tanamas et al. 2010b).  
Collectively these changes are termed bone marrow lesions (BMLs).  The cause of BMLs is 
poorly understood but they may be a response to an acute inflammatory event, oedema or 
contusion and gradually become replaced by more permanent bone marrow remodelling 
(Wildi et al. 2010).  They are associated with cartilage loss (Hunter et al. 2006;Felson et al. 
2003) and correlate with OA severity (Wildi et al. 2010;Tanamas et al. 2010b).  There is 
debate about whether their presence is associated with pain in OA with some studies 
observing a relationship (Ip et al. 2011; Lo et al. 2009; Felson et al. 2007; Felson et al. 2001) 
and others not (Davies-Tuck et al. 2009; Kornaat et al. 2007). 
BMLs are often associated with subchondral bone cysts.  These are thought to be formed 
following necrosis caused by collision between opposing joint surfaces, and are more likely to 
occur where there is significant cartilage erosion (Marra et al. 2008).  Most progress but some 
also regress and they are associated with reduced cartilage volume and an increased risk of 
knee replacement (Tanamas et al. 2010a). 
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2.1.2 The cartilage in the pathophysiology of OA 
In health the cartilage maintains a balance between synthesis and breakdown.  In early OA 
there is an increase in cartilage synthesis (Pritzker et al. 2006) but later  this balance tips in 
favour of degeneration (Goldring et al. 2006; Mandelbaum et al. 2005).  Histological 
examination of cartilage shows focal changes associated with OA (Mankin et al. 1971) as 
opposed to the more widespread changes associated with rheumatoid arthritis.  Radiographic 
and MRI studies of the cartilage show changes over time that seem to be associated with 
severity or progress of OA (Eckstein et al. 2011; Cibere et al. 2011; Hanna et al. 2009; 
Eckstein et al. 2009; Amin et al. 2009; Eckstein et al. 2006; Amin et al. 2005).  The 
Osteoarthritis Research Society International (OARSI) have developed a grading system for 
histopathological changes (Figure 2-1) (Pritzker et al. 2006) which also serves to provide a 
visual representation of the longitudinal change of the cartilage.   
Cartilage breakdown is catalysed by matrix metalloproteases (MMPs) and in healthy cartilage 
this activity is balanced by Tissue Inhibitors of MMPs (TIMPs).  The expression of MMPs is 
upregulated by pro-inflammatory cytokines so that there is a imbalance in favour of MMPs 
over TIMPs (Hegemann et al. 2003).  Pro-inflammatory cytokines also interfere with the 
synthetic activities of chondrocytes (Fernandes et al. 2002) and thus contribute to the 
destruction of the cartilage. 
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Figure 2-1: OARSI stages of the deterioration of articular cartilage in OA 
 
2.1.3 The synovium in the pathophysiology of OA 
It is thought that breakdown products from the cartilage matrix are released into the synovial 
fluid and detected by the synovium, which leads to an inflammatory reaction (Pelletier et al. 
2008). Synovitis can occur early in the course of OA and may not be clinically detectable.  
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According to arthroscopic studies it occurs in up to 50% of people with knee OA (Ayral et al. 
2005).  Moderate to severe synovitis is associated with increased WOMAC pain score 
(Guermazi et al. 2008). This degree of synovitis can be clinically detectable in many people 
due to the production of heat, swelling and effusion (Sellam and Berenbaum 2010; Benito et 
al. 2005).  The symptoms and signs of synovitis tend to worsen along with the radiological 
progression of OA (D'Agostino et al. 2005; Ledingham et al. 1995).  The severity of synovitis 
correlates with the degree of cartilage damage (Ayral et al. 2005).   
Similar to rheumatoid arthritis (RA) macrophages are activated in the inflamed OA synovium 
producing pro-inflammatory cytokines and vascular endothelial growth factor (VEGF) 
(Benito et al. 2005; Farahat et al. 1993). The levels of pro-inflammatory cytokines are lower 
in OA than in RA however, and unlike the situation in RA the use of anti-TNFα therapy does 
not prevent the expression of IL-1β (Bondeson et al. 2006).  Despite synovial inflammation 
being a localised condition in OA increased levels of IL-6 and C-reactive protein have been 
found in the circulation of patients with active synovitis (Pearle et al. 2007). 
2.1.4 Angiogenesis in the pathophysiology of OA 
Cartilage is normally avascular and is supplied with nutrients and oxygen by the synovium 
and subchondral bone (Martel-Pelletier, Lajeunesse, Reboul, & Pelletier 2007).  There is 
consistent evidence that in OA, blood vessels penetrate the tidemark between the calcified and 
non-calcified cartilage from the subchondral bone to vascularise the cartilage (Walsh et al. 
2007).   
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Angiogenesis of the cartilage from the subchondral bone is facilitated by the activity of the 
MMPs, which degrade the matrix creating space for new blood vessels and enhance processes 
relating to the endothelium of the blood vessels (Rundhaug 2005).  The vascular channels 
formed also contain sensory and sympathetic nerve fibres and these may contribute to the pain 
of OA (Suri et al. 2007).   
Epiphyseal growth involves the ossification of cartilage, with apoptosis of hypertrophic 
chondrocytes providing a structure that can be mineralised.  This process is inhibited in 
normal cartilage because of the absence of blood vessels.  The invasion of blood vessels and 
the production of angiogenic factors in OA can lead to the ossification of the cartilage 
(Babarina et al. 2001).  This process contributes to the thinning of the articular cartilage.  
Angiogenesis is also important in the development of osteophytes, bony spurs that form at 
joint margins by the same process of endochondral ossification (Moskowitz et al. 1981). 
Osteophytes are thought to contribute to the pain of OA (Neogi et al. 2009;  Lanyon et al. 
1998) as a combination of hypoxia, compressive forces and inflammation sensitise the 
sensory nerves that grow alongside the new blood vessels (Ashraf 2008). 
Synovitis and angiogenesis have a reciprocal relationship where the activity of one influences 
the activity of the other (Ashraf and Walsh 2008; Afuwape et al. 2003).  Inhibition of 
angiogenesis inhibits synovitis (Afuwape et al. 2003), and can disrupt its progression from an 
acute to a chronic condition (Ashraf et al. 2010).  Synovitis stimulates angiogenesis by the 
secretion of VEGF from macrophages, angiogenic factors from endothelial cells and 
fibroblasts, and the presence of pro-angiogenic inflammation-induced hypoxia, (Bonnet and 
Walsh 2005).  
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Newly formed blood vessels contribute to oedema; inflammatory mediators are attracted to 
and can reach the site, and there may be difficulty modulating inflammation due to deficiency 
in neural and peptide regulatory factors (Bonnet and Walsh 2005). The angiogenesis of the 
synovium therefore contributes to the inflammatory process, and facilitates it progression 
from an acute state to a chronic state. 
2.1.5 Pannus in OA 
Often people with OA will also have localised patches of pannus-like tissue, a thin layer of 
tissue over-laying the articular surface (Shibakawa et al. 2003).  Shibakawa et al. (2003) 
characterise the pannus-like tissue as being either vascular or fibrous in character.  It produces 
catabolic factors such as IL-1β and MMPs and therefore contributes to the destruction of the 
cartilage.  Its origins are not clear.  In RA the pannus originates from the synovial membrane 
but this is not the case in OA and it is felt that it probably originates from either the 
mesenchymal cells or from the cartilage itself, (Yuan et al. 2004; Shibakawa et al. 2003). 
2.2 Pain in OA 
2.2.1 Nociception in the joint 
Nociception is the sensory process that translates noxious (an actual or potentially damaging) 
stimuli into signals that will ultimately be interpreted by the brain as the perception of pain.  
The instruments of nociception are sensory nerve endings, also known as nociceptors.   
There are two main types of sensory fibre that terminate in nociceptors, the small 
unmyelinated C fibre and the fast myelinated Aδ fibre. The C-fibre has a relatively slow 
transmission speed (2 m s
-1
) and can be subdivided into polymodal nociceptors that respond to 
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a number of different stimuli, and those that respond to a single stimulus type for example 
chemical, thermal or mechanical.  A proportion of C fibres are called ‘silent’ because they 
don’t respond to noxious stimuli unless there is inflammation or tissue damage present.  C-
fibres are found in the synovial layer, fibrous capsule, fat, ligaments, periosteum and menisci 
contain terminals of Aδ and C fibres (Schaible 2006) and the infrapatellar fat pad (Dye et al. 
1998).  Normal cartilage does not contain nociceptors but the process of angiogenesis in OA 
is accompanied by neurogenesis so that cartilage becomes responsive to noxious stimuli (Suri 
et al. 2007).   
The Aδ fibres (20 m s-1) are responsible for the transmission of short, sharp sensation, for 
example noxious pinch.  Aδ fibres are found in the same tissues as C-fibres.  A third type of 
sensory fibre called the Aβ fibre, is not involved in pain transmission in normal conditions but 
detects information about non-noxious touch, vibration and pressure (Millan 1999). The 
fibrous capsule of the joint, ligaments, menisci and periosteum contain thick myelinated Aβ 
nerve endings.   
There are a number of conditions that will lead to initiation of pain signals from within the 
synovial joint.  Movement outside the normal range activates a number of Aβ, Aδ and C 
fibres that are sensitive to movement and/or pressure (Schaible 2006; Schaible and Grubb 
1993).  The sensitivity of these fibres increases in inflammatory conditions and they show 
increased responses in the normal working range of the joint and some spontaneous activity 
when the joint is at rest (Grigg et al. 1986; Coggeshall et al. 1983).  This leads to hyperalgesia 
in the joint (Grubb et al. 1991).   
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Synovial inflammation leads to plasma extravasation and this increases the volume of 
synovial fluid, thus increasing intra-articular pressure. Increased pressure correlates positively 
with increased pain (Goddard and Gosling 1988).  Goddard and Gosling demonstrated that 
medial rotation or extension of the hip, which are associated with increased pain in people 
with OA, causes an elevation of intra-articular pressure. 
Figure 2-2: Chemical mediators of pain in the periphery 
 
Reprinted including text with Permission: Potential peripheral mediators of peripheral sensitization after inflammation. 
Inflammation leads to the release of numerous chemicals from mast cells, macrophages, immune cells, and injured cells that 
may act directly or indirectly to alter the sensitivity of peripheral nerve terminals. ASIC, acid-sensing ion channel; CRH, 
corticotrophin-releasing hormone; GIRK, G-protein-coupled inward rectifying potassium channel; iGluR, ionotropic 
glutamate receptor; IL-1β, interleukin-1β; IL-6, interleukin-6; mGluR, metabotropic glutamate receptor; NGF, nerve growth 
factor; PAF, platelet-activating factor; PGE2, prostaglandin E2; PKA, protein kinase A; PKC, protein kinase C; SSTR2A, 
somatostatin receptor 2A; TNF-α, tumour necrosis factor-α; TrkA, tyrosine kinase receptor A; TTXr, tetrodotoxin-resistant 
sodium channel; μ, mu-opioid receptor; M2 muscarinic receptor; 5HT, serotonin; LIF, leukemia inhibitory factor. (Artwork 
by Ian Suk, Johns Hopkins University, adapted from Woolf & Costigan 1999.)  
2.2.1.1 Initiation of pain in the joint 
The process of cartilage breakdown is driven by the production of a number of pro-
inflammatory and excitatory mediators. Each of these acts as a ligand in conjunction with 
28 
 
specific receptors expressed on the surface of sensory nerve fibres and immune cells (Figure 
2-2).   
2.2.1.2 Inflammatory mediators in the pathophysiology of OA 
Chondrocytes, mononuclear cells, osteoblasts, synoviocytes and adipocytes of the 
infrapatellar fat pad can all produce the pro-inflammatory cytokines interleukin 1-beta (IL-
1β), interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFα).    In OA the local 
concentration of these cytokines increases in synovial fluid, synovial membrane, (Sellam and 
Berenbaum 2010) subchondral bone, (Lisignoli et al. 1999) cartilage (Saklatvala 2007) and 
muscles (Levinger et al. 2011).   
IL-1β and TNFα receptor expression is increased on fibroblasts and chondrocytes (Fernandes 
et al. 2002; Alaaeddine et al. 1997; Sadouk et al. 1995) (Martel-Pelletier et al. 1992).  This 
makes these cells in OA more sensitive to IL-1β and TNFα activation thus enhancing 
production of MMPs (Goldring and Berenbaum 2004; Martel-Pelletier et al. 1992).    
IL-1β and TNFα are also involved in the production of nitric oxide (NO) and prostaglandin 
E2 (PGE2) (El Mansouri et al. 2011).  NO plays a role in suppression of the synthesis of the 
matrix (Taskiran et al. 1994), inhibits chondrocyte proliferation and induces apoptosis of 
chondrocytes (Blanco and Lotz 1995; Blanco et al. 1995).  PGE2 is one of the major 
mediators involved in destruction of the cartilage and the progression of OA (Li et al. 2009; 
Martel-Pelletier et al. 2003; Hardy et al. 2002). 
IL-6 is produced in low levels by normal chondrocytes but its production is upregulated by 
IL-1β, TNFα (Bender et al. 1990; Guerne et al. 1990; Guerne et al. 1989) and PGE2 (Wang et 
29 
 
al. 2010). IL-6 and its soluble receptor (sIL-6R) are also produced by the infrapatellar fat pad 
(Distel et al. 2009).  IL-6 and sIL-6R reduce proteoglycan synthesis and stimulates the 
production of NO in the cartilage (Guerne et al. 1999). 
2.2.1.3 Anti-inflammatory mediators in the pathophysiology of OA 
A number of other cytokines are involved in the maintenance of the cartilage.  Chondrocytes 
respond to the process of degradation by increasing the synthesis of matrix components and 
releasing anti-inflammatory cytokines (IL-4, IL-10, IL-13).  These anti-inflammatory 
cytokines can reduce TNFα-induced PGE2 release (Alaaeddine et al. 1999).  IL-4 can down-
regulate the expression of pro-inflammatory cytokines (Martel-Pelletier et al. 1999) and their 
downstream products such as MMPs and NO (Fernandes et al. 2002; Nishisaka et al. 2001; 
Nemoto et al. 1997).  However, soluble IL-4 receptor (sIL-4R) is found in increased levels in 
the serum of people with OA and it is thought that the increased ratio of sIL-4R to IL-4 
reduces the availability of IL-4 to chondrocytes and therefore inhibits its normally protective 
function (Silvestri et al. 2006).   
2.2.2 Osteoarthritis as an inflammatory disease 
Having explored the peripheral mechanism of OA it is clear that there are inflammatory 
processes involved.  It seems clear that OA is an inflammatory arthritis but in degree it differs 
greatly from a systemic inflammatory disease such as Rheumatoid Arthritis (RA) and 
examination of serum and synovial fluid supports this.  
Measures of systemic inflammation such as C-reactive protein tend to be much lower in OA 
than Rheumatoid Arthritis (RA) (Mahmoud et al. 2005; Sitton et al. 1987) although the 
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correlation of this much-relied upon inflammatory with disease activity in RA is thought by 
some to be weak (Keenan et al. 2008). 
Other markers of inflammatory processes found in the serum and synovial fluid of people 
with OA and RA also suggest a much more active and systemic inflammatory process is 
present in RA compared with OA.  Comparison of serum in the two diseases has identified 
higher levels in RA of nitrates and nitrates (Ersoy et al. 2002), advanced glycation end (AGE) 
product pentosidine (Chen et al. 1999), adipocytokines such as resistin and leptin (Ibrahim et 
al. 2008), Tumour Necrosis Factor alpha (TNFα) and matrix metalloprotease-3 (Mahmoud et 
al. 2005).  In synovial fluid RA patients have higher levels of pro-inflammatory cytokines 
such as IL-1β, IL-6, TNFα, IFNγ (Kokebie et al. 2011; Manicourt et al. 2000;Schlaak et al. 
1996), adipocytokines (Ibrahim et al. 2008), matrix metalloproteases 1 and 3 (Mahmoud et al. 
2005) and VEGF (Biswas et al. 2011). 
There are similarities between the pathophysiology of RA and OA such as the increased 
expression of pro-inflammatory cytokines in both diseases and an increased immune response 
(Biswas et al. 2011; Leheita et al. 2005) as well as broadly similar histopathological changes 
in the synovium in OA and RA without effusion (Baeten et al. 2000).   
2.2.3 Primary afferent fibre terminations in the dorsal horn 
The central endings of the primary afferent fibres lie within the laminae or layers found within 
the spinal cord.  Although there is overlap at the edges of each the structure and function of 
each lamina are different (Table 2.1,and Figure 2-3). 
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Table 2.1: Dorsal horn nociceptive neuron types and termination within the dorsal horn 
Type of neuron Location in 
dorsal horn 
laminae (L) 
Stimulus type 
that initiates 
response 
Primary 
afferent 
terminations 
Receptive field 
Nociceptive 
neurons 
L1, LII 
Also LV, LVI, 
LVII, LX 
High intensity 
peripheral 
stimuli 
Aδ, C 
 
Limited 
Nonspecific 
nociceptive 
neurons (Wide 
Dynamic Range) 
Primarily LV 
Some LI , LII 
High and low 
intensity 
peripheral 
stimuli 
Aβ, Aδ,C Variable but can 
be extensive.  
Activity greatest 
when centre of 
field stimulated. 
 
The locations of the terminals of the primary afferents is highly organised: C and Aδ fibres 
terminate largely in lamina I and II and some in V, while Aβ fibres terminate largely in the 
deeper laminae (Willis and Coggeshall 2004) (Figure 2-3).   
Figure 2-3: Sensory nerve pathways and terminations in the dorsal horn 
 
Reprinted with permission (Milligan and Watkins 2009)  
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The location of the receptive fields of the primary afferents translates to the location of their 
terminals within the dorsal horn so that a somatotopic map is created. The arbors of the 
central terminals also run rostrocaudally and are able to excite hundreds of neurons each 
(Woolf and Salter 2006). 
2.2.3.1 Classes of dorsal horn neurons 
DH neurons can be divided into three classes: projection neurons, propriospinal neurons and 
local interneurons (Willis and Coggeshall 2004).   Projection neurons transfer information 
from the DH to the brain and also can initiate descending facilitation and inhibition.  
Propriospinal neurons communicate between spinal segments and have a role in reflex 
responses as well as movement.  Interneurons are localised neurons whose axons travel only a 
short distance within the spinal cord and may be either excitatory or inhibitory.  
Projection neurons can be categorised as nociceptive specific or non-specific nociceptive 
cells.  The latter are more commonly known as wide dynamic range cells.  Nociceptive 
specific cells are located primarily in lamina I (LI) and to a lesser extent in LII, VI, VII and 
IX.  These cells respond to high intensity stimuli and have a limited receptive field.  The wide 
dynamic range (WDR) cells are located predominantly in LV and to a lesser extent in LI and 
LII and respond to stimuli of varying intensities.  The WDR cells increase the frequency with 
which they fire according to the intensity of the stimulus they receive and therefore can code 
stimulus intensity.   
The WDR cells receive input from non-nociceptive A-β fibres as well as input from 
nociceptive C and A-δ fibres.  Their receptive fields are much larger than the nociceptive-
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specific cells and their response varies according to the origin of the stimulus, being greatest 
when the stimulus originates close the centre of the receptive field and decreasing as the 
stimulus moves closer to the outer edges (Calvino and Grilo 2006).  The receptive fields of 
WDR cells overlap to some extent and both innocuous and noxious stimuli can activate more 
than one WDR.  However, tactile (mechanical, such as touch) stimuli activate a limited 
number of neurones; those whose receptive field centres are close to the site of stimulation.  
Noxious stimuli activate more WDR cells, those whose receptive field centres are close to the 
site of stimuli and also those whose receptive field fringes overlap with the site of stimulation 
(LeBars 2002). 
Inflammation leads to an increase in the size of the receptive field via two mechanisms.  
Primary hyperalgesia is the production of algesic substances local to the site of inflammation.  
These substances activate silent nociceptors and also lower the activation threshold of 
nociceptors creating a situation where sub-threshold stimuli can lead to the generation of 
action potentials.  This leads to an increased barrage of afferent impulses reaching the dorsal 
horn cells which creates an amplification process.     
2.2.3.2 Synaptic transmission of pain signals in the dorsal horn 
Depolarisation of the primary afferent fibre leads to the release of glutamate and other 
neurotransmitters.  Glutamate binds with and activates ion channel α-amino-hydroxy-5-
methyl-4-isoxazoleproprionic acid (AMPA) receptors.  This causes a sub-threshold change in 
amplitude that can summate leading to the generation of an action potential  (Woolf and Salter 
2006).  AMPA receptors are also found on the primary afferent fibres and modulate the 
release of glutamate from the primary afferent fibres (Lu et al. 2002; Ferreira and Lorenzetti 
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1994).   AMPA receptors also contribute to the plasticity of the dorsal horn and long-term 
potentiation (Lee et al. 2003) both by alteration of their structure and their quantity as a result 
of synaptic activity.   
Intense pain or burst firing of primary afferent fibres leads to the release of other transmitters 
such as neuropeptides and growth factors including Substance P, Calcitonin Gene Related 
Peptide (CGRP), and Brain Derived Neurotrophic Factor (BDNF), from the primary afferent 
fibres (Benarroch 2010). These transmitters lead to slow post-synaptic depolarisations lasting 
tens of seconds (Yaksh 2006).  The result is an increase in intracellular calcium caused by 
summation of trains of signals from primary afferent fibres and leads to release of the 
magnesium ion block in the N-methyl-D-aspartate (NMDA) receptor ion channel.   
The NMDA receptor can be activated by glutamate providing a suitable co-agonist is present. 
The co-agonist can be either glycine (Johnson and Ascher 1987) or D-serine (Wolosker 2007; 
Schell et al. 1997; Schell et al. 1995; Kleckner and Dingledine 1988). Serine is produced by 
activated glial cells (Halassa and Haydon 2010).   Animal studies have shown that increasing 
the amount of either serine or glycine in the extracellular fluid enhances NMDA receptor 
activity (Zhang et al. 2001b; Wood 1995).   
Activation of the NMDA receptor leads to a prolonged excitatory post-synaptic potential in 
comparison to the transient potentials mediated by non-NMDA receptors like the AMPA 
receptor (Mori and Mishina 1995).  It also leads to a greater increase in intracellular calcium 
levels.  The consequences of increased intracellular calcium levels include the production of 
nitric oxide (NO), and prostaglandin, molecules that contribute to enhanced release of 
glutamate from the primary afferent fibre, an amplification mechanism.  
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NO is created from arginine and this process also generates the by-product citrulline 
(Garthwaite 1991).  NO is a gaseous molecule that is synthesised on demand and cannot be 
stored in the cell.  NO diffuses to its site of action in the primary afferent fibre where it leads 
to increased release of glutamate from the primary afferent fibre (Vetter et al. 2001; 
Kawamata and Omote 1999). 
Prostaglandins are produced as a consequence of increased intracellular Ca
2+
 and presence of 
extracellular cyclo-oxygenase (cox) enzymes (Yang et al. 1996).    The process is modulated 
by glial uptake of glutamate from the synaptic cleft (Svensson et al. 2003).   
An increase in CSF prostaglandins, especially PGE2 has been demonstrated to follow 
peripheral inflammation in some animal models, a process that appears to be dependent on 
central induction of cox-2 from spinal neurons by interleukin 1 beta (IL-1β) (Hosl et al. 2006; 
Samad et al. 2001) in a process that is driven by both neural and humoral communication 
from the periphery (Samad et al. 2001).    
Prostaglandins contribute to an increase in pain in two ways.  Firstly activation of the PGE2 
receptor on projection neurons disrupts the inhibitory action of glycine at the glycine receptor 
(Reinold et al. 2005; Zeilhofer 2005; Harvey et al. 2004).  Secondly activation of 
prostaglandin EP receptors, which are expressed in primary afferent fibres (Bar et al. 2004) 
increase influx of Ca
2+
 into the primary afferent fibre and facilitate the release of 
neurotransmitters like glutamate thus amplifying pain transmission.  
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2.2.4 Glia and cytokines in pain and mood 
Relatively recently it has been discovered that transmission of pain signals does not just 
involve primary afferent fibres, interneurons and projection neurons.  The term the tri-partite 
synapse refers to an evolution in understanding of synaptic transmission and we now 
appreciate that glial cells form a third and important component of synaptic transmission 
(Halassa et al. 2007; Nadkarni and Jung 2007).   
Glial cells comprise approximately 70% of the cell population in the central nervous system 
(Inoue and Tsuda 2009). There are two types of glial cells found within the dorsal horn, 
astrocytes and microglia.  Astrocytes perform a supportive role to the nerve cells and closely 
associate with synapses communicating with those cells by gap junctions (McMahon and 
Malcangio 2009).  Microglia are the resident macrophages of the CNS and make up about 
10% of the glial population (Stoll and Jander 1999).  In physiological conditions glial cells are 
vital to homeostasis but they can become activated by afferent pain signalling and contribute 
to the amplification and maintenance of pain. 
2.2.4.1 Activated glial cells as modulators of pathological pain 
Glia become activated in response to peripheral nerve or tissue injury via activation of a 
number of cell surface receptors including AMPA and NMDA (glutamate), and NK1 
(Substance P) (Abbadie et al. 2009; Milligan and Watkins 2009; Tsuda et al. 2009).  The 
activation of these receptors leads to an excitatory response with the release of glutamate, 
ATP, Tumour Necrosis Factor-α (TNFα), IL-1β (interleukin 1-β), IL-6 (interleukin-6), NO, 
prostaglandin, and Brain Derived Neurotropic Factor (BDNF).  In this way glial cells 
contribute to the amplification and facilitation of pain in pathological conditions. 
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Serine and GABA are also produced by glia (Lee and Soltesz 2011; Rao et al. 2003).  Their 
release from the glia is enhanced by agonism of non-NMDA glutamate receptors (Schell et al. 
1995), in other words, the release of serine and GABA from glia can be stimulated by the 
glutamate increasing levels of extracellular glutamate. 
2.2.4.2 Pro-inflammatory cytokines and pain signalling 
Cytokines are large peptides that have a key role in the regulation of the inflammatory 
response; their major function is inter and intracellular communication (Cunha and Ferreira 
2003). The three main pro-inflammatory cytokines IL-1β, IL-6 and TNFα have well 
documented pronociceptive effects within the dorsal horn.  Other pro-inflammatory cytokines 
include IL-2, IL7, IL-8 and IL-12; although there is less published about this latter group in 
terms of dorsal horn activity their role is beginning to be defined. 
IL-1β enhances NMDA receptor phosphorylation (Zhang et al. 2008a; Guo et al. 2007) and 
calcium influx via that receptor (Kawasaki et al. 2008; Viviani et al. 2003).  IL-1β also 
suppresses GABA and glycine inhibitory post-synaptic currents (Kawasaki et al. 2008) and so 
this cytokine facilitates pain both by enhancing the excitatory process and also by 
disinhibition.  Increased IL-1β in an animal model of inflammatory pain (Complete Freund’s 
Adjuvant to the rat hind paw) is mediated by both humoral and neural mechanisms (Samad et 
al. 2001; Cartmell et al. 2000) and is associated with an increase in cox-2 (Samad et al. 2001) 
(see also 2.2.4.4).  
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IL-2 is released from activated glia (Labuzek et al. 2005) and is thought to have a biphasic 
effect, at lower doses producing a thermal anti-nociception but at higher doses producing 
mechanical and thermal hyperalgesia (Cata et al. 2008). 
IL-6 has both anti- and pro-inflammatory functions.  It is involved in the production of IL-1 
receptor antagonist, a soluble antagonist that inhibits the activity of IL-1 and as a result of this 
IL-6 has an anti-inflammatory action (Jordan et al. 1995).  Following nerve injury IL-6 has an 
inhibitory action on primary afferent fibres (Flatters et al. 2003).  IL-6 also has a pro-
inflammatory function via the induction of IL-1β and TNFα, increasing microglial activation 
and increasing cox-2 mRNA (Schoeniger-Skinner et al. 2007). 
IL-8 is produced by activated astrocytes in response to pro-inflammatory stimuli (Meeuwsen 
et al. 2003).  In animal models of discogenic pain its release from macrophages within the 
disc has been identified as a key pro-inflammatory process and independent from TNFα in 
terms of the cytokine cascade.  This means that ameliorating the effect of IL-8 would require 
it to be targeted specifically (Takada et al. 2012; Kim et al. 2011b).   
Interferon-γ (IFNγ) activates microglia in the spinal cord (Tsuda et al. 2009) and promotes the 
expression of other pro-inflammatory cytokines from the glial cells (Dong et al. 2001;Satoh 
and Kuroda 2001).  IFNγ has been demonstrated to enhance pain response to stimulus via 
disinhibition of GABA receptors (Vikman et al. 2007; Vikman et al. 2003). 
TNFα is expressed by activated astrocytes and microglia (Shen et al. 2009; DeLeo et al. 
2000).  Two TNFα receptors (TNFR1 and TNFR2) have been located in the dorsal horn.  
TNFR1 are found on DRG neurons and also non-neuronal cells, while TNFR2 are found 
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exclusively on non-neuronal cells (Li et al. 2004).  Both receptors are upregulated after nerve 
injury (Schafers et al. 2003).  TNFR1 activation leads to an upregulation in IL-6 in the spinal 
cord and DRG (Lee et al. 2009).   
TNFα released by glial cells acts on post-synaptic TNF receptors leading to an increase in the 
expression of AMPA receptors, (Stellwagen et al. 2005; Beattie et al. 2002) which will lead to 
an increase in post-synaptic cell permeability to calcium.  Stellwagen et al also demonstrated 
that TNFα decreases the post-synaptic expression of GABAA receptors and this further shifts 
the excitatory/inhibitory balance in favour of excitation. 
Recent evidence has shown the microglial production of nitric oxide and TNFα can be 
inhibited by use of a selective serotonin inhibitor via IFNγ inhibition (Horikawa et al. 2010). 
2.2.4.3 Anti-inflammatory cytokines and pain signalling 
IL-10 is an anti-inflammatory cytokine that has the capacity to reverse the excitatory effects 
of the pro-inflammatory cytokines.  Intrathecal quisqualic acid produces an excitotoxic injury 
in rats which is accompanied by increases in TNFα and IL-1β and pain behaviour; systemic 
injection of IL-10 given within 30 minutes of the intrathecal injection prevents or delays 
much of the process (Plunkett et al. 2001).   
The ability of IL-10 seemingly to halt some of the damage and changes caused in neurogenic 
insults has led to investigations into the potential therapeutic effects of this cytokine (Lau et 
al. 2012; Sloane et al. 2009; Zhou et al. 2008; Milligan et al. 2006).   
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Less work has been published on the roles of other anti-inflammatory cytokines such as IL-4 
and IL-5 in the CNS but IL-4 has also been demonstrated to have the ability to reverse 
behavioural and biochemical manifestations of neuropathic pain (Hao et al. 2006). 
2.2.4.4 Neural and humoral activation of dorsal horn glia in inflammatory conditions 
IL-1β, IL-6 and TNFα concentrations in the cerebrospinal fluid and markers of glial activation 
are noted in animal models of inflammatory pain (Guo et al. 2007; Raghavendra et al. 2004; 
Bao et al. 2001).  Guo et al established that glial activation could be prevented by local 
anaesthetic block of neuronal input and proposed that inflammatory activation of glia is due to 
neuronal signalling via the primary afferent fibres.  This mechanism is supported by the 
observation that the onset of fever is rapid (10-12min) and the transcription and production of 
cytokines from immune cells takes up to 30min. A quick response is mediated by the vagus 
nerve (Blatteis et al. 2005) which through its wide innervation is able to transmit immune 
information to the central nervous system and vice versa (Eskandari et al. 2003; Hosoi et al. 
2002). 
In addition to the neuronal signalling of peripheral inflammation there is also a humoral route.  
A number of different mechanisms have been proposed for this.   The process of active 
transport of cytokines across the blood brain barrier (BBB) has been supported by the findings 
of several studies in which radio-labelled cytokines including IL-1α, IL-1β, IL-6 and TNFα 
were tracked across the blood brain barrier (Banks et al. 1994; Gutierrez et al. 1994; Gutierrez 
et al. 1993; Banks and Kastin 1992; Banks et al. 1991; Banks and Kastin 1991; Banks et al. 
1989).   
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The second mechanism is activation of receptors on the endothelial walls of capillaries 
forming the blood brain barrier.  The cells of the BBB respond to immune cell-mediated 
activation or lipopolysaccharide by releasing cytokine.  This process can be initiated from 
either direction (Verma et al. 2006).  The circumventricular organs (CVO), which include the 
pineal gland and posterior pituitary are located close to the ventricles and do not have a 
complete blood brain barrier (Gross 1992).  This enables the direct secretion of hormones into 
the blood stream (Peruzzo et al. 2000).   Any cytokines crossing here from the blood stream 
cannot proceed to the brain due to the protection of specialised cells called tanycytes (ibid) 
located in the ventricular walls. The cytokines instead interact with neural projections 
connecting these areas with other parts of the brain (Banks and Erickson 2010). 
The consequence of these interactions of cytokines with receptors in these regions would be 
the release of prostaglandins, cytokines and other mediators into the central nervous system 
using a mechanism whereby a relatively small quantity of blood borne cytokine could be 
amplified to provide a strong signal.   
While there is evidence to support all these mechanisms of communication there is also 
evidence that suggests that their reliance on blood borne cytokine communication is unlikely 
to be the predominant method of communication.    
Maier et al. (1998) propose that the predominant communication pathway between the 
immune response and the central nervous system is via the vagus nerve. The vagus innervates 
widely including lymph nodes and tissues involved in the immune response, it also terminates 
in the nucleus tractus solitarius in the brainstem, an area that is highly involved in the ‘sick 
response’.  Sub-diaphragmatic vagotomy has been used to demonstrate that this is a key 
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pathway for immune-brain communication and Maier et al. point out that cytokines are also 
known to signal via the activation of other nerves.   
2.2.5 Supraspinal modulation of pain and links with mood 
Pain signals are not only subject to modulation from within the dorsal horn but are also 
influenced by feedback via the descending pathways. Descending influences on pain are both 
facilitatory and inhibitory and the degree of pain experienced depends on the balance between 
the two. Many of the substrates and pathways involved in supraspinal facilitation and 
inhibition of pain are also involved in the mediation of anxiety, depression and stress and 
therefore this section will combine a discussion of the processes of both to highlight where 
interaction occurs.   
There are three key brainstem centres that are of concern for descending modulation of pain; 
the periaqueductal grey (PAG), the rostroventral medulla (RVM) and the locus coeruleus 
(LC).  Persistent tissue injury leads to excitation of the descending modulatory systems, both 
facilitatory and inhibitory (Miki et al. 2002).   
The PAG is situated in the midbrain. It receives nociceptive input and facilitates pain-related 
behaviours, cardiovascular changes (Dostrovsky and Craig 2006), anti-nociceptive pain 
modulation (Millan 2002) and opioid tolerance (Tortorici et al. 2009; Tortorici et al. 2001).  
The PAG receives inputs from a number of supraspinal sites including the hypothalamus, 
limbic system and amygdala, and the anterior cingulate cortex.  These connections facilitate 
the integration of autonomic, affective and cognitive information with nociceptive 
information (Millan 2002).  
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The PAG projects to the RVM and the LC.  The RVM also receives extensive input from 
other supraspinal structures enabling integrate autonomic and sensory information (Millan 
2002).   The RVM is rich in serotonergic cells and projects direct to the dorsal horn.  The LC 
is rich in noradrenergic cells and also projects to the dorsal horn.  
2.2.5.1 Pain, mood and 5-hydoxytryptamine  
The RVM contains the Nucleus Raphe Magnus (NRM), an area rich in serotonergic (5-HT 
producing) cells (Hentall et al. 2006).  The cells contained within this structure include so-
called On-cells, off-cells and neutral cells.  The on-cells have a facilitatory effect on pain 
processing via descending pathways connecting with the dorsal horn, and their activity can be 
depressed by opioids.  Off-cells have an inhibitory effect.  Active discharge of RVM on-cells 
is required to sustain allodynia and injection of local anaesthetic into this area leads to a 
reversal of these symptoms (Ossipov et al. 2000).   
5-HT fibres project to the dorsal horn from the RVM and synapse with neurons within the 
dorsal horn, predominantly in the superficial laminae (Mason 2001; Calejesan et al. 1998; 
Aimone et al. 1987) and via secondary connections have influence over the cells in the deeper 
dorsal horn (Heinricher et al. 2009).  5-HT contributes to pain inhibition via activation of 
spinal receptors on inhibitory interneurons leading to the release of gamma amino butyric acid 
(GABA). 
Increasing the availability of 5-HT by use of re-uptake inhibitors such as the tricyclic 
antidepressants and serotonin and noradrenaline re-uptake inhibitors has a long-recognised 
role in the management of pain, initially focused on  neuropathic pain (Saarto and Wiffen 
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2007) but now also being explored in other types of pain including OA (Citrome and Weiss-
Citrome 2012). The use of these drugs is associated both with pain relief and alleviation of 
low mood (Demyttenaere et al. 2012; Hegerl et al. 2012).   
The role of 5-HT in anxiety, stress and depression is mediated via the hypothalamic pituitary 
adrenal (HPA) axis.  Acute stress is associated with analgesia because it increases activity of 
5-HT neurons (Abbott et al. 1986). However, stress can also have the opposite effect due to 
corticotropic releasing factor mediated inhibition of the 5-HT producing neurons (Kirby et al. 
2008; Price et al. 2002; Kirby et al. 1995).   
The level of 5-HT in the CNS is dependent on the level of tryptophan, from which it is 
synthesised.  Tryptophan is actively transported across the blood brain barrier in a quantity 
dependent on its serum concentration relative to the concentration of other large neutral amino 
acids in the blood that compete for the same transport system (Frazer et al. 1999).  These 
amino acids, (including tyrosine, phenylalanine, valine, leucine and isoleucine), outnumber 
tryptophan by approximately 8:1 (Baumann 1985). The ratio of tryptophan to these competing 
amino acids has been shown to be lower in severe depression than in normal subjects or those 
with minor depression (Maes et al. 1993).  A reduced ratio will lead to reduction in the central 
availability of tryptophan for metabolism to serotonin.  This has led to some efforts to use 
tryptophan supplementation as a pain-relieving agent with equivocal results (Ceccherelli et al. 
1991; Ekblom et al. 1991; Stockstill et al. 1989; Seltzer et al. 1982).   
Another way in which 5-HT availability is reduced in the CNS is by pro-inflammatory 
cytokine mediated switch from the manufacture of 5-HT from tryptophan to the manufacture 
instead of quinolinic acid (QA) (Muller and Schwarz 2007).  One of the factors that is known 
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to influence this process is depression – which is associated with both an increase in the 
concentrations of pro-inflammatory cytokines and the preference for the kynurenine pathway 
(leading to the production of QA) (Laugeray et al. 2010; Swardfager et al. 2009; Miller et al. 
2008; Myint et al. 2007).  Increased levels of cytokine-induced QA are associated with higher 
levels of depression (Raison et al. 2010).  Pro-inflammatory cytokines also enhance 5-HT 
transporter function whereas IL-4, an anti-inflammatory cytokine, decreases 5-HT uptake 
(Mossner et al. 2001) and so cytokine activity in the CNS can affect 5-HT availability in a 
number of ways. 
2.2.5.2 Pain, mood and noradrenaline 
The locus coeruleus (LC) is part of the pons and produces noradrenalin (NA) in response 
activation by acute pain signalling from the dorsal horn (Jones 1991).  It connects extensively 
to other supraspinal regions and receives input from the PAG.  Descending NA pathways to 
the dorsal horn from the LC reduce pain (Jones and Gebhart 1988) by activating α1 receptors 
on interneurons to release GABA and glycine (Gassner et al. 2009; Baba et al. 2000).  NA 
also acts by volume transmission on α2 adrenoreceptors, which are found mainly on terminals 
of primary afferent fibres and projection neurons mainly in laminas I and II of the dorsal horn 
(Pertovaara 2006; Millan 2002; North and Yoshimura 1984).  NA leads to pain reduction via 
α2 adrenoreceptors by hyper-polarisation (North and Yoshimura 1984), depressing the release 
of Substance P (Kuraishi et al. 1985) and glutamate (Pan et al. 2002; Ueda et al. 1995).    
Stress and depression increase levels of corticotrophin releasing factor (CRF) in the CNS 
(Hauger et al. 2009) including the LC and this stimulates increased production of noradrenalin 
(NA) released into the cortex (Curtis et al. 1997).  NA in turn stimulates the increased release 
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of CRF (Chrousos 1998).  This suggests that stress will lead to an increase in NA and this has 
been demonstrated in combat veterans with post-traumatic stress disorder who have higher 
levels of CSF NA than healthy normal controls (Geracioti, Jr. et al. 2001) and triggering 
increased stress in these individuals led to an increase in CSF NA (Geracioti, Jr. et al. 2008). 
Wong et al. ( 2000) found CSF NA was elevated around the clock and was closely associated 
with hypercortisolism in people with melancholic depression.  Others have found no 
difference in CSF NA between people with depression and normal controls (Placidi et al. 
2001; Geracioti, Jr. et al. 1997a; Gjerris et al. 1987b).  Acute pain is associated with an 
increase in CSF NA (Eisenach et al. 1996) but not low back pain (Hyyppa et al. 1985) or 
trigeminal facial pain (Bouckoms et al. 1992).  There has been one report of CSF NA being 
elevated in chronic pain which correlated with the duration of the pain but did not correlate 
with pain intensity or depression (Strittmatter et al. 2005).   
The interpretation of NA levels is complicated. Although NA has an inhibitory effect via its 
interaction with primary afferent fibres and interneurons in the dorsal horn, and therefore 
increased CSF levels of NA might suggest pain inhibition, it can have a facilitatory effect via 
α1 adrenoreceptors in the dorsal reticular nucleus, a part of the brain that has a significant role 
in the facilitation of pain (Martins et al. 2010).   
2.2.5.3 Pain, mood, GABA and glycine  
Interneurons are intrinsic cells within the central nervous system and within the dorsal horn 
are described as being excitatory cells (containing glutamate) or inhibitory (containing 
gamma-amino-butyric acid (GABA) and/or glycine) (Todd and Spike 1993).  The knowledge 
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that has accumulated to date about interneurons has mainly been able to detail the inhibitory 
role. Approximately 30% of the interneurons in lamina I and II and 45% in lamina III have 
been shown to contain GABA and are therefore inhibitory (Todd and Sullivan 1990) and it 
has been assumed that all interneurons that are not GABAergic are likely to be glutamatergic 
(Todd and Spike 1993).   
In addition to 5-HT and NA evoked release of GABA and glycine there is also evidence that 
Brain Derived Neurotrophic Factor (BDNF) released from activated glia also stimulates the 
release of these two inhibitory modulators (Bardoni et al. 2007).  BDNF can also lead to a 
reversal in polarity of the GABA and glycine receptors so that in certain conditions (such as 
those produced by neuropathic pain) GABA and glycine have an excitatory effect (Molinaro 
et al. 2008; Coull et al. 2003). 
Glycine and GABA are often co-localised and released in the same vesicles from spinal cord 
interneurones (Jonas et al. 1998) which synapse pre and post-synaptically with neurons in the 
dorsal horn.  Although the two transmitters are often co-released the position of their 
receptors suggests that one or other tends to take the predominant inhibitory role dependent 
on the location (Todd and Koeber 2006).  GABAergic interneurons are located throughout the 
dorsal horn and although glycine is often co-localised with GABA cells positive for this 
neurotransmitter tend to be denser in the deeper laminae (III-IV) (Todd and Lochhead 1990).   
Glycinergic interneurons play a part in the tonic inhibition of pain input through the dorsal 
horn demonstrated by the emergence of pain if their inhibitory function is blocked (Sorkin 
and Puig 1996;Sivilotti and Woolf 1994).  Prostaglandins facilitate pain in this way in the 
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dorsal horn by interfering with glycine receptors and therefore causing disinhibition (Reinold 
et al. 2005; Zeilhofer 2005).   
There have been a number of studies that record a significantly lower level of CSF GABA in 
patients with depression in comparison with a variety of control groups (Vieira et al. 2006; 
Gerner et al. 1984; Kasa et al. 1982; Gerner and Hare 1981; Gold et al. 1980).  Other studies 
have failed to find a significant difference (Roy et al. 1991; Post et al. 1980; Zimmer et al. 
1980) but have observed a trend towards a reduction of GABA.   
2.3 Summary 
Osteoarthritis, up until the relatively recent past, has been considered a disease of wear and 
tear because of a focus on the deterioration of load bearing cartilage.  The pathophysiology of 
OA is being revealed as more complex than this, involving both degeneration and 
regeneration of tissues including but not exclusive to cartilage, bone, synovium and fat.  The 
cartilage, which in health is avascular and without innervation is changed radically by the 
disease process and together with changes in subchondral bone helps to explain the persistent 
pain that develops in OA and seems to get worse over time for many people.  
OA in the periphery involves a number of inflammatory processes like those seen in diseases 
where inflammation is considered a characteristic – for example Rheumatoid Arthritis.  The 
degree of inflammation is greater in Rheumatoid Arthritis but many of the processes are the 
same.  The release of cytokines systemically from inflammatory pains plays as important role 
as peripheral pain is communicated to the dorsal horn not just neurally but also humorally. 
Raised levels of pro-inflammatory cytokines communicate with the CNS by active transport 
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across the blood brain barrier or by interaction with endothelial cells to stimulate induction of 
cytokines within the CNS.  Although this dual mechanism of communication exists it is felt 
that the dominant form of communication is neural. 
Pain signals reaching the dorsal horn trigger the release of excitatory amino acids and 
neuropeptides that diffuse across the synaptic cleft and create excitatory potentials in second 
order neurons and interneurons.  Summation of post-synaptic potentials can lead to the 
development of a suprathreshold potential in the second order neuron which then transmits an 
action potential to higher structures.  In severe or prolonged pain the short term activity of 
glutamate is accompanied by longer term post-synaptic potentials created by the 
neuropeptides, Substance P and CGRP.  Summation to threshold potential is more easily 
achieved due to the longevity of each potential and sustained potential enables an increased 
concentration of intracellular calcium ions which leads to a number of plastic changes in the 
post-synaptic cells.   
Nitric oxide is produced from arginine creating the by-product citrulline (Guo et al. 2007). 
The increase in intracellular calcium also releases a magnesium ion from the NMDA receptor 
channel and thus makes this available for activation.  Nitric oxide produced in the post-
synaptic neuron diffuses to the primary afferent fibre and leads to an increased release of 
glutamate and other excitatory transmitters (Bar et al. 2004;Vetter et al. 2001;Kawamata and 
Omote 1999). Formation of peroxynitrite, (produced in a reaction between superoxide and 
nitric oxide) results from NMDA receptor activation and this inactivates both the glial 
glutamate transporter and glutamine synthetase (Chen et al. 2010) so that synaptic glutamate 
concentrations increase.  This triggers an increased release of serine (Halassa and Haydon 
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2010), IL-β, IL-6 and TNFα  from glia. Serine acts as a co-agonist with glutamate at the 
NMDA receptor leading to a further increase of intracellular Ca
2+
, which facilitates the 
release of arachidonic acid from the cell walls of the post-synaptic neurons.  Increased levels 
of serine increase NMDA receptor activity (Zhang et al. 2001b).     
Synaptic glutamate is taken up from the synapse into glia where it is transformed to glutamine 
and then transported back to the primary afferent fibre and interneurons where it can be 
converted back to glutamate or GABA. 
Pro-inflammatory cytokines such as IL-1β, IL-2, IL-6, IL-7, IL-8, IL-12, IFNγ and TNFα 
work in a coordinated fashion with a degree of redundancy to activate of glial cells, stimulate 
the release of further pro-inflammatory molecules including cytokines and prostaglandin, up-
regulate AMPA receptors, enhance NMDA phosphorylation and disinhibit GABA and 
glycine mediated responses.  The anti-inflammatory cytokines can reverse the actions of the 
pro-inflammatory cytokines but less has been written about the concentrations of these 
molecules in pain models.  
The evidence suggests that central sensitisation will be marked by increased levels of the pro-
inflammatory cytokines, and excitatory amino acids.  It is also likely that this pain state will 
be accompanied by a reduction in the concentration of inhibitory molecules such as GABA, 
glycine and the anti-inflammatory cytokines.   
Pain signals are conducted from the dorsal horn to the brain stem and then the cortex.  Here 
arousal, awareness, and physiological response to pain are initiated.  Simultaneously there is 
an integration of emotion and pain and a bidirectional influence can be seen.  The descending 
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pathways from the brain-stem to the dorsal horn provide a means of both facilitation and 
inhibition of pain signaling and are influenced by the incoming pain signals and by 
supraspinal mood-related changes.    The descending pathways originating in the RVM and 
LC influence the pain experience both by facilitation and inhibition of pain signaling 
pathways in the dorsal horn. Noradrenaline and 5-HT produce direct effects on neurons as 
well as stimulating the release of GABA and glycine. RVM cells demonstrate plasticity in 
response to ongoing stimulation and these changes are important in creating an imbalance 
between facilitation and inhibition in favour of facilitation in ongoing pain conditions.  Input 
from the RVM is also necessary to maintain allodynia.  The PAG and RVM are also subject 
to modulation from cytokines and other transmitters associated with stress and depression and 
so these conditions have an impact on the descending modulation of pain.  
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Chapter 3 The use of cerebrospinal fluid for the study 
of pain in OA 
Cerebrospinal fluid is used by many researchers to explore diseases that affect the central 
nervous system.  In this section the anatomy of CSF flow will be described and the evidence 
for is use in clinical studies will be critically explored.  A number of factors that suggest 
caution is required in interpreting results will be identified. 
Cerebrospinal fluid (CSF) is formed in the choroid plexus of the lateral, third and fourth 
ventricles.  It flows via apertures in the fourth ventricle into the arachnoid space between the 
pia mater and the arachnoid mater.  Here it circulates around the brain and spinal cord (Figure 
3-1).   
Figure 3-1: CSF production and circulation 
 
It is adsorbed into the venous circulation via collections of arachnoid villi named arachnoid 
granulations.  These are finger-like projections of arachnoid mater that protrude into the 
fibrous dura mater and extend into the superior sagittal sinus (Figure 3-2).   
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Figure 3-2: the relationship between arachnoid villi and the superior sagittal sinus (source Wikipedia Commons) 
 
Approximately 140 ml of CSF fills the ventricles, the spinal canal and the subarachnoid 
spaces (Brown et al. 2004).  Constant production of CSF ensures that the total volume is 
replaced approximately four times per day (Wright 1978). 
CSF has several functions.  It is thought that is provides a cushioning effect for the brain 
(Laterra et al. 1999) and reduces its effective weight by approximately 60% (Segal 1993).  By 
displacement, the CSF can mitigate the effects of increased intracranial pressure (Laterra et al. 
1999).    
CSF also provides a source of fluid to the brain in the event of dehydration and is a major 
transport system between neuronal structures for nutrients, hormones, and transmitters 
(Laterra et al. 1999; Johanson 1999).  CSF is in constant communication with interstitial fluid 
in the brain and the spinal cord and therefore it is thought that lumbar fluid contains 
compounds that have been exchanged at the level of the brain and the spinal cord itself. It acts 
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as a drain or sink for the central nervous system, diluting and removing the products of 
metabolism and synaptic activity (Segal 1993).  These functions of CSF have led to it being 
used to study a variety of disorders in the belief that it reflects the synaptic concentrations in 
neurotransmitters.   
3.1 Precedent for the use of CSF in clinical studies 
A wide range of studies have used CSF to reflect the activity of amino acids and cytokines in 
the brain and spinal cord in painful conditions and affective disorders – although never as 
comorbid conditions (Table 3.1).  Critical appraisal of these studies reveals that practices have 
changed considerably since the earliest studies.  Over time research has moved on from 
determination whether a substance of interest is present to identifying changes in 
concentrations of substances related to the presence or absence of a condition.   Improvement 
of ethical standards has also made it increasingly difficult to recruit participants specifically to 
have CSF aspirated without any clinical reason to do so.    
Although some studies have continued to access CSF from small numbers of healthy normal 
control participants it is far more common for control samples to come from people who are 
having spinal anaesthesia or lumbar puncture for clinical reasons (Table 3.2). 
Control conditions in one study are often used as cases in other studies.  An example of this 
can be seen in Alexander’s studies of complex regional pain syndrome (CRPS) (2007; 2005) 
where the control participants had painful conditions such as spondylolisthesis and 
radiculopathy, and neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS).  
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These conditions are likely to produce significant changes in amino acid concentrations 
including glutamate (Shaw et al. 1995; Perry et al. 1990).  
Table 3.1: Clinical studies using CSF to explore painful conditions or affective disorders 
Depression and/or anxiety 
Berrettini  et al ( 1986; 1983; 1982); Bertilsson  et al ( 1982); 
Bridges  et al ( 1976): Frye  et al ( 2006); Geracioti  et al ( 1997b); 
Gerner  et al ( 1984); Gerner and Hare ( 1981); Gjerris  et al ( 1988; 
1987a; 1987b; 1987c); Gold  et al ( 1980); Goodnick  et al ( 1980); 
Honig  et al ( 1988): Kasa et al ( 1982); Levine  et al ( 2000; 1999); 
Roy et al ( 1991; 1988) 
 
CRPS 
 
Alexander et al  ( 2005); Alexander et al ( 2007); Munts et al  ( 
2008) 
 
Idiopathic pain, functional 
pain 
Almay et al ( 1987); Jorgensen et al ( 1993) 
 
Migraine or headaches 
 
Bach et al (1992); Bo et al (2009); Gallai et al (2003); Langemark  
et al ( 1995); Martinez  et al ( 2012; 1993a; 1993b); McGale  et al 
(1977); Rozen et al  (2007); Sarchielli  et al (2001); Sarchielli and 
Gallai (2004); Vieira et al (2006); Welch et al (1975) 
 
Facial pain 
 
Bouckoms et al (1993) 
 
Back pain (idiopathic, disc 
herniation) 
 
Brisby et al (2002); Chan et al  (1992); Garseth et al (2002); 
Hyyppa et al (1985); Kimura et al (1999); McGale et al (1977) 
 
Neuropathic pain (diabetic; 
post-herpetic) 
 
 
Backonja  et al (2008); Chan et al (1992); Kikuchi  et al (1999); 
Kotani et al (2004; 2000): Ludwig et al (2008); Mertens (2000) 
 
Painful labour 
 
Eisenach et al  ( 1996); Hsu et al ( 2001); Olofsson et al ( 1997) 
 
Fibromyalgia 
 
Kadetoff et al (2012); Larson et al ( 2000): Legangneux et al 
(2001); Peres et al ( 2004); Sarchielli et al (2007a; 2007b) 
 
Osteoarthritis Lundborg et al (2010); 
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Table 3.2: Control groups used in clinical amino acid and cytokine studies of CSF 
Healthy volunteers 
Backonja et al  (2008); Jorgensen  et al  
(1993); Kimura et al (2001); Larson et al 
(2000); Olofsson et al (1997) 
Neurological tests - no 
abnormality detected 
 
Bo et al (2009), Gallai et al (2003), Garseth  
et al (2002); Peres  et al (2004) 
Non-inflammatory neurological 
symptoms 
Kadetoff et al (2012) 
Painless polyneuropathy Ludwig  et al (2008); Chan  et al (1992) 
Gynaecological or urological 
surgery 
 
Lundborg  et al (2012) 
 
OA 
 
Munts  et al (2008); Garseth  et al (2002) 
 
Peripheral neuropathy 
 
Alexander  et al (2005; 2007) 
 
Spondylolisthesis 
 
Alexander  et al (2005; 2007) 
 
ALS 
 
Alexander  et al (2005; 2007) 
 
Radiculopathy 
 
Alexander  et al (2005; 2007), Garseth  et al  
(2002) 
 
Pain free surgical patients 
 
Kimura  et al (1999);  Olofsson  et al (1997) 
Elective C-section 
 
Eisenach  et al (1996); Hsu  et al (2001)  
 
3.2 Representation of pain and affective disorder by lumbar CSF  
Where stipulated (and in some cases it could be inferred from other information) it was clear 
that the lumbar spine was the chosen level for access to spinal fluid in all the studies retrieved.  
The lumbar spine is considered to provide the most accessible route by which CSF can be 
collected.   
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Research into affective disorders has a focus on the release and activity of neurotransmitters 
in the brain but CSF from the lumbar spine is used in the expectation that its constituents will 
reflect what is happening in the brain because of its circulatory.  As CSF flows from the brain, 
around the spinal cord and back to the brain, it will collect substances from extracellular fluid; 
there is a free-flow of substances between the two fluid compartments partly dependent on 
diffusion gradients (Veening and Barendregt 2010). Indeed, one of the ways that signalling 
takes place in the brain and spinal cord is via volume transmission using the CSF and 
extracellular fluid (ECF) as a transport system which results both from diffusion of substances 
into the CSF and from release of substances from dendritic terminals that lie within the CSF 
(Vigh-Teichmann and Vigh 1989).  CSF contacting neurons also exist throughout the spine 
lying close to the central canal (Vigh et al. 2004).  It is possible that bioactive substances in 
the CSF can diffuse into the spinal cord and also activate receptors on the spinal CSF 
contacting neurons. These neurons are GABAergic and express P2X2 (ATP) receptors, which 
led Stoeckel et al. to suggest a role in autonomic function.  Although there is a great deal 
more to be discovered about these neurons it remains a theoretical possibility that volume 
transmission from the brain stem to the spinal cord may modulate activity in addition to the 
more direct influence of the descending pathways. 
This mixing of substances of interest can be both a help and a hindrance.  On the one hand 
lumbar CSF will reflect changes in concentrations of substances due to affective disorder and 
pain – even when that pain may have been communicated to segments of the spinal cord some 
distance from the lumbar puncture.  In the case of lower limb surgery the primary afferent 
fibres from the knee enter the spinal cord at between L3 and S2, and those from the hips at L2 
and L4 (Figure 3-3).  There is some overlap in the areas served by each dorsal root with each 
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dermatome being fed by three dorsal roots (Bear et al. 2001).  On entry to the dorsal horn the 
primary afferent fibres branch and travel a short distance both caudally and rostrally in the 
zone of Lissauer before they synapse with the dorsal horn.  In this way neuronal 
communication from the hips and knees takes place close to the site of CSF collection. 
However, there is no guarantee that the changes in the concentrations of substances that are 
being observed are related to the phenomenon being studied – hence the need for as good, 
matched and healthy a control group as possible.   
Despite the mixing effect suggested by the ‘free’ exchange of many substances between CSF 
and ECF, there are known rostro-caudal gradients for some amino acids and monoamines as 
demonstrated for GABA and taurine (Crawford et al. 1988; Perschak et al. 1987; Grove et al. 
1982a; Bohlen et al. 1979).  Reverse gradients have been observed for other amino acids and 
monoamine metabolites (Gjerris et al. 1988; Crawford et al. 1988).  This creates yet more 
noise for the interpretation of CSF constituents. 
In addition to a gradient between ventricular, cervical and lumbar CSF experiments have also 
demonstrated concentration gradients in serial measurements taken from the same subjects 
(Hill et al. 1999a; Blennow et al. 1993).  Thus, in order to make comparisons between 
subjects or groups of subjects the CSF being assayed must be drawn from the same 
anatomical site and be of a similar volume, for example the first 2 ml drawn. 
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Figure 3-3: The dermatomes of the human body (source Wikipedia Commons) 
 
Finally, there is also potentially an effect on CSF constituents of performing the lumbar 
puncture.  The procedure begins with the injection of local anaesthesia to the cutaneous 
tissues and muscles prior to the insertion of a needle into the epidural space, through the dura 
mater and into the sub-dural space.  It is anecdotally reported that anticipation of lumbar 
puncture is anxiety-provoking.  Although there is no direct evidence to support this, research 
exploring the use of sedatives with spinal anaesthesia provides indirect evidence (Kestin et al. 
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1990).  There is however, a body of evidence that the action of lumbar puncture produces a 
physiological stress response in terms of elevation of adrenocorticotrophic hormone (ACTH) 
and cortisol in the plasma of subjects who have undergone a lumbar puncture (Lerner et al. 
2000; Geracioti, Jr. et al. 1999; Petrie et al. 1999; Hill et al. 1999b; Geracioti, Jr. et al. 1997c; 
Chappell et al. 1994; Breier et al. 1988).  The main feature of this stress response is activation 
of the hypothalamic-pituitary-adrenal axis (HPA axis).  One of the results of HPA axis 
activation is an increase in NA release into the dorsal horn, leading to an increase in GABA 
and glycine (Baba et al. 2000).  Thus it is possible that the activity of performing a lumbar 
puncture will lead to increased GABA and glycine in the samples taken.  
3.3 Contamination of CSF 
Collection of CSF requires the disruption of tissues in the back and this causes some bleeding.  
In addition the epidural space contains a venous plexus (Harrison 1999; Parkin and Harrison 
1985) and it is therefore possible that CSF aspirated from a needle puncture may be 
contaminated with cells and plasma.  Although CSF contains proteins the protein 
concentration of blood is between 200 and 400 times higher and proteases in whole blood can 
cause protein degradation in CSF (You et al. 2005), which in turn affects the concentration of 
analytes.  In order to prevent blood contamination of CSF it is necessary to either filter or 
centrifuge the sample immediately after collection.  A number of studies use a centrifuge at 
4 C and 3000G for 10-15 minutes either before or after sample storage to remove cellular 
material from their CSF samples (Alexander et al. 2007; Alexander et al. 2005; Peres et al. 
2004; Sarchielli et al. 2001).  An alternative method is to use a small filter (e.g. 0.22 
micrometre) (Larson et al. 2000).  This size of filter is fine enough to remove particulate 
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matter such as red blood cells and bacteria and enzymes greater than 20 000KDa (Millipore 
2012).   
3.4 Storage of CSF 
The conditions in which the CSF is stored and how it is processed can affect the level of 
amino acids.  Grove et al. (1982a) report ‘normal’ concentrations of GABA taken from a 
variety of studies to be between 87 picomole (pmol) ml
-1
 and 534 pmol ml
-1
 .  This wide 
variation is partly because GABA does vary between individuals (Hare et al. 1981; Bohlen et 
al. 1978) but also because enzymatic activity in the sample degrades GABA conjugates such 
as homocarnosine to their its constituents (Grove et al. 1982b).   
Freezing the samples at -20
o
C or -80
o
C may arrest the process of degradation but it begins 
again as soon as the sample is thawed (Grove et al. 1982a).  Abbott et al. (1981) describe 
large increases in GABA concentration relating to freeze-thaw cycles, proposing that this is a 
result of the process of freezing and thawing but Ferraro et al. (Ferraro et al. 1983) found no 
increase in GABA in a similar experiment.  Both Grove et al. (Grove et al. 1982a) and Ferraro  
et al. (1983) suggest that it is the assay technique employed by Abbott  et al. ( 1981) that led 
to the GABA increase.   
Acid precipitation has been used on CSF samples to arrest enzymatic degradation of the 
sample and to precipitate out protein that would otherwise reduce the efficiency of the assay 
process.  Acids such as sulphosalicylic acid (SSA) and trichloroacetic acid (TCA) are used 
and these have been blamed for hydrolysis of GABA conjugates leading to falsely high 
GABA concentrations (Perry et al. 1982; Grossman et al. 1980).  This effect has not been 
62 
 
observed by others using acid precipitation (Ferraro et al. 1983; Grove et al. 1982b). 
However, Grossman et al. (1980) assayed homocarnosine and GABA in a standard acidified 
solution of homocarnosine that was divided into two aliquots, one stored at -20
o
C and one left 
at room temperature.  GABA and histidine increased by up to 22-fold in the sample stored at -
20
o
C and by 1.7 fold in the sample stored at room temperature.  This suggests that the 
combination of storage temperature and acidification does have an effect on degradation of 
homocarnosine but there is no explanation as to why lower temperature would increase the 
degradation.   
Ferraro et al. (1983) hypothesise that the large increase in GABA observed by Perry  et al. ( 
1982) is related to the length of time that the CSF sample was subjected to temperatures 
above room temperature during the assay technique rather than hydrolysis of homocarnosine 
by acidification.  However, Ferraro et al. (1983) identify a positive correlation between 
GABA concentration and the concentration of SSA added to the sample.  Similarly glutamate 
is known to increase in acidified samples (Csernansky et al. 1996), an effect that can be 
counteracted when the acidified sample is subjected to immediate neutralisation (Aliprandi et 
al. 2002; Ferrarese et al. 1993).  
There is a great deal of evidence to support the relationship between GABA increase and 
sample temperature.  Samples left at room temperature for up to forty-eight hours yielded an 
increase in GABA of between 400 and 900% of the original value (Grossman et al. 1980; 
Bohlen et al. 1978).  Similarly glutamate increases by as much as 50% as a result of 
degradation of glutamine at room temperature (Ferrarese et al. 1993). However, when Perry et 
al. (1982) added radiolabeled homocarnosine to CSF and allowed the sample to stand at room 
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temperature for four hours in an attempt to experimentally replicate this finding, they did not 
find any radiolabeled GABA.  The likely reason for this is that the degradation takes place 
slowly.   Storage of samples at -70
o
C, whether treated or untreated, arrests enzymatic 
degradation.  Glutamate stability has been demonstrated for up to two years (Espey et al. 
2002) and GABA stability of untreated samples has been demonstrated at temperatures of -
20
o
C and -80
o
C for up to eleven months (Grossman et al. 1980).  However, acidified samples 
stored at -20
o
C were not stable.   
3.5 Risks to participants of CSF withdrawal in clinical studies 
There are a number of risks associated with lumbar puncture including post-dural puncture 
headache, infection or damage to neural structures (see below).  These risks were explained to 
the potential participants by the anaesthetists who were taking consent for their interventions.  
3.5.1 Post-dural puncture headache 
The incidence of post-dural puncture headache for women in labour, a group said to have the 
highest risk (Gosch et al. 2005), is thought to be between 1.5 and 11%  (Choi et al. 2003). The 
risk of inducing a post-dural puncture headache increases with female gender and young age 
but the most important factors are the outer diameter of the needle used and the shape of the 
bevel (Halpern and Preston 1994).  The incidence of headache varies according to the type of 
needle used, and the position of the needle as it is introduced through the dura.  Larger gauge 
needles are associated with a higher incidence of headache (Turnbull and Shepherd 2003; 
Choi et al. 2003; Halpern and Preston 1994) but there is a lower limit on gauge because 
needles smaller than 29 Gauge are said to lead to failure of the anaesthetic (Turnbull and 
Shepherd 2003).  Hatfalvi ( 1995) advocates an angled approach to the dura rather than 
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perpendicular and observed that following this advice reduced the rate of dural punctures he 
caused to zero.   
Post dural puncture headache is attributed to continued leakage of CSF from the flap made in 
the collagenous dura mater by the passage of the needle.  The rate of loss of CSF through the 
perforation is said to be greater than the rate of production of CSF (0.084 – 4.5 ml s-1 
compared with 0.35 ml min
-1
) (Turnbull and Shepherd 2003).  Two theories are proposed for 
the genesis of a headache because of this persistent leakage.  One theory is that the lowering 
the CSF pressure causes a tension on neural structures, which produces pain.  The alternative 
theory is that the volume of the blood, CSF and brain is maintained as a constant, therefore 
loss of CSF will lead to venous dilation to maintain the volume of the system and this 
produces headache (Turnbull and Shepherd 2003).  The headache is reported to worsen when 
the person sits or stands and reduces in intensity when the person lies down, as the pressure of 
the CSF reduces.   
Dural puncture headache is not inevitable and the removal of up to 34 ml of CSF at a time 
from patients in a study where 342 subjects underwent a total of 428 lumbar punctures led to 
headache in only 0.97% of cases (Peskind et al. 2005).  There was no relationship between the 
volume of CSF taken and the likelihood of post-dural puncture headache.  The headache was 
also not affected by the position of the patient during the lumbar puncture, nor by the length 
of time that the patient spent recumbent after the procedure.  This information can be 
provided to reassure potential participants. 
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3.5.2 Neurological complications and infection 
Introduction of a needle into the subdural space can cause direct trauma to the nerve roots and 
this will be experienced by the patient as paraesthesia, numbness, weakness or persistent pain.  
Reports of the incidence of these effects vary and sometimes attribution is difficult when 
positioning, application of dressings and casts and surgery itself might have contributed to 
post-operative complications (Horlocker et al. 1997).  The most up-to-date evidence available 
is from Horlocker et al. (1997) whose retrospective review of more than 4500 spinal 
anaesthetic procedures identified an incidence of 0.13% for persistent paraesthesia.   
Infection following spinal anaesthesia is often reported in case studies (Huang et al. 
2005;Donnelly et al. 1998;Schmutzhard et al. 1986).  A review reports the incidence as 
between 1 in 1 000 and 1 in 100 000 (Grewal et al. 2006); it is considerably less than this in 
the Horlocker series.  
3.6 Summary 
CSF is widely used to explore diseases and processes that affect or are signalled via the 
central nervous system.  CSF circulation arguably creates a fluid that represents activity at all 
levels of the spinal cord and brain but there is limited evidence available to substantiate this.  
The collection of CSF in clinical studies relies upon collection from the lumbar spine.  There 
is some evidence that collection of fluid from other levels of the spinal cord or from the 
ventricles themselves may provide different results.  However, the use of well-matched 
control participants can help the interpretation of the data collected provided that known 
confounding factors are addressed. The collection of CSF in clinical trials carries some risks 
for participants and in the UK at least participants are recruited from populations that are 
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already allowing access to the subdural space for a clinical purpose.  This has the effect of 
creating potential populations of control participants but does not facilitate good matching 
with cases. 
Storage and processing of CSF can also have an influence over the results obtained in assays. 
CSF samples must be frozen after collection and  either before or after freezing they should be 
subject to filtration to remove particulate contamination by red blood cells and enzymes that 
may degrade the substrates of interest.  In addition to filtration some researchers also use acid 
additives to precipitate out proteins but this has been associated with alteration in glutamate 
and GABA levels. In order to prevent degradation of samples prior to analysis they must be 
stored at low temperatures (<20 C) and must not be left at room temperature during the 
analysis process.  
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Chapter 4 The management of osteoarthritis  
A number of guidelines have been produced that serve to bring together myriad research 
findings and perspectives on the most appropriate and effective management of OA. The 
Osteoarthritis Research International (OARSI) group was formed in 2005 with the purpose of 
arriving at an international multidisciplinary consensus agreement for recommended 
management of OA (Zhang et al. 2008b).  There followed a systematic review of existing 
guidelines and the development, and subsequent updating of evidence based management 
guidelines (Zhang et al. 2010b).   
The EULAR (European League Against Rheumatism) Standing Committee for International 
Clinical Studies including Therapeutic Trials (ESCISIT) has also published consensus 
statements on the management of knee osteoarthritis (Jordan et al. 2003) based on expert 
opinion and systematic review of the evidence.  These guidelines recommend an 
individualised and multifaceted approach to OA management.  In 2008 the National Institute 
for Clinical Excellence (NICE) also published evidence based guidelines for the management 
of OA (NICE 2008).  NICE ( 2008) recognise that each individual will have their own 
preferences in terms of how to adopt recommended practices such as following an exercise 
programme and managing their weight.  It is important that the individual has sufficient 
information to enable them to understand their condition, to follow healthy behaviours and to 
provide informed consent when that is appropriate.  The NICE guidance is exceptional in the 
attention given within the document to concordance and pragmatism. Although there are some 
differences in the material reviewed to produce the guidelines and in some of the detail, 
broadly all the guidelines make similar recommendations (Table 4.1)
68 
 
Table 4.1: Summary of guidelines for the management of OA 
Strategy   Aim Comments 
Education/information  Improve concordance. 
Improve healthy behaviour. 
Facilitate self-management. 
Facilitate informed consent. 
Information is only helpful when it is wanted and delivered in a 
usable way to the individual. 
Education can be delivered individually or in groups, face to face 
or by telephone.  Education for carers/partners can also be 
useful. 
Exercise  Improve muscle strength and aerobic 
fitness. 
Improve pain, function and gait. 
Improve post-operative recovery time. 
Can be delivered in a group or solo, at home or in a health care 
setting. 
Uncertainty about utility of water based exercise. 
Weight reduction ? Decrease joint loading. 
Decrease systemic inflammatory 
markers. 
General health benefits. 
Limited evidence of benefit of weight loss for slowing 
progression of OA or decreasing pain.  Combined with 
exercise weight loss improves pain. 
TENS ? Pain relief 
Improvement in knee stiffness. 
Some benefit in the short term has been demonstrated. 
Requires good patient education. 
Acupuncture ? Pain relief. Some short term benefits.  Electro-acupuncture is not 
recommended by NICE. 
Electromagnetic 
therapy 
X Pain relief. Not recommended, no proven benefit. 
Glucosamine  X Pain relief. 
Reduction in stiffness. 
Modest benefit over placebo in knee pain.  Relatively safe but 
costly.  Not recommended. 
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Chondroitin sulphate ? Reduced disease progression Poor evidence but possible benefit 
Anti-resorptive bone 
acting agents (e.g.   
X Reduced disease progression No evidence of benefit in OA. 
Paracetamol  Pain relief Recommended. 
Relatively safe profile. 
Topical NSAIDS  Pain relief Recommended after or in addition to Paracetamol. 
Better safety profile than oral NSAIDS 
Oral NSAIDS or cox-2 
selective anti-
inflammatories. 
 Pain relief Recommended if Paracetamol ± topical NSAIDs is not 
sufficient. 
Caution required due to side effects. 
Proton pump inhibitors recommended to be used in conjunction 
with NSAIDS. 
Opioids  Pain relief Can be very helpful but benefits often limited by side effects.  
Some concerns over tolerance and addiction with long term 
use. 
Intra-articular steroids ? 
X 
Pain relief 
Reduced stiffness 
Good short term relief but less beneficial over the longer term 
and probable diminishing benefits over the long-term. 
Intra-articular 
hyaluronic acid 
X 
X 
X 
Pain relief 
Improved physical function 
Reduced stiffness 
Not recommended although there is a small benefit and further 
research is called for.   
Arthroscopic 
lavage/debrideme
nt 
X 
X 
X 
Pain relief 
Improved physical function 
Reduced stiffness 
Not recommended unless the person has a history of mechanical 
locking. 
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4.1 Non-pharmacological management of OA pain 
Transcutaneous Electrical Nerve Stimulation (TENS) is thought to be an effective pain 
reliever in osteoarthritis (Aiyejusunle et al. 2007; Bjordal et al. 2007) and can be an effective 
adjunct to physiotherapy, adding to improvements in physical function (Cheing and Hui-Chan 
2004).  However, the strength of evidence for TENS efficacy in OA is poor and more robust 
studies are called for (Rutjes et al. 2009).   
Acupuncture is also helpful in pain management and facilitating a functional improvement 
when used alone or in conjunction with other therapies such as TENS (Itoh et al. 2008) but 
again there are studies that demonstrate that acupuncture is no better than placebo (Suarez-
Almazor et al. 2010) or that the benefits are small but clinically insignificant (Manheimer et 
al. 2010).   
The OARSI guidelines for the management of OA based on systematic review (Zhang et al. 
2010b) gives acupuncture a number needed to treat of 4 (95% confidence interval 3 to 9) 
meaning that for every four people treated with acupuncture one will obtain symptomatic 
relief.  The NNT for TENS was calculated to be 2 (95% confidence interval 1 to 5).  Although 
the evidence for both TENS and acupuncture is equivocal both are included in management 
guidelines for OA. 
Medical management of OA also includes exercise therapy in the form of aerobic, water-
based or strengthening exercises and all have been shown to be beneficial in terms of pain 
relief and also improved function (Pisters et al. 2010a; Pisters et al. 2010b; Hernandez-Molina 
et al. 2008; Bartels et al. 2007; Roddy et al. 2005).  Physical activity can also help to preserve 
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muscle strength, which can have a positive influence on post-operative recovery in those who 
have arthroplasty (Topp et al. 2009; Roder et al. 2007). In conjunction with this people with 
OA are encouraged to reduce weight if this is appropriate.  A reduction of 5% in body weight 
can reduce physical disability and sometimes but not always pain (Christensen et al. 2007).   
4.2 Pharmacological management of OA pain 
The guidelines for the management of OA pain (NICE 2008;Zhang et al. 2005;Jordan et al. 
2003) (Table 4.1) advise that all patients use paracetamol or topical NSAIDS as the first 
choice analgesic; the rationale for this is that it these drugs are relatively safe and have proven 
efficacy (Towheed et al. 2006; Wegman et al. 2004; Mason et al. 2004).  The benefits of 
topical NSAIDS are well established and adverse events and risks associated with these 
preparations are smaller than their oral counterparts but there is less evidence of their benefit 
beyond a few weeks use (NICE 2008).   
Oral NSAIDs are the second line recommendation for the medical management of OA.  
Concerns about the of NSAIDs safety (see below) have led to their use being restricted. It is 
estimated that approximately 10-20% of all patients who take NSAIDS experience dyspepsia 
and the risk of serious gastric complications (Wolfe et al. 1999).  The development of cyclo-
oxygenase-2 selective anti-inflammatories was initially heralded as a means to increase the 
number of people who could benefit from the pain relieving effects of NSAIDS due to the 
lower incidence of gastro-intestinal effects with these drugs (Laine et al. 2007;Hawkey et al. 
2004; Hawkey and Skelly 2002).  However, there is an increased risk of cardiovascular events 
with non-selective NSAIDs especially when used in the long-term (Cannon et al. 2006; 
McGettigan and Henry 2006; Hernandez-Diaz et al. 2006; Garcia Rodriguez and Gonzalez-
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Perez 2005).  Known risk factors for adverse events include older age, previous history of 
gastric bleeding and concurrent use of other anti-inflammatory drugs including low-dose 
aspirin (Lanas et al. 2010; Gonzalez et al. 2010).  Unfortunately people who suffer from 
symptomatic OA often fall into the higher risk categories for either gastric or cardiovascular 
risk or both. There is also evidence that the anti-platelet effects of low dose aspirin are 
disrupted by some NSAIDS such as ibuprofen and naproxen (White 2007), and this suggests 
that the use of NSAIDs by those who are in the high risks groups needs careful management.  
The guidelines recommend that proton pump inhibitors are prescribed with NSAIDS and cox-
2 inhibitors (NICE 2008). 
Tramadol is considered a ‘weak’ opioid and is recommended for OA pain management 
(Schug 2007; Zhang et al. 2005; Jordan et al. 2003).  Its use has been somewhat limited by the 
side effects of nausea, vomiting, dizziness, somnolence and changes in bowel habits (NICE 
2008; Avouac et al. 2007; Babul et al. 2004) but slow titration to the optimal dose has been 
shown to limit the incidence of side effects and improve compliance (Ruoff 1999; Petrone et 
al. 1999).  Tramadol seems to be effective for the partial relief of OA pain with up to 12.5% 
pain relief reported in a meta-analysis of studies relating to OA pain (Cepeda et al. 2007).  
One study has also demonstrated a concurrent improvement in pain-related sleep disturbance 
in people with OA (Florete et al. 2008). 
The use of ‘strong’ opioids such as morphine in the control of long-term non-malignant pain 
is relatively newly explored.  There is widespread acceptance that these drugs can be useful in 
the control of pain when Paracetamol and NSAIDS are insufficient, but there is also a fear 
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about prescribing them because of the potential for dependency, tolerance and addiction 
(Belgrade et al. 2006) as well as a relatively high incidence of side effects.   
The side effects of long-term opioid use include constipation, drowsiness, difficulty in 
concentrating, lack of energy and nausea and are generally dose dependent (Wirz et al. 2008; 
Holzer 2008; Giacomuzzi et al. 2005; Kerr et al. 1991).  Side effects and risks of opioid use 
may be increased in older people who have co-morbid conditions and may be taking a number 
of medications (Smith and Bruckenthal 2010). Side effects limit the usefulness of opioids for 
long-term management of pain, decreasing the maximum tolerable dose and contributing to 
reduction in quality of life (Manchikanti et al. 2009; Noble et al. 2008; Jensen et al. 2006).   
Both the British Pain Society (BPS) and the European Federation of Chapters (EFIC) of the 
International Association for the Study of Pain (IASP) recognise the risk to pain sufferers of 
addiction in the long-term opioid use and have prepared guidelines for clinicians (British Pain 
Society 2005; Kalso et al. 2003), which advise careful assessment and close monitoring while 
recognising that opioids can be useful.   
Long term use of opioids is also limited by tolerance; the need for escalating doses of the drug 
to achieve a constant effect.   There is evidence that the development of tolerance begins 
almost immediately that morphine is given (Snijdelaar et al. 2004).  However, a number of 
studies have observed gradual and acceptable increases in morphine dosage, which are not 
explained by the development of tolerance (Jensen et al. 2006; Cowan et al. 2002; Roth et al. 
2000; Portenoy and Foley 1986).  In long-term users of opioids it has been discovered that 
reducing, stopping or switching the drug, with the necessary physical and psychological 
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support leads to an improvement in pain (Aurilio et al. 2009; Mitra 2008; Baron and 
McDonald 2006).   
It has also been reported that people with co-morbid pain and anxiety or depression get less 
analgesic benefit from opioids than others (Riley and Hastie 2008).  These factors taken 
together demonstrate that while opioids have a place in the long term management of OA pain 
they are not a panacea and their usefulness is tempered by some limitations and side effects. 
4.3 Joint replacement for OA 
4.3.1 Criteria for joint replacement 
The NICE guidelines (2008) state that approximately 120 000 hip and knee replacements are 
carried out each year for people whose pain and loss of function prevents them from carrying 
out everyday activities and disrupts their sleep.  The main criteria for surgery for which there 
appears to be a consensus are pain, loss of function and radiographic changes (Toronto 
Arthroplasty Research Writing Group 2011; Dreinhofer et al. 2006; National Institutes for 
Health 2004; National Institutes for Health 1995).  The threshold at which surgery is 
considered varies considerably with some believing for example that the presence of rest pain 
and night pain being present on at least one day per week was sufficient indication for surgery 
and others believing that these symptoms had to be troublesome most nights of the week  
(Dreinhofer et al. 2006).  In the same survey more physicians than surgeons considered 
functional restrictions such as climbing stairs and putting on socks relevant.  Walking distance 
was important to both physicians and surgeons but the level of restriction was different with 
surgeons tending to define this as <1km and physicians as <0.5km.   
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4.3.2 Outcomes and expectations of surgery 
Many people with OA have high expectations of joint replacement surgery.  Most expect that 
they will have no pain or a significant improvement in pain after their initial recovery period 
(Mannion et al. 2009; Lingard et al. 2006; Mancuso et al. 1997) as well as improvements in 
walking, psychological state and ability to perform activities (Mannion et al. 2009; Mancuso 
et al. 1997).  Having a number of realistic expectations from surgery is associated with an 
increased likelihood of improvement post-operatively (Judge et al. 2011; Becker et al. 2011).  
The sort of expectations that have this positive effect are functional (e.g. walking further, 
household chores, exercise, driving,  normal/improved sex life), or pain-related (e.g. having 
less pain, being pain free, being able to perform certain activities without pain).  
Improvement after surgery is often measured in terms of pain relief and functional ability.  
Equally important is the patient’s satisfaction with the surgery outcome and it is 
recommended that the outcome from surgery takes this into consideration (Becker et al. 
2011).  Additionally patients have concerns about participation issues such as their 
relationships with others, the part they are able to play in their community and specific issues 
that are not covered in the most commonly used outcome measures like ability to drive 
(Alviar et al. 2011).  
4.3.3 Factors influencing outcome of total hip or knee arthroplasty 
The surgery is considered relatively low risk with a relatively brief recovery period of 6-12 
weeks and the prospect of returning to moderate levels of activity such as playing golf, tennis 
and swimming (NICE 2008).  The majority of published studies with follow up ranging from 
a few months to many years document functional improvements following both hip and knee 
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replacement surgery (Becker et al. 2011; Xie et al. 2010; Thomasson et al. 2009).  However, 
there are number of factors reported that can affect functional outcome including age, gender, 
obesity, and social deprivation.    
4.3.3.1 The effect of age on outcome of hip or knee arthroplasty 
Performing surgery on younger and fitter patients can carry a risk that due to higher post-
operative activity levels there will be an increased risk of revision being required but survival 
of the prosthesis without revision generally seems high and many studies report greater than 
90% survival without revision at 8+ years (de Kam et al. 2010; Ritter et al. 2007; Duffy et al. 
2007; Crowder et al. 2005).   On the other hand, operating on older, less fit people who have 
greater functional restrictions and more pain as measured by the Western Ontario and 
McMasters Universities Osteoarthritis Index (WOMAC) (Bellamy et al. 1988) is associated 
with poorer outcomes in terms of pain and function (Chang et al. 2010).  Determining the 
influence of old age on outcome of surgery is complex because the presence of co-morbidities 
that can affect outcome measures such as walking restriction (Thomasson et al. 2009).  In 
patient’s aged 61-74 years the gain in Quality Adjusted Life Years (QALYs) was found to be 
an average of 4.59 giving a cost per QALY of 1795 Euros in a European study (Krummenauer 
et al. 2009), the same cost/QALY as pre-hospital thrombolysis therapy administered by 
paramedics for STEMI patients (Scuffham and Tippett 2008) 
4.3.3.2 The effect of gender on outcome of arthroplasty 
There are reports that women tend to have poorer outcomes than men (Singh et al. 
2008;Holtzman et al. 2002) with speculation that this may be mediated by greater levels of 
arthritis helplessness (Gandhi et al. 2009), worse pain and function pre-operatively (Holtzman 
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et al. 2002) or anatomical differences between the genders (Johnson et al. 2011).  The 
evidence suggests that women improve as much as men post-operatively when pre-operative 
differences are taken into account (Johnson et al. 2011; Lavernia et al. 2011; Lin et al. 2009; 
Gandhi et al. 2009).  
4.3.3.3 The effect of obesity on outcome of arthroplasty 
Obesity represents an increased risk for the need for arthroplasty (Bourne et al. 2007; Harms 
et al. 2007; de Guia et al. 2006).  There is a great deal of published research about whether 
obesity affects the outcome of hip and knee replacements with both neutral and negative 
findings being abundant.  A recent meta-analysis (Haverkamp et al. 2011) of fifteen studies of 
hip arthroplasty found that septic (but not aseptic) loosening was more common in the obese 
patient, as was early infection and venous thromboembolism.  Dislocation was also more 
common in obese people.  This meta-analysis was unable to draw any conclusions about 
whether there was any difference in terms of pain, function or participation.   
The outcomes seem to be similar in total knee arthroplasty; patients are reported to make the 
same or greater gains than those of normal weight in terms of function (Rajgopal et al. 2008; 
Hamoui et al. 2006) and quality of life (McQueen et al. 2007).  Post-operative infection has 
been reported as being a higher risk in the morbidly obese (Jarvenpaa et al. 2010; Namba et 
al. 2005) and also not occurring with any greater frequency than on those of normal weight 
(Amin et al. 2006).  Further there is some suggestion that although eventual outcomes, or 
improvements are the same for both normal weight and obese patients those gains are less 
efficient and come at a higher clinical cost for the obese patient who may require more drugs 
and more therapy service input (Vincent and Vincent 2008; Vincent et al. 2007). 
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4.3.3.4 Socioeconomic factors affecting outcome of arthroplasty 
People who are socially deprived tend to undergo arthroplasty earlier than those who are not.  
They also have a greater number of co-morbidities and worse symptoms (Clement et al. 2011; 
Davis et al. 2006; Ackerman et al. 2005).  The suggestion is that this group of people is 
probably under-represented in terms of the numbers being offered surgery.  There is debate 
about whether social deprivation is associated with poorer outcome of surgery.  Clement et al 
(2011) found that the deprived had a worse outcome in terms of pain and function and are less 
satisfied with the outcome of their surgery when compared with their more affluent peers.  
However, Davis et al. ( 2008) found that there was no difference in outcome, in fact their 
gains appeared to be greater because they began with worse pre-operative WOMAC scores 
and ended up with similar scores at the two year follow up point.   
4.3.3.5 The effect of delaying surgery 
There is conflicting evidence about whether people once listed for surgery experience any 
significant deterioration in pain or function.  Some studies report observable deterioration 
over a 6 to 9 month period (Desmeules et al. 2010; Chakravarty et al. 2005) while others do 
not (Hoogeboom et al. 2009; Kelly et al. 2001).   
Economic benefits of shorter waiting time for surgery have been noted (Saleh et al. 
1999;Saleh et al. 1997).  However, historically the operation has been delayed for as long as 
possible (Crawford and Murray 1997), probably due to a perception that prostheses have a 
limited life span.  The durability of hip and knee replacements is said to be improving due to 
increased understanding of the mechanical and patient-related factors that affect it (Walker et 
al. 2010).  Survivorship of the unrevised total knee prosthesis is currently greater than 80% at 
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15-17 years (Parratte et al. 2010; Rand et al. 2003) and up to 90% for total hip replacements 
(Callaghan et al. 2008) although there are a number of factors that can affect this including the 
prosthesis used and the manner of the replacement.   
Delaying surgery can mean that the OA sufferer is in poorer general health and has greater 
pain and functional limitations.  As a result of this delayed surgery is often associated with 
poorer post-operative outcomes (Montin et al. 2008; Holtzman et al. 2002; Fortin et al. 2002).   
4.3.4 Pain outcome after joint replacement 
Surgical success rates are cited as 80% by some but Edwards et al. (2009) comment that this 
is rarely defined as complete pain relief.  A number of studies exploring outcome of joint 
replacement suggest that the weight of evidence of excellent pain relief is so great that there is 
no longer any need to demonstrate this benefit (Thomasson et al. 2009), but outcomes are not 
so overwhelmingly positive as that statement suggests. Although most people report a 
clinically significant improvement in pain (Montin et al. 2008; McMurray et al. 2005;Fortin et 
al. 2002; Jones et al. 2000) there is a relatively high prevalence of persistent pain after 
surgery.   
4.3.4.1 Persistent post-operative pain resulting from malalignment of the implant 
Malalignment of the implant in knee arthroplasty can also lead to persistent post-operative 
pain  and it is estimated that this occurs in up to 10% of primary surgeries (Mason et al. 
2007).  Revision surgery is often able to correct the malalignment and this tends to resolve the 
pain also (Pietsch and Hofmann 2011). 
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4.3.4.2 Persistent post-operative pain resulting from infection in the joint 
Infection can lead to failure of the joint replacement and pain and it is estimated that this 
happens in between 0.4 and 2% of total knee replacements (Garvin and Konigsberg 2011).  
Reports of revision surgery for failure of total hip replacement suggest that the cause of the 
failure is infection in between 8 and 15% of cases (Jafari et al. 2010; Bozic et al. 2009; Ogino 
et al. 2008).  It is difficult to diagnose and treat (Kalore et al. 2011) and a significant 
proportion of those affected continue to have pain once treatment is completed (Wang et al. 
2002). 
4.3.4.3 Persistent post-surgical pain due to aseptic loosening of the prosthesis 
Pathological changes in the bone remnants following arthroplasty are thought to lead to 
loosening of the implant due to pseudoarthrosis, collapsed osteonecrosis, cement socket de-
bonding and bone-cement loosening (Zustin et al. 2010).   
Osteolysis is relatively common problem following total joint replacement.  The process is 
caused by wear on the replaced surfaces creating particulate material which potentially leads 
to bone loss and prosthetic loosening requiring revision surgery (Mall et al. 2011).  Osteolysis 
is preceded by synovial inflammation but not all synovial inflammation predicts osteolysis.   
4.3.4.4 Persistent post-operative pain resulting from intra-operative or post-operative 
nerve damage 
Intra-operative nerve damage is thought to account for up to 7.6% of cases of persistent post-
surgical pain (Brown et al. 2008).  The causes include direct nerve injury, significant leg 
lengthening, improper retractor placement, cement extrusion, patient positioning, and post-
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operative haematoma (Zwolak et al. 2011; Brown et al. 2008; Pritchett 2004; Maloney and 
Keeney 2004; Johanson et al. 1983).  Risk factors for nerve damage include the complexity or 
difficulty of the operation, the surgical approach taken, bilateral procedures, tourniquet time, 
rheumatoid arthritis, continuous local anaesthetic infusion via indwelling catheter and 
younger age (Jacob et al. 2011; Feibel et al. 2009; Eggli et al. 1999; van der Linde and Tonino 
1997; Weale et al. 1996; Navarro et al. 1995).   Approximately 80% of people who suffer a 
nerve injury will experience continued functional problems, and one of the predictors of 
continued problems is the presence of neurogenic pain (Edwards et al. 1987; Johanson et al. 
1983).  However, recovery is possible and can be spontaneous (Andrews et al. 2008) or it can 
be aided by surgery (Ducic et al. 2010). 
4.3.4.5 Persistent post-surgical pain due to increased innervation of tissues 
It has been shown that people who have anterior knee pain following arthroplasty have 
increased sensory innervation of the infrapatellar fat pad (IPFP) compared to people with OA 
knee (Lehner et al. 2008).  This study demonstrated that the number of sympathetic fibres did 
not increase at the same time and this led to an alteration in the ratio of sensory to sympathetic 
fibres away from the usual 1:1 to 8:1 in favour of the sensory fibres.  This suggests that 
sympathetically driven inhibition of the sensory fibres will be less and Lehner and colleagues 
suggest that this imbalance could lead to increased sensitivity, potentially contributing to an 
increased risk of persistent post-operative pain. 
4.3.4.6 Persistent pain due to persistent sources of inflammation 
Replacement of an osteoarthritic joint does not necessarily remove all sources of nociception 
from it. Although osteophytes are removed the infrapatellar fat pad may be retained.  Leaving 
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the infrapatellar fat pad seems to be weakly associated with having continued pain in the knee 
at five years (Meneghini et al. 2007).  Hyper-innervation by sensory fibres in the infrapatellar 
fat pad has been observed in the post-operative patient and is thought to cause an imbalance 
between the analgesic effects of the sympathetic innervation and the algesic activity of the 
sensory fibres (Lehner et al. 2008).  This imbalance doesn’t exist in the pre-operative 
arthroplasty patient.   
 
Synovial inflammation has been observed in 39% of post-operative patients at between 1 and 
3 years follow up but the presence or degree of this did not correlate with pain (Cooper et al. 
2010).   
  
4.4 Summary and rationale for the present study 
OA is diagnosed using a combination of subjective reporting of pain and physical symptoms, 
clinical examination and X-ray.  The prevalence in the UK population is difficult to define 
due to the range of different criteria used in epidemiological studies but it is a common 
disorder that often has physical, social and psychological consequences for the sufferer.  The 
risk factors for OA include non-modifiable variables such as congenital joint deformity, 
ethnicity and gender, as well as modifiable variables such as obesity, and occupation.   It is 
assumed that due to the increase in longevity and obesity in the population that the economic 
and personal burden of OA will continue to rise over time.     
Many people are able to self-manage OA without support from health professionals.  
However, many people with OA tend to have a poorer quality of life than their healthy 
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counterparts.  They suffer from pain, stiffness, functional impairment, depression, fatigue and 
increased risk of falls.  One of the more significant effects of OA for the individual is the loss 
of social participation they experience and one of the important measures of the outcome of 
various management strategies from the sufferer’s perspective is whether there is recovery of 
satisfying participation for the individual. Health professionals tend to measure treatment 
outcome more in terms of pain and functional restriction. 
There are a number of evidence based guidelines available for OA management.   The main 
guidance in the United Kingdom comes from the National Institute for Health and Clinical 
Excellence (NICE 2008).  All guidance including NICE recommend individualised treatment 
aimed at maximising concordance with self-management strategies including education, 
exercise aimed at muscle strengthening and aerobic fitness and the use of Paracetamol and 
topical NSAIDS as a first line.  Although the evidence is weaker to support weight loss this is 
also recommended.  More invasive treatments such as joint injections have short term benefit 
for those who pain causes more lifestyle disruption and more than 100, 000 people per year 
will be offered joint replacement surgery.  
Although most people report satisfaction post-operatively a significant proportion of people 
experience chronic pain after the surgery.  There are a number of reasons for this continued 
pain and it is suspected that a small proportion is due to persistence in central sensitisation. 
Previous research suggests that pain at rest may be an indicator of the likelihood that this may 
affect an individual.  Further investigation of this facet of OA pain is warranted.  
Work on central sensitisation has begun to explore the role of non-neuronal cells and the 
immune activation and the results suggest that these relatively unexplored pathways are 
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important.   There is very little published about spinal transmission of OA pain and together 
with the potential for persistent central sensitisation to be an important factor in continued 
post-operative pain this justifies exploration.   
There are limitations in the current explorations of human pain mechanisms.  One of the 
primary limitations is that many clinical studies examine pain in isolation of its affective 
component.  Depression, anxiety and pain share common neurochemistry, and it accepted that 
there is an influential reciprocal relationship between them.  This study will be one of the first 
to try to take into consideration the affective dimension of pain when exploring the 
transmission of pain at the level of the spinal cord.  It is hoped that this will allow a more 
meaningful interpretation of the data in order that it translates better to the real, but rather 
complicated clinical picture of pain in humans.    
The need for a better understanding of OA pain in order to improve knowledge and choices 
for health professional and OA sufferers, the search for newer pharmaceutical options, the 
need to bring nociceptive pain into the tripartite framework, the need to consider the influence 
of affect on pain transmission and the increasing prevalence of OA due to the ageing 
population are components of the main aim of this study: to investigate the transmission of 
OA pain at the level of the spinal cord.   
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4.5 Aims and Hypotheses 
The aim of this study is to explore the mechanism of pain transmission at the level of the 
spinal cord in patients with hip and knee OA.  To this end a group of amino acids and 
cytokines were selected for assay (Table 4.2) from the cerebrospinal fluid of patients who 
were undergoing surgical joint replacement (arthroplasty).   The cytokine choices were 
partially driven by the availability of a high-sensitivity multiplex kit. 
Table 4.2: Amino acids and cytokines selected for assay 
Excitatory 
amino acids 
Inhibitory amino 
acids 
Neutral 
Amino 
acids 
Pro-
inflammatory 
cytokines 
Anti-
inflammatory 
cytokines 
Glutamate 
Aspartate 
Arginine 
Citrulline 
Serine 
Glutamine 
GABA 
Glycine 
Leucine 
Isoleucine 
Phenylalanine 
Tyrosine 
Tryptophan 
Valine 
IL-1β 
IL-2 
IL-6 
IL-7 
IL-8 
IL-12 
IFNγ 
TNFα 
IL-4 
IL-5 
IL-10 
IL-13 
 
A comparison group of people having spinal anaesthesia who do not have pain had the same 
measurements and samples taken.  The purpose of this exploration is to improve our 
understanding of the mechanism of OA pain in order to improve pain relief in this population. 
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4.5.1 Hypothesis 
The study has two broad hypotheses.   
Hypothesis 1: 
The levels of locally produced amino acids and cytokines found in pre-operative 
cerebrospinal fluid samples from symptomatic osteoarthritis cases (OA) differ from those in 
pain-free controls (control) after taking into consideration the influence of age, gender and 
psychological distress (total HAD score). 
Hypothesis 2: 
The levels of locally produced amino acids and cytokines found in pre-operative 
cerebrospinal fluid samples from OA participants with pain at rest (PAR) will differ from 
those who have no pain at rest (0PAR) after taking into consideration the influence of age, 
gender and psychological distress.  
These hypotheses can be broken down into a number of theoretically driven aims based on the 
suggested roles of the amino acids and cytokines being studied. 
A1: To identify a significant increase in IL-1β, IL-2, IL-6, IL-7, IL-8, IL-12, IFNγ 
and TNFα concentrations in the OA group in comparison to the control group. 
A2: To identify a significant increase in IL-1β, IL-2, IL-6, IL-7, IL-8, IL-12, IFNγ 
and TNFα concentrations in the PAR group in comparison with the 0PAR 
group. 
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A3: To determine whether differences in IL-1β, IL-2, IL-6, IL-7, IL-8, IL-12, IFNγ 
and TNFα persist between these groups after adjusting for the age, gender, and 
psychological distress. 
B1: To identify a significant decrease in IL-4, IL-5, IL-10 and IL-13 concentration 
in OA cases in comparison with control cases.  
 
B2: To identify a significant decrease in IL-4, IL-5, IL-10 and IL-13 concentration 
in PAR cases in comparison with 0PAR cases. 
B2: To determine whether differences of IL-4, IL-5, IL-10 and IL-13 persist 
between these groups after adjusting for the potential confounders of age, 
gender, and psychological distress. 
C1: To identify a significant increase in glutamate, aspartate, arginine, citrulline, 
glycine, serine and glutamine in the OA group in comparison with controls.  
C2:  To identify a significant increase in glutamate, aspartate, arginine, citrulline, 
glycine, serine and glutamine in the PAR group in comparison with the 0PAR 
group. 
C3:  To identify whether differences in glutamate, aspartate, arginine, citrulline, 
glycine, serine and glutamine between these groups persist after adjusting for 
age, gender, and psychological distress. 
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D1: To identify a significant decrease in GABA and glycine concentrations when 
the OA group is compared with controls.  
D2: To identify a significant decrease in GABA and glycine concentrations when 
the PAR group is compared with the 0PAR group.  
D3:  To determine whether differences in GABA and glycine in these groups persist 
after adjusting for age, gender, and psychological distress. 
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Chapter 5  Method 
5.1 Ethical approval and governance 
At the time of the inception of this study multiple Local Research Ethics Committees (LREC) 
were involved in the approval process.  Approval was granted by Solihull LREC, South 
Birmingham LREC and East Birmingham LREC (Appendix 1). Research and Development 
approval was sought and obtained from Solihull and Heartlands NHS Trust and the University 
Hospitals Birmingham NHS Trust. 
An amendment was made to the study after initial approval (Appendix 1).  This broadened the 
inclusion criteria and altered the recruitment process (Figure 5-1 and Figure 5-2).  
5.2 The sample 
This study used a sample of convenience.  Patients who were having surgery under spinal 
anaesthesia were approached on the morning of their surgery.  Two broad categories of 
patients were considered for eligibility.  The first group were patients having replacement of 
knee or hip joints, diagnosed with osteoarthritis using radiographic, pain and disability 
criteria.   The second group were patients having a spinal anaesthetic for surgery for a 
disorder unlikely to be characterised by the presence of pain.  The largest group of patients 
who were likely to fall into this category were those having transurethral prostate or bladder 
surgery.   
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5.2.1 Feasibility 
At the time of recruitment for this study the NHS Trust had 15 elective orthopaedic lists per 
week and 4 elective urological lists (Appendix 2).  Three urologists and 4 orthopaedic 
surgeons agreed after face to face meetings that the research nurse could approach and recruit 
patients from their theatre lists for the study.  A senior Consultant anaesthetist was 
responsible for recruiting colleagues to the study for the purpose of collection of CSF during 
the anaesthetic induction procedure.  Verbal consent was obtained from all anaesthetists 
responsible for orthopaedic and urology lists.  This allowed collection of CSF samples at 
between 9 and 10 orthopaedic lists and 4 urology lists per week. The maximum numbers of 
samples that it would be possible to collect per week were estimated to be 10 OA and 10 
control participants.  It was anticipated that sample collection could continue for 12 months 
providing an estimated maximum number of 400 samples for each group (40 weeks collection 
x 10 samples).   
5.2.2 Sample size and power calculation 
A search was conducted to find any study where any of the amino acid and cytokine levels in 
the CSF were compared between a pain group and a control group, without imposing strict 
requirements on the composition of the control group or specifying the type of pain.  There 
was a wide variability in the levels reported and many studies had control subjects who were 
likely to have altered levels of these analytes.  It was therefore concluded that a prospective 
sample size calculation was not possible.  The study therefore set out to recruit as many 
participants as possible and use retrospective calculations to determine the power achieved. 
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5.2.3 Recruitment 
Participants were initially recruited from the elective orthopaedic waiting list via the 
admissions clinic where they were seen a week before their planned arthroplasty (Figure 5-1). 
After this method was trialled for a four week period two major barriers to recruitment were 
discovered. The pre-admission clinic did not have an anaesthetist present and the research 
nurse (AS) was not qualified to discuss fully the risks and benefits of a spinal anaesthetic with 
the potential participant.  Raising the possibility of a spinal anaesthetic with potential 
participants raised their anxiety levels and there was no effective procedure available to 
alleviate this anxiety before the patient left the clinic.  This was felt to be an unnecessary and 
unforeseen stress for the patient.   
The second difficulty was that participants who consented to take part in the study were given 
an operation date that was subject to change at short notice, and once admitted the participant 
may not agree to or be suitable for a spinal anaesthetic.  This meant that a large number of 
participants were recruited at pre-assessment but did not participate in the study. 
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Figure 5-1: Recruitment process number 1 
 
 
A change was made to the recruitment process and approved by the LREC (Appendix 1) 
meaning that patients were recruited to the study on the day of their surgery after they had 
provided informed consent for a spinal anaesthetic with an independent anaesthetist (Figure 
5-2). 
93 
 
Figure 5-2: Recruitment process number 2 
 
5.3 Inclusion and exclusion criteria 
Inclusion and exclusion criteria were established following a literature search exploring the 
published changes in amino acid levels in human CSF (Appendix 6).  This literature search 
was conducted using the initial search terms ‘amino acid’ and (CSF or spinal or dorsal not 
GM-CSF) with a limit of human studies.  A series of searches were conducted following this 
utilising the names of diseases, disorders and their synonyms and generic descriptors of these 
diseases (e.g. Parkinson’s or neurodegen*) where * is a truncation symbol.  In this way a 
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general picture was developed of the disorders and diseases where changes in amino acids in 
lumbar cerebrospinal fluid had been detected. 
5.3.1 Inclusion criteria 
a) Age > 50 years 
b) Women should be post-menopause 
c) Able to provide informed consent 
d) Consented to surgery with spinal anaesthesia 
e) For the OA recruits:  
i. diagnosis of OA in medical notes by orthopaedic team based on a history of 
pain, function and radiographic evidence.  
ii. Predominant pain in hip or knee 
iii. Listed for primary arthroplasty of the hip or knee 
f) For the control recruits: 
i. Pain free 
ii. No diagnosed arthritis or inflammatory condition (see exclusion criteria) 
 
5.3.2 Exclusion criteria 
a) Pain other than OA pain (including for example, headache, rheumatoid arthritis, post-
herpetic neuralgia, neuropathic pain including diabetic neuropathy, low back pain).  
b) Recurrent intermittent pain e.g. migraine, chronic tension headache. 
c) Neurodegenerative disorder (including for example Parkinson’s disease, Motor 
Neurone Disease, Multiple Sclerosis, Alzheimer’s disease). 
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d) Anorexia (eating disorder) 
e) Alcoholism 
f) Psychiatric disorder other than anxiety or depression (e.g. schizophrenia) 
g) Head trauma or cerebrovascular accident within 6 months. 
h) Current inflammatory disorder other than osteoarthritis (e.g. active (painful) gout) 
i) Active cancer within past 6 months 
j) Pregnancy 
k) Current investigations for neurological disorder. 
l) Use of immunosuppressants. 
m) Use of steroid (excluding use of steroid inhalers for COPD or asthma less than once 
per day). 
5.4 Measurement tools and data collection 
Demographic data was collected from the medical records and the participant with cross-
verification being used to establish key information such as diagnosis (Appendix 5). The data 
collected were: 
Demographic data 
Age in years  
Sex (M/F)  
Ethnicity (classified according to the Office for National Statistics ethnicity codes ( 2001). 
Past and current medical history 
Based on a search of the admission records for the participant 
Grouping of this data was completed prior to entry into the SPSS database 
Cardiovascular disease including ischaemic heart disease and hypertension 
Endocrine disorder excluding diabetes mellitus 
Diabetes mellitus 
Renal disorders 
Respiratory disorders 
Previous major surgery 
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Previous minor surgery including urological procedures 
Cancer or haematological disorders (an exclusion criterion) 
Rheumatological disorder including fibromyalgia (an exclusion criterion) 
Neurological or neuromuscular disorders (an exclusion criterion) 
Operative procedure planned 
5.4.1 Medication  
A complete list of the participant’s current medication was recorded.  This list formed the 
basis for a more complete discussion of the participant’s use of medication. 
Name of medication, herbal remedy, homeopathic remedy or supplement 
Dose and daily total used in past week 
Usual dosing schedule (regular/as required) 
Date medication stopped if appropriate 
5.4.2 Pain intensity 
There are a number of ways of measuring pain in research studies.  Much osteoarthritis 
research uses the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) 
(Bellamy et al. 1988) which is a multi-dimensional tool that allows the measurement of pain, 
stiffness and physical function.  Pain is measured using a Likert scale or visual analogue scale 
for the intensity of pain evoked by walking, using stairs, sitting or lying and standing. The 
pain score is generated by summing all the pain items, which gives a number between 0 and 
20 if using the Likert scale. This approach creates an intensity score that takes into 
consideration the fact that pain intensity in OA is related to activities undertaken.  However, 
one of the requirements in the current study to differentiate between pain at rest and pain on 
movement and there have been no studies using the WOMAC in this way. 
Participants were asked to rate their current pain using a 0-10 numerical rating scale with a 
visual box-scale to support this (Figure 5-3).  Both the numerical rating scale and the 11 point 
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box scale have been demonstrated to have validity in measuring a single construct of 
subjective pain intensity with an Eigenvalue of 0.90 (Jensen et al. 1986).  It is also a scale that 
is easy for participants to understand, and it is easy to administer (Herr et al. 2004).   
The 11-point box rating scale (Figure 5-3) does not have the same sensitivity to detect change 
in pain intensity as tools such as the Visual Analogue Scale (VAS) or the 101-point numerical 
rating scale (Jensen and Karoly 2010) but this is not a requirement in the present study as the 
pain score is of greater interest that a change in pain as a result of treatment or disease 
progression. 
 
Figure 5-3: Box rating scale 
0 1 2 3 4 5 6 7 8 9 10 
No pain            Worst pain imaginable 
Participants were asked to score their current pain intensity at rest and then to estimate their 
pain on movement.  Evidence suggests that recall of recent pain is accurate in people with OA 
(Allen et al. 2010) and using recall was considered preferable to asking the participant to 
evoke pain.  The participants were then asked to rate their average pain in the past three 
months and their average pain in the last twelve months using the same scale in order to 
assess stability of pain or otherwise.  Finally the participant was asked to state the site of their 
worst OA pain and give an estimation of its duration.   
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Control participants were asked if they had any pain now or any pain in the last week.  If they 
had more than one brief episode of acute pain within the past week, or a history of headaches 
or migraines they were ruled out from the study.   
5.4.3 Screening for neuropathic pain 
In participants with diabetes the Michigan Neuropathy Screening Instrument (Feldman et al. 
1994) was used to rule out peripheral diabetic neuropathy.  This instrument consists of 15 
questions about the person’s medical history that would indicate increased risk for peripheral 
neuropathy designed to determine whether the person is experiencing allodynia, paraesthesia 
or anaesthesia in the feet.  This is followed up by a physical examination where the physical 
appearance of the feet is noted including any ulceration and then vibration sense, ankle 
reflexes and monofilament tests are conducted.  High scores in this latter section are reserved 
for a decrease or absence of the expected perception with a maximum of 10 points available.  
Inter-rater reliability is good (Bax et al. 1996).  The instrument has good sensitivity (65%) 
and specificity (83%) and overall has a diagnostic accuracy of 80% (Moghtaderi et al. 2006).  
Formal diagnosis of diabetic neuropathy would also require electrophysiological testing but 
this instrument is accurate for the purposes of excluding potential cases from this study. 
5.4.4 Anxiety and depression measurement 
Anxiety and depression are complex constructs, and somatic symptoms co-exist with 
emotional, for example insomnia or hypersomnia, and loss of appetite.  These symptoms are 
often features of co-morbid physical illness and this can cause an increase in the number of 
false positives picked up by psychological assessment tools applied to a physically ill 
population (Snaith 1987; Kutner et al. 1985; Steuer et al. 1980).  The development of the 
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Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith 1983) was a response 
to this as it aims to limit the use of these ambiguous items and so is generally thought to be 
appropriate for use in hospitalised populations.  It also does not use symptoms that are 
associated with severe psychopathology and is therefore thought to be more acceptable to a 
general population and more sensitive to less severe forms of anxiety and distress (Herrmann 
1997). 
The HADS is a fourteen-item scale (Table 5.1) in which respondents identify a level of 
agreement with 7 items related to feelings or depression and 7 items relating to feelings of 
anxiety.  The responses are ordinal and are recorded numerically with values between 0 and 3.  
The maximum score for both anxiety and depression is twenty-one.  The questionnaire can be 
self-administered as it was in the present study and takes minutes to complete.  The ease of 
understanding of the items, and the speed of completion were key requirements in the present 
study as the time for data collection prior to transfer to the theatre department was relatively 
brief. The data returned by the responses is ordinal in nature due to the properties of the 
Likert-scale used (Svensson 2001). 
Table 5.1: HADS items 
Anxiety item Depression item 
A1 I feel tense or wound up D1 I still enjoy the things I used to enjoy 
A2 I get a sort of frightened feeling as if 
something awful is about to happen to 
me. 
D2 
I can laugh and see the funny side of things 
A3 Worrying thoughts go through my mind D3 I feel cheerful 
A4 I can sit at ease and feel relaxed D4 I feel as if I am slowed down 
A5 I get a sort of frightened feeling like 
'butterflies' in the stomach 
D5 
I have lost interest in my appearance 
A6 I feel restless as if I have to be on the 
move 
D6 
I look forward with enjoyment to things 
A7 
I get sudden feelings of panic 
D7 I can enjoy a good book or radio or TV 
programme 
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5.4.4.1 The factor structure of the HADS 
The HADS aims to differentiate between patients with mild (normal) anxiety and depression, 
those where anxiety and depression are on the borderline in terms of requiring treatment and 
those for whom anxiety and depression requires further assessment and perhaps treatment.   
Numerous studies have explored the factor structure of the HADS.  A review by Bjelland et 
al. ( 2002) examined nineteen of these studies. Eleven of the nineteen studies that reported a 
factor analysis of HADS data identified a two factor structure in samples of people with a 
psychiatric disorder or depression (2 studies), cancer (4 studies), HIV infection (1 study) and 
in the general population (3 studies).  Five studies identified a three factor structure in 
samples of people with cancer (2 studies), dermatological conditions (1 study) and from the 
general population (3 studies).  Two studies identified a four factor structure in samples with 
end stage renal disease and in a sample from the general population.  On the whole the factors 
identified were consistent with the sub-scales of anxiety and depression but there was a 
consistent finding that one of the anxiety items (‘I can sit at ease and feel relaxed’) had a 
relatively low anxiety loading (<0.6) and some loadings on the depression subscale (>0.45).  
In Rasch analysis of the HADS this item has also proved to fit poorly in a two factor solution 
(Gibbons et al. 2011; Pallant and Tennant 2007; Pallant and Bailey 2005). 
Despite the high number of studies exploring the HADS factor structure using principle 
components analysis (PCA) in a variety of populations, there is an argument that this is 
inappropriate due to the underlying level of measurement of the data.  The HADS returns a 
numerical score but this is obtained from ordinal data and therefore it has been suggested 
recently that it is more appropriate to explore the psychometric properties of the scale using 
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the Rasch model (Pallant and Tennant 2007).  Using this model Pallant and Tennant ( 2007) 
examined the HADS responses of 296 people with musculoskeletal problems who were 
attending an  outpatient rehabilitation programme.  Their analysis supported the use of the 14-
item HADS scale as a global measure of psychological distress although they note that not all 
items fit the model well. Their work is echoed by Gibbons et al ( 2011) who also find support 
for a unidimensional solution to the HADS in their study of people with motor neurone 
disease.  Both studies identify A6: I fell restless as if I have to be on the move as a poor fit 
whatever solution.  Pallant and Tennant (2007) retain all the items in their solution but 
Gibbons et al (2011) remove D5: I have lost interest in my appearance and find a better fit.   
One of the hypothesised reasons for the poor fit of items in Gibbons et al (2011) is that their 
cohort of participants interpret the meaning of the item differently because of the functional 
effects of motor neurone disease – thus in their exploration of the HADS as a two factor scale 
they found that ‘I feel slowed down’ was a poor fit and suggested that this item is more about 
physical function than mental fatigue.  There is potential for this to be a confounding factor in 
the present study. 
Pallant and Tennant (2007) recommend a cut-off point indicating psychological distress of 12 
using the total HADs score (HADS-T).  They found that this was able to capture all 
participants who score >8 for anxiety, >8 for depression or >8 for both which is the cut-off 
point for individual factors recommended by Bjelland et al. (2002). Pallant and Tennant 
(2007) offers the most appropriate guidance for the current study due to the similarity of the 
participant populations and therefore the HADS data will be used as a single measure of 
psychological distress.   
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5.4.4.2 Completion of the questionnaire 
Participants were encouraged to complete the HADS questionnaire themselves and when 
necessary the investigator read the items and responses to the participant.  Clarification of 
items was given when asked for; usually this consisted of reminding the participant that the 
items related to current mood. 
5.4.4.3 Scoring the HADS and data management 
Raw scores for each HADS item were entered into the SPSS database.  Anxiety and 
depression scores and a total HADS (HADS-T) was created from the raw data and a 
categorical variable was also created to represent no psychological distress (HADS-T≤11), 
and psychological distress (HADS-T ≥12). 
5.5 CSF collection, storage and processing 
This study will use the contents of cerebrospinal fluid taken from the lumbar region as an 
indicator of pain and mood related processes taking part in the dorsal horn and the brain. 
Prior to commencement of the anaesthetic procedure the research nurse (AS) prepared a work 
space and equipment on the anaesthetic room bench.  The equipment required was brought to 
the anaesthetic room in an adapted tool box and comprised: 
 Dewar flask (1L) containing 500ml liquid nitrogen 
 Sterile syringes (2ml, 5ml) 
 Sterile 0.22 micrometer Millipore filter (Millex-GS, Millipore) 
 Sterile flat bottomed screw top 5ml container (NHS supplies) 
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 Pipette (Pipet-lite Standard 20-200µl; Anachem) 
 Sterile pipette tips 200 μl (Plastibrand, Sigma Aldrich) 
 Sterile Eppendorf 0.2ml PCR tubes (Sigma Aldrich) 
 Permanent marker pen (Sharpie) 
 Forceps 
5.5.1 The lumbar puncture 
The research nurse (AS) assisted the participant to adopt one of two preferred positions for the 
dural puncture.  The first is a side-lying posture where the participants back is parallel to the 
edge of the theatre trolley and his or her knees are drawn up towards the chest and head drawn 
towards the knees, with the aim of ‘opening’ the spaces between lumbar vertebrae.  The 
alternative posture is seated on the theatre trolley.  The participant’s knees are drawn up 
towards the chest with the aid of a stool for his or her feet to rest upon and he or she is asked 
to bow the head towards the knees.  In both postures the participant was asked to try to ‘push 
out’ the lower spine as if creating a greater curvature.  
5.5.1.1 Equipment 
 Clean dressing trolley 
 Sterile ‘epidural pack’ 
 Spinal needle 
 Sterile 5ml syringe x 2 
 Sterile gloves 
 Chlorhexidine/alcohol solution 
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Once the patient was comfortably positioned and minimally supported by the research nurse 
the anaesthetist cleansed the skin around the lumbar spine with a chlorhexidine/alcohol 
solution (2% chlorhexidine gluconate and 70% isopropyl alcohol) and allowed to dry while 
final preparations were made to the sterile field and equipment. 
The anaesthetist injected a maximum of 5ml of 10mg ml
-1
 local anaesthetic (1% lignocaine) 
into the subcutaneous tissues, muscles and ligaments of the lumbar region at the level of L4/5 
or L3/4.   A 25 gauge spinal needle (Smiths Medical, Ashford, Kent, UK) was then advanced 
through the skin and subcutaneous tissue to access the sub-dural space using the loss of 
resistance technique to establish correct placement (Tran et al. 2009;Hoffmann et al. 1999).  
Once the needle was judged to be in the subdural space at lumbar region and spinal fluid was 
seen to leak from the needle under gravity a 5ml syringe was attached to the spinal needle and 
gently pressure applied to aspirate up to 2ml of spinal fluid.  Once the fluid was collected an 
operating department practitioner took over from AS in caring for the patient and AS moved 
to the anaesthetic room work bench to process the CSF sample. 
After the anaesthetist had collected 2ml of CSF the researcher filtered this immediately 
through a 0.22 micrometer filter (Millex-GS; Millipore, Watford, UK) into a sterile receptacle 
to remove cells from the sample.  The CSF was then divided into 200 microlitre (µl) aliquots 
using a pipette (Pipet-lite Standard 20-200µl; Anachem, Luton, UK) in propylene Eppendorf 
safe-lock 0.5ml tubes (Sigma-Aldrich, Dorset, UK).  Each tube was labelled using indelible 
ink with the participant’s unique sequential numeric identifier.  The tubes were sealed and 
then immersed in liquid nitrogen until boiling stopped in order to rapidly freeze the contents.  
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The tubes were then transported to the freezer room a short distance away still inside the 
Dewar flask. 
Once in the freezer room a storage box with sufficient capacity was removed from the minus 
80 C freezer (Nalgene cryobox (10x 10), Sigma-Aldrich) and the labelled tubes checked for 
intact seal and labelling and placed inside sequentially. The lid of the box was labelled with 
the corresponding participant ID and then the box placed flat into the freezer.    
The tubes were then stored at -80ºC freezer until analysis. Storage durations ranged from a 
minimum of 1 month to a maximum of 18 months.  The freezer was checked daily to ensure a 
stable temperature was maintained throughout the storage period. 
5.6 Laboratory analysis of amino acids 
Assay of amino acids was carried out using the method described below by Naomi Langman 
under the guidance of Dr. Kevin Whitehead at the University of Birmingham. 
Single aliquots from each participant were placed on ice to thaw to room temperature prior to 
the assay procedure.   
5.6.1 Reverse phase high pressure liquid chromatography 
High pressure liquid chromatography (HPLC) is a method for separation of components in a 
mixture (Figure 5-4).  The process relies upon the fact that each component will have a 
different degree of affinity for a specifically selected solvent in which they are contained (the 
mobile phase) and for the medium through which this solvent is passed (the stationary phase).  
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Each component will therefore take a slightly different length of time to pass through a 
column, and is detected upon leaving the column.   
This technique was used to separate the selected amino acids in CSF samples. Before being 
injected into the column and pumped through the system the CSF was combined with an 
agent that alters the component properties in such a way that they can be detected as they 
leave the column; this is called the derivatising agent.  In this case the amino acids are 
derivatised with ortho-phthaldiahyde/3-mercaptoproprionic acid (OPA/3-MPA).  This method 
of derivatisation renders the amino acids into highly fluorescent components (Jones and 
Gilligan 1983) so that they may be detected using fluorescence, which is a highly sensitive 
method.  This method was developed by colleagues to improve the efficiency and rapidity of 
HPLC analysis of amino acids in biological fluids (Devall et al. 2007). 
Figure 5-4: HPLC schematic 
 
Wikipedia commons: http://en.wikipedia.org/wiki/File:HPLC_apparatus.svg 
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The derivatising agent was prepared by mixing 975 µl of incomplete o-pthaldialdehyde 
reagent (1mg ml
-1
 Sigma UK) in potassium borate buffer (pH 10.4, Sigma, Dorset, UK) with 
25 µl of 10% (v/v) 3-mercaptopropinonic acid (Sigma-Aldrich) in methanol (Fischer 
Scientific, Leicester, UK).  Exactly 3µl of the derivatising agent was mixed three times with 
10 µl of thawed cerebrospinal fluid and allowed to react for 60 seconds.  Derivatisation was 
carried out automatically by a CMA/280 (CMA/Microdialysis Sweden) refrigerated 
autosampler (8 ºC) incorporating a 20 µl injection loop.  
The mobile phase consisted of : 
A: HPLC grade deionised water (18MΩ resistivity, Elga Water Systems UK), 
B: 95% methanol and 5% 100mM sodium acetate buffer (pH 6.95)  
C: 5% methanol.   
 
A tertiary gradient elution profile was used (Table 5.2) which was programmed to run for 
17min.   
Table 5.2: Changes in the mobile phase in the HypersilTM  ODS column during a 17 min chromatographic run. 
Time A B C 
0 48 2 50 
27 20 30 50 
47 0 70 30 
48 0 100 0 
50 0 100 0 
51 48 2 50 
60 48 2 50 
 
The mobile phase was pumped by a PM-80 twin-reciprocating pump through a LC-26A 
vacuum degasser (both BAS Technicol UK) a 2ml min
-1
.  Derivatisation and sample injection 
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(20 µl) were automated by a CMA/200 (CMA/Microdialysis Sweden) refrigerated 
autosampler (8 ºC) incorporating a 20 µl injection loop. The separation was performed using a 
HypersilTM octadecyl siliane (ODS) 5 µm particle size reverse phase analytical column (3.0 
mm x 150 mm; Chrompack UK) maintained at 30ºC.  Fluorescence was detected by a 
CMA/280 fluorescence detector (maximum excitation 340-360 nm; maximum emission 
495nm; CMA/Microdialysis Sweden).  The amino acid peaks were identified on the basis of 
retention times with the data being collected and analysed using EZChrom software (Aston 
Scientific, UK).  Quantification was made with reference to a three-point calibration curve.   
Standard curves were created from the injection of 10 µL of prepared standard solutions 
containing 20 pmol, 100 pmol and 200 pmol of the amino acids; arginine, aspartate, citrulline, 
GABA, glutamate, glutamine, glycine, isoleucine, leucine, phenylalanine, serine, tryptophan, 
tyrosine and valine.  These solutions were prepared from stock solutions of the amino acids 
containing 200 µM (Sigma-Aldrich) in water and stored at -80ºC.  Standard curves were 
forced through the origin for all amino acids except for glycine and serine where 
consideration was made for background levels that are present in detectable amounts in HPLC 
grade water.  A typical chromatograph of the standards can be seen in Figure 5-5. 
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Figure 5-5: Typical chromatogram produced from a range of standards using the HypersilTM ODS column (courtesy 
of N. Langman). 
 
All samples were in range of the sensitivity settings except for glutamine therefore a sample 
was diluted 10-fold to allow glutamine assay.  A typical CSF chromatograph can be seen in 
Figure 5-6 which illustrates that glutamine is off-scale. 
Figure 5-6: Example CSF chromatograph using HypersilTM ODS column (courtesy of N. Langman). 
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5.7 Laboratory analysis of cytokines 
Assay of cytokines was carried out by A. Swift with the guidance and assistance of Dr Alison 
Hart at the University of Warwick. 
Multiplex microbead array assay is a relatively new technology.  It is often compared with 
Enzyme Linked Immunosorbent Assay (ELISA) because both assays use an antibody to 
capture a soluble ligand and detection of this paired complex with a second reporter antibody 
(Elshal and McCoy 2006). Multiplex differs in that it uses fluorescence detection and can be 
used for multiple analytes (Kellar and Douglass 2003).  Up to 100 different analytes can be 
detected simultaneously as a result of the technology that uses a different red and near infra-
red spectral ‘address’ for each of the bead populations used in each assay.  At the time of this 
assay a newly developed high-sensitivity cytokine kit had been developed by Luminex, 
allowing the simultaneous assay of 13 cytokines.  It is important to guard against cross-
reactivity within the analytes being investigated and therefore an ‘off-the-shelf’ kit was 
chosen rather than creating a bespoke array of beads.  
CSF levels of the chosen cytokines were determined by a high sensitivity 13-plex panel 
(LINCOplex HSCYTO-60SK, Luminex) on undiluted samples using Bioplex software (Bio-
Rad, California).  This kit simultaneously quantifies GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13 and TNFα. 
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The manufacturer’s literature stated that the minimum detectable concentration for each 
cytokine was:  
IL-1β   0.06 pg ml-1  
IL-2   0.16 pg ml
-1
 
IL-4   0.13 pg ml
-1
 
IL-5   0.01 pg ml
-1
 
IL-6   0.1 pg ml
-1  
 
IL-7   0.12 pg ml
-1  
IL-8   0.11 pg mL
-1 
IL-10   0.15 pg ml
-1
 
IL-12(p70)  0.11 pg ml
-1
 
IL-13   0.48 pg ml
-1
 
IFNγ   0.29 pg ml-1 
GM-CSF  0.46 pg ml
-1
 
TNFα   0.05 pg ml-1 
 
The kit was stored as recommended at 4 ºC prior to use and before the analysis began was 
placed on the laboratory bench to reach room temperature (21ºC).  Single 200 µl aliquots of 
the samples to be assayed were thawed on ice prior to the procedure beginning. 
Two 96-well plates were prepared.  The wash buffer (10 mM phosphate buffered saline 
[PBS], 0.05% Proclin, 0.05% polyethylene sorbitan monolaurate [Tween 20], pH 7.4), and 
standards (containing a cocktail of mixed lyophilized cytokines) were prepared according the 
manufacturer’s instructions (all from Linco Research, Luminex).  200 µl of wash buffer was 
added to each well of the plate, which was then sealed and shaken for 10 min on a plate 
shaker at room temperature.  A vacuum of 100 mmHg was applied to the plate to remove the 
excess wash buffer.   
The bottle containing the prepared beads was provided in the kit and was sonicated for 30 
seconds and held on a vortex for a further 60 s; 25 µl of the bead mix was then added to each 
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well of the plate with intermittent shaking of the bottle to maintain mixing.  A 100 mmHg 
vacuum was again applied to the plate to remove the liquid from the well plate.   
The next step was to add 50 µl of control solution or standard to each well according to a plan 
documented on a Well Map Worksheet provided with the kit.  The 2000 pg ml
-1
 standard was 
prepared by reconstituting one vial of the standard with 250 µl de-ionised water producing a 
solution of 2000 pg ml
-1
 for each analyte.  Six polypropylene microcentrifuge tubes (Sigma 
UK) were pre-labelled with 400, 80, 16, 3.2, 0.64 and 0.13 pg ml-1 and 200 µl of assay buffer 
(50 mM PBS, 25 mM ehtylenediaminetetraaceticacid [EDTA], 0.08% sodium azide, 0.05% 
Tween 20, 1% bovine serum albumin [BSA], Lincoplex) was added to each tube.  A serial 
dilution was then conducted beginning by adding 50 µl of the 2000 pg ml
-1
 standard to the 
400 pg ml
-1
 vial and mixing thorough.  The process was continued until then final dilution 
creating 0.13pg ml
-1
 tube was mixed.   Assay buffer was used for the 0 pg ml
-1
 standard.  
50 µl of assay buffer was added to each well on the plate.  Each sample was then centrifuged 
in turn before 50 µl was added to the appropriate well in the plate (the samples were added to 
both plates to create duplicates).  The plates were then sealed and incubated overnight on a 
plate shaker at 4 ºC. 
The following morning a 100 mmHg vacuum was applied to each plate to remove excess 
fluid.  The detection antibodies were allowed to warm to room temperature and 50 µl was 
added to each well.  The plates were sealed and allowed to incubate on a plate shaker for one 
hour at room temperature.  Following this 50 µl Streptavidin-Phycoerythrin was added to 
prepare the samples for detection.  The lid was replaced and sealed and the plates shaken for a 
further 30 minutes.  A vacuum was once again applied to remove the liquid.  Well wash 
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buffer (200 µl) was added to each well and removed by vacuum two times.  Finally 100 µl of 
sheath fluid (used to suspend the bead reagent prior to introduction to the analyser: composed 
of phosphate buffered saline with ProClin®300 and sodium azide (<0.1%) preservatives) was 
added to each well and the plate sealed and shaken on the plate shaker for a further five 
minutes.  The plates were then placed in the BioPlex analyser using the settings advised by 
the manufacturer of the bead kit.   
The calibration data (Figure 5-7) demonstrates that for most of the cytokines there was a high 
degree of accuracy in the lower ranges but in some cases this was lost in the upper ranges. 
Figure 5-7: Standard curves for cytokine multiplex assay (produced by A Swift). 
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5.8 Statistical analysis 
All data was coded and entered into SPSS version 18.0.  The data was checked against 
original paper records before preliminary data exploration was conducted.  All data analysis 
unless otherwise specified will be undertaken using the SPSS programme. 
5.8.1 Analytical subgroupings 
The differences in amino acids and cytokines as specified in the hypotheses will be assessed 
between the osteoarthritis group and the control group (Table 5.3).  Subgroups will be formed 
from the OA group to create a group who have no pain at rest (0PAR) and those who have 
pain at rest≥1 (PAR).   
Table 5.3: Amino acid and cytokine groupings  
Excitatory 
amino acids 
Inhibitory amino 
acids 
Neutral 
Amino 
acids 
Pro-
inflammatory 
cytokines 
Anti-
inflammatory 
cytokines 
Glutamate 
Aspartate 
Arginine 
Citrulline 
Serine 
Glutamine 
GABA 
Glycine 
Leucine 
Isoleucine 
Phenylalanine 
Tyrosine 
Tryptophan 
Valine 
IL-1β 
IL-2 
IL-6 
IL-7 
IL-8 
IL-12 
IFNγ 
TNFα 
IL-4 
IL-5 
IL-10 
IL-13 
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5.8.2 Descriptive data and preliminary data exploration 
Demographic data will be presented as frequencies and percentages with comparisons 
between groups being made using chi squared tests or when fewer than 5 cases are expected 
to occupy one or more cells, Fisher’s exact test.   
Data relating to the medication and medical history of the participants will be provided in 
order to give as thorough a picture as possible of the sample but this data will not be utilitised 
in any of the analyses due to small group sizes. 
POM, PAR and HADS are considered ordinal level measurements and therefore comparisons 
of these scores between groups and sub-groups will be made using non-parametric statistical 
tests.  Mann-Whitney U test will be used to compare pain scores between groups and 
Friedman will be used to explore differences in estimated pain on movement at the three 
different time points requested of the participants.  
Missing values and outliers in the amino acid and cytokine data will be identified prior to 
further analysis.  Outliers and extreme values can be problematic in a number of statistical 
analyses.   Outliers and extreme values in the amino acid and cytokine data will be identified 
by visually inspecting box-plots.   Outliers are defined as data points that lay more than 1.5 
but less than 3 interquartile ranges (IQR) from the median.  Extreme values are defined as 
those data points more than 3 IQR from the median. These values will be checked against 
paper records and corrected where appropriate. Outliers will not be removed from the dataset 
as a matter of course but residuals will be inspected during regression analysis to determine 
whether any of the outlying cases have undue influence. 
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Prior to data analysis retrospective power calculations for amino acids and cytokines will be 
performed using the online power calculation software from Decision Support Systems 
(2011).  
5.8.3 Univariate analysis of amino acid and cytokine concentrations 
This section of the results chapter will explore univariate relationships between the amino 
acids and cytokines (the independent variables) of the control and OA groups, and between 
the same variables in the PAR and 0PAR groups. In keeping with the hypothesis of the study 
that differences between groups will persist after adjustments are made for age, gender and 
HADS-T these statistical analysis of the differences between groups will take these into 
account. It was hoped to use medication as a further covariate but the sample sizes once 
groups have been created would preclude this. 
Normality of this data will be tested using a combination of visual inspection of histograms 
and Kolmogorov-Smirnov tests.   In the case that amino acids and cytokines are distributed 
normally summary data for these variables will be presented in the form of mean and standard 
deviation.  In the event that the amino acids and cytokines are not normally distributed 
summary data will be presented as median and interquartile range.  
ANCOVA will be used to identify differences in amino acids and cytokines in each group 
(control/OA and PAR/0PAR).  In the event that data residuals are not distributed the 
ANCOVA will be supported by bootstrap analysis.  This involves the repetitive sampling of 
data points to construct a distribution of F statistic values from which the significance of the 
original F statistic can be identified and can be used to over-come non-normality of the data 
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set (Tabachnick and Fidell 2001).  Bootstrap analysis if necessary will be conducted using 
STATA with programming by Linda Nichols, University of Birmingham. 
A p value of less than 0.05 will be used as a cut-off point for the identification of results that 
are significant. Bland and Altman (1995) suggest that in cases where a number of statistical 
tests are being carried out the p value should be adjusted to take into consideration the fact 
that each test is unlikely to be completely independent of the others.  Following this reasoning 
the acceptable p value for each set of tests conducted should be 0.05 divided by the number of 
tests being conducted.  Perneger (1998) argues that this rule should only be applied if the 
study were looking for a significant difference in all of the variables – a universal error rate.  
He goes on to explain that the original Bonferroni adjustment was intended as a decision 
making aid relating to quality assurance and is therefore not relevant to the application it has 
found in inferential statistics.  Further he states that the reader can apply his or her own 
interpretation of the selected p value and that using too stringent a p value will increase the 
risk of potentially important results being missed.   
Decisions about the significance of results also need to take into consideration the theoretical 
or clinical relevance of the result.  This is an exploratory study and therefore has been little 
information published about the analytes in osteoarthritis pain and none in humans.  It is 
therefore considered appropriate to retain an individual p value of 0.05 for each test but to 
view each result in its clinical and theoretical context.  
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5.8.4 Regression analysis 
Binary logistic regression analyses will be performed in order to determine those variables 
that most usefully predict  
a) membership of the OA group,  
b) membership of the PAR group 
c) membership of the HADS-T ≥12 (psychological distress) group. 
The selection of binary logistic regression as opposed to multiple linear regression for the 
OA/control and PAR/0PAR is because they are naturally dichotomous groups.  Participants 
either have pain as a result of OA or do not, and either have pain at rest or do not.  
Determination of the cut-off point to signify the presence or absence of psychological distress 
is less exact, and although Pallant and Tennant (2007) recommend a score of 12 as 
representative of the likely presence of psychological distress it is possible that this cut off 
point could differ dependent on the population being studied.  Therefore, as well as exploring 
the presence or absence psychological distress with a binary logistic regression, HADS-T will 
also be explored using a linear regression technique. 
The sample size dictates the number of independent variables (IV) that can be safely entered 
into the regression equation.  Tabachnick and Fiddell (2001) use the equation   
where m = the number of IV.  Therefore, if this regression was to include all the possible IVs 
the sample size would be .  If the regression included between 6 and 8 
independent variables the required sample size would be between 98 and 114.  A number of 
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criteria will be applied to the IVs in order to determine which are most appropriate for the 
analysis, which will have the secondary and beneficial effect of reducing their number.    
The criteria applied to the independent variables will include inspection of the number of 
missing values for each independent variable in order to maximise the number of cases that 
will be entered into regression analysis.  
In addition to this correlations between independent variables will be inspected in order to 
identify strong relationships.  Pearson correlations will be used in the event that raw data is 
normally distributed or Spearman correlation in the event that raw data is not normally 
distributed. The amino acids and cytokines fall in natural groupings (Table 5.3), which were 
determined before the study and are based on research evidence identifying their primary role 
in pain signalling. Correlation data will be presented in these groupings and plotted 
diagrammatically in order to enable consideration of correlations between pairs of 
independent variables within their own group as well as between groups.   
The value of r that will trigger further inspection of the correlation between two independent 
variables will take into consideration the theoretical biological relationship between the two 
as well as the number of cases entered into the test.  Cohen (1988) described some ‘rule of 
thumb’ guidelines for the interpretation of strength of association with 0.1 being considered 
small, 0.3 being medium and greater than 0.5 being large.  However, Cohen and subsequently 
others (e.g. De Vaus 2002) explained that these guidelines did not consider the sample size 
(small samples often produce higher correlation coefficients), nor the clinical or theoretical 
relationship between two variables.  In this study all correlations greater than r=0.4 at a level 
of p<0.05 will be inspected.    A criteria of r > 0.8, p<0.05, will be used to denote a strong 
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relationship between a pair of independent variables: in pairs where this occurs consideration 
will be given to removal of one of the pair from entry into the regression model to reduce the 
risk of redundancy in the analysis (Pallant 2007; Tabachnick and Fidell 2001).   
Correlation coefficients will be used to determine whether the large neutral amino acid group 
should be summed to act as a single predictor, or whether one of this group appears to be 
pivotal and can be used alone.  Summation has been used to create a composite large neutral 
amino acid score (ΣLNAA) in research investigating depression, where the amino acids 
competing with tryptophan to cross the blood brain barrier have been simply summed prior to 
statistical analysis (Moreno et al. 2010; Porter et al. 2005; Capuron et al. 2002).   
Multicollinearity can reduce the trustworthiness of the b coefficients, (revealed as large b 
standard errors) and can make it difficult to interpret the importance of an individual 
predictor.  It is therefore important to assess the model for multicollinearity and this can be 
conducted within the regression analysis by examination of the tolerance and variance 
inflation factor (VIF).  Multicollinearity will be identified if any IV has a tolerance of less 
than 0.1 and VIF of greater than 10 (Pallant 2007: 155; Field 2009: 224). 
Logistic regression will begin with an initial model comprised of age, gender and HADS-T 
(plus the constant).  The next step will use a forward step-wise process to add selected 
predictor variables.  Selection of the most appropriate variable(s) will be based the most 
significant score statistic using an entry criterion of p=0.15.  This is recommended as it makes 
it less likely that important variable will be excluded (Bendel and Afifi 1977). The process 
also removes variables if they contribute less to the model than the most recently entered 
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variable. The criteria for removal will be that the independent variable contribution is not 
significant at the 0.10 level.   
The forward stepwise method is a form of selection of variables by purely statistical criteria 
and although it is criticised for this reason it can be helpful in the initial stages of building a 
model as it can be used to eliminate variables that are superfluous (Tabachnick and Fidell 
2001).   
The model produced by binary logistic regression will be assessed using a number of criteria 
(Field 2009).   
a) Percentage correct classification of cases: the percentage of cases correctly classified 
by the model.  The cut-off for classification will be the default SPSS setting of 50%. 
b) Model prediction better than initial model (containing only the constant): this is 
assessed by a Goodness of fit test, which returns a χ2 value.  Significance of p<0.05 
indicates that the model containing the selected independent variables performs better 
than the initial model. 
c) Hosmer and Lemeshow ‘poorness of fit’: This statistic indicates whether the model 
performs better than the initial model and returns a χ2 value. A p greater than 0.05 
indicates that the model does perform better than the initial model. 
d) The Wald statistic: this calculates the statistical significance of each of the coefficients 
in the model.  A p value of less than 0.05 identifies the predictor variable as making a 
significant contribution to the model. 
e) The odds ratio: an indication the change in odds caused by a unit change in the 
predictor variable. A positive odds ratio indicates that membership of the group 
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becomes more likely as the value of the predictor variable increases.  A negative value 
indicates that the likelihood of group membership decreases as the value of the 
predictor variable increases.  
f) Nagelkerke R2: This value gives an indication of how much variance in the outcome 
variable is explained by the model.   
Following the regression process it is important to check that influential or unusual cases have 
not unduly affected the outcome. Detection of outliers that bias the model will be performed 
by examination of the standardised residuals (residuals divided by their estimated standard 
deviation).  There should be no standardised residuals with an absolute value>3.29, less than 
1% of cases should have a standardised residual absolute value >2.58 and less than 5% of 
cases should have a standardised residual absolute value >1.96 (Field 2009).  The 
standardised residuals for outlying cases will be inspected via the case-wise listings produced 
by SPSS as part of the regression process (Burns and Burns 2009).  
The potential influence of individual cases will be assessed by examining Cook’s distance 
(Di), DFBeta and leverage.  Cook’s distance measures the effect of deleting an individual 
observation on the regression coefficient. McDonald’s guidelines (2002) will be used to 
evaluate Cook’s distance (Table 5.4).  These guidelines are based on the assumption that there 
are more than 15 cases.  
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Table 5.4: McDonald's guidance on Cook's Distance for influential cases in regression analysis 
Cut-off point for influential 
case (Di) 
Number of predictors 
including the intercept 
>0.7 1 
>0.8 2 
>0.85 >3 
  
DFBeta similarly shows how much a b coefficient would change if the case were dropped 
from the regression.  A standardised DFBeta of greater than 1 is suggested to indicate a case 
with unusual influence (Field 2009).  High leverage is a term used to describe an outlying data 
point that is very far away from the mean and has a large residual.  The result of a value with 
a high leverage is that it can pull the regression line toward it and therefore have undue 
influence over the outcome.  SPSS calculates a version of leverage where the maximum value 
is equal to 1 and would mean that the case has complete influence over the prediction (Field 
2009).  It is suggested that cases with leverage of 3 to 5 times the average should be 
investigated.  Average leverage is calculated   where  is the number of predictors and n 
the sample size (Field 2009).    
In the multiple linear regression (for HADS-T) the R
2
 value will be given as in indication of 
how much variability of HADS-T is accounted for by the predictors.  An F-ratio is used to 
determine whether the change in R
2
 from the amount of variance explained by the initial 
model (containing only the constant) and the variance explained by the model is significantly 
different.  An F-ratio with a p value of less than 0.05 indicates that the variance accounted for 
by the model significantly improves on the variance explained by the initial model. 
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An ANOVA is reported in the linear regression model which provides an indication of 
whether the model is better at predicting HADS-T than using the mean HADS-T as a ‘best 
guess’ (Field 2009: 236).  Beta coefficients (b) will be reported along with their standard 
error.  The t statistic calculated from the b indicates whether the predictor variable contributes 
significantly to the model and a value of p<0.05 will be used to indicate this is the case.  
Multiple linear regression requires residuals to be uncorrelated and this is tested with the 
Durbin-Watson test.  This test returns a value between 0 and 4.  A value of 2 indicates the 
residuals are not correlated.  The value returned by the Durbin-Watson test will be compared 
with the values given in the original paper (Durbin and Watson 1951) using a p value of 0.05.  
The upper and lower bounds of the critical value for d are given.  When the value for the 
observed d is below the lower bound the test is significant (serial correlation has occurred), 
when it is above the upper bound it is not significant (serial correlation has not occurred).  An 
observed value of d that lies between the upper and lower bound means that the test has been 
inconclusive.   
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Chapter 6 Results 
6.1 Demographic and descriptive data 
The total number of control participants entered into the analysis was 21 and the total number 
of OA participants was 59.   
CSF samples were taken from 27 control cases and 67 OA cases on dates between 15 July 
2003 and 2 March 2005.  The number of patients who declined to participate in the study was 
not recorded. Two controls and 1 OA case had missing amino acid data and so were excluded 
from all analyses.  A further three controls were excluded because they were having hip or 
knee surgery and although they did not admit to pain it was not possible to rule out a 
progressive or inflammatory process.  Seven further OA cases were excluded because they 
were undergoing bladder surgery rather than hip or knee replacement, and one additional 
control because he had not received an all-clear notification with regard to previous bladder 
carcinoma.  No data was retained regarding spoiled samples (i.e. contaminated with blood) 
but this was a rare occurrence and resulted in fewer than 5 participants being excluded from 
the study after consent.  
Ninety-one per cent (n=19) of the control group were admitted for investigation or surgery of 
the bladder, and 9% (n=2) for transvaginal taping. In the OA group 34% (n=20) were 
admitted for primary total hip replacement, 43% (n=25) for primary total knee replacement 
and in 23% of cases (n=14) the joint being replaced was either hip or knee but was not 
recorded.  
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The age and gender of the OA participants in this study is similar the national demographic 
profile for hip and knee arthroplasty which comprises approximately 40% males with an 
average age of 69 years (Table 6.1).   
Table 6.1: Age and gender of participants 
 Control 
(n=21) 
OA 
(n=59) 
Statistic/probability 
 
Male 
16 (76%) 28 (47%) 
a
p= 0.020
 
 
Age: mean  (SD) 67.1 (11.9) 
range 42-85 
68.9 (11.2) 
range 45-88 
 
b
t78=-0.5, p= 0.601
 
 
aFisher’s exact test; bindependent t test 
 
Most members of the OA group and some members of the control group took anti-
inflammatory or analgesic medication (Table 6.2).  Anti-inflammatory medications (and low 
dose aspirin) was stopped by participants at least 10 days before surgery. 
Table 6.2: NSAID and analgesic use in OA and control participants 
Medication type Name Control 
n(%) 
OA 
n(%) 
None  17 (81) 10 (17) 
 Paracetamol 1 (3) 12 (20) 
Combination Coproxamol 1 (3) 7 (12) 
 Codydramol 0 (0) 4 (7) 
 Cocodamol 1 (3) 11 (19) 
NSAID  1 (3) 31 (53) 
Strong opioid Tramadol 0 (0) 7 (12) 
 Morphine 0 (0) 2 (3) 
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The past medical history and general medication use is shown in Table 6.3 and Table 6.4.  
Totals in these tables may exceed the total number of participants as participants can specify 
more than one condition or treatment.   
Table 6.3: Past medical history of participants 
  Control 
(n=21) 
OA 
(n=59) 
Cardiovascular Hypertension 3 21 
Angina 1 5 
Previous stroke  1 
 Previous MI  1 
Peripheral vascular disease 1 1 
Respiratory Asthma 1 9 
COPD 1 2 
Endocrine Diabetes type 1 1  
Diabetes type 2 2 5 
Hypothyroid 1 2 
Hyperthyroid  1 
Gastrointestinal Peptic/duodenal ulcer 2 4 
Hiatus hernia 1 1 
Skin Psoriasis  1 
Psychological Depression 1 1 
Anxiety  1 
Psychosis 1  
Musculoskeletal Gout 3 4 
Previous surgery  13 43 
Other Previous opioid abuse  1 
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Table 6.4: General medication use  
Drug Control OA 
Aspirin 75mg 4 (19%) 9 (15%) 
Antihypertensive 6 (28%) 33 (56%) 
Proton pump Inhibitor 2 (10%) 10(17%) 
Antiprotozoal (Quinnine)  2 (3%) 
Indigestion 1(5%) 3 (5%) 
Laxative  2 (3%) 
Inhaled steroids 2 (10%) 10 (17%) 
Antihistamine  1 (2%) 
Bronchodilators 2 (10%) 8 (13%) 
Hypnotics/anxiolytics  7 (12%) 
Lipid regulation 4 (19%) 8 (14%) 
Hypoglycaemic agent 1 (5%) 6 (10%) 
Glaucoma  1 (2%) 
Urinary retention/prostate 6 (29%) 3 (5%) 
Thyroxine 1 (5%) 4 (7%) 
Ferrous sulphate  2 (3%) 
Antipsychotic  1 (2%) 
Anticoagulant  2 (3%) 
Bisphosphonate  4 (7%) 
Antidepressant SSRI (Sertraline, paroxetine)  6 (10%) 
Antidepressant SNRI (Venlafaxine)  3 (5%) 
Antidepressant tricyclic (Amitriptyline, doxepin) 1 (5%) 1 (2%) 
Allopurinol 2 (10%)  
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6.1.1 Pain on movement (POM) and pain at rest (PAR) 
The participants in the control group had zero POM and zero PAR.  The distribution of POM 
and PAR scores in the OA group is not normal (Figure 6-1, Figure 6-2 and Table 6.5) 
Figure 6-1: Distribution of POM scores  
 
Figure 6-2: Distribution of PAR scores 
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Table 6.5: Kolmogorov-Smirnov normality tests for POM and PAR in the OA group 
 Statistic Degrees of freedom Significance 
POM 0.131 59 p = 0.014 
PAR 0.231 59 p = <0.001 
 
The median POM in the OA group was stable in the 12 months leading up to the study (Table 
6.6: = 3.83, p=0.147).   The median PAR in the OA group was 2 (range 0-9, IQ range 5).   
Table 6.6: Median pain on movement now, last three months and last 12 months 
Pain on movement Median (IQR) 
Current 6(4) 
Average last 3 months 6(3) 
Average last 12 months 6 (3) 
 
When the PAR/0PAR groups were compared there was no significant difference in gender, 
age, or proportions of hip or knee sites of pain (Table 6.7).  POM was significantly higher in 
the PAR group (Table 6.7, and Figure 6-3).  
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Table 6.7: Gender and POM difference between PAR and 0PAR groups 
 0PAR 
n(%) 
PAR 
n(%) 
Statistic 
n(%) 24 (41) 35 (59) 
 
Male: n(%) 14 (58) 14 (40) a =1.919, p=0.131 
Age: Median (IQR) 72 (15) 67 (18) 
b
U=368.500, p=0.426 
POM : Median (IQR) 5 (3) 6 (3) 
b
U=603, p=0.004
 
Hip: n(%) 6 (13) 14 (31) 
a
 =0.336, p=0.258 
Knee: n(%) 11 (24) 14 (31) 
a
Chi-squared; 
b
 Mann-Whitney U test;  
 
Figure 6-3: Box plots comparing median pain on movement between 0PAR and PAR groups. 
 
6.1.2 Psychological distress (HADS-T) 
HADS-T is significantly higher in the OA group than in the control group (Figure 6-4, and 
Table 6.8) despite the presence of a control outlier (HADS-T=22).   
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Figure 6-4: Box plot of Total HADS for control and OA group 
 
There are a significantly greater proportion of participants with psychological distress 
(HADS-T≥12) in the OA group than the control group (Table 6.8). 
Table 6.8: Differences in HADS-T≥12 between the control and the OA groups 
 Control OA Statistic 
Median (IQ) 6(7) 13 (8) 
a
U=854, p<0.001 
Proportion HADS-T ≥12 n=4 (19%) n=34 (57%) bp=0.006 
a
 Mann-Whitney U test;  
b
 Fisher’s exact test 
Median HADS-T does not differ in 0PAR and PAR groups (Figure 6-5 and Table 6.9). The 
proportion of OA participants who have psychological distress (HADS-T≥12) in the 0PAR 
and PAR groups is the same (Table 6.9). 
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Figure 6-5: Box plot of HADS-T scores for 0PAR and PAR groups 
 
Table 6.9: Differences HADS-T between the 0PAR and PAR groups 
 0PAR PAR Statistic 
Median (IQR) 13 (8) 13 (8) 
a
U=380, p=0.858 
Proportion HADS-T ≥12 n=15 (65%) 19 (56%) b =0.497, p=0.335 
a
 Mann-Whitney U test; 
b
 Chi-Squared test 
 
6.2 Cytokine and amino acid data 
6.2.1 Missing values for cytokines and amino acids 
The whole sample was put forward for amino acid and cytokine assay.  There are few missing 
cases in the amino acid data but many more in the cytokine data (Table 6.10). 
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Table 6.10: Missing cases and cases below the limit of detection (LOD) in the amino acid and cytokine data 
 
Control OA 
 
Missing cases 
Cases below 
LOD Missing cases 
Cases below 
LOD 
 
n % n % n % n % 
Glutamate 1 5 0 0 0 0 0 0 
Aspartate 0 0 0 0 3 5 0 0 
Arginine 0 0 0 0 1 2 0 0 
Citrulline 0 0 0 0 0 0 0 0 
Serine 0 0 0 0 0 0 0 0 
Glutamine 1 5 0 0 1 2 0 0 
GABA 0 0 0 0 0 0 0 0 
Glycine 0 0 0 0 1 2 0 0 
Tryptophan 0 0 0 0 0 0 0 0 
Leucine 0 0 0 0 0 0 0 0 
Isoleucine 0 0 0 0 0 0 0 0 
Phenylalanine 0 0 0 0 1 2 0 0 
Tyrosine 1 5 0 0 1 2 0 0 
Valine 0 0 0 0 0 0 0 0 
IL-1β 2 10 16 90 13 22 46 78 
IL-2 4 20 1 5 20 34 2 3 
IL-6 2 10 0 0 9 15 1 2 
IL-7 2 10 1 5 9 15 4 7 
IL-8 2 10 0 0 9 15 0 0 
IL-12 2 10 9 43 11 19 27 46 
IFNγ 2 10 8 38 11 19 21 36 
TNFα 2 10 0 0 9 15 0 0 
IL-4 2 10 8 38 10 17 38 64 
IL-5 2 10 1 5 9 15 1 2 
IL-10 2 10 0 0 10 17 0 0 
IL-13 4 20 8 38 10 17 35 60 
 
 
 
 
 
 
  
  
  
IL-1β will be excluded from all analyses as there were very few participants with 
concentrations of this cytokine above the limit of detection. 
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6.2.2 Cytokine and amino acid descriptive data 
6.2.2.1 Retrospective power calculations for amino acid and cytokines 
Retrospective power calculations were performed an all cytokines and amino acids using a 
significance level of 0.05 (Table 6.11 and Table 6.12).  Serine, IL-12 and TNFα are 
adequately powered. 
 
Table 6.11: Mean, SD and power calculation for amino acids in control and OA group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aμmol l-1;  bpmol ml-1 
 
 
 
 
 
Control OA 
 
 
n mean SD n mean SD 
power 
Glutamatea 20 0.740 0.212 59 0.749 0.198 7% 
Aspartatea 21 0.329 0.066 56 0.336 0.074 10.5% 
Argininea 21 19.564 5.986 58 18.367 3.753 21.6% 
Citrullinea 21 2.741 0.959 59 2.711 0.825 6.2% 
Serinea 21 18.841 5.502 59 22.601 4.888 85.85% 
Glutaminea 20 408.667 149.517 58 485.511 141.136 64.3% 
GABAb 21 99.233 29.780 59 103.355 34.929 13% 
Glycinea 21 9.621 4.734 58 10.171 2.639 12.7% 
Tryptophana 21 0.921 0.303 59 0.980 0.301 44.6% 
Leucinea 21 12.230 3.256 59 12.919 3.285 20.9% 
Isoleucinea 21 4.507 1.153 59 4.478 1.192 6.6% 
Phenylalaninea 21 8.146 1.493 58 8.424 1.637 17.1% 
Tyrosinea 20 7.491 1.235 58 7.776 1.835 19% 
Valinea 21 14.735 3.702 59 16.042 4.183 38.2% 
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Table 6.12: Mean, SD and power calculation for cytokines in OA and control group 
 Control OA  
 n Mean SD N Mean SD Power 
IL-2 16 0.036 0.038 36 0.043 0.042 15% 
IL-6 19 3.282 1.557 48 3.847 2.184 32.1% 
IL-7 18 0.183 0.088 45 0.160 0.097 22.8% 
IL-8 19 24.214 8.863 49 25.344 9.515 11.8% 
IL-12 10 0.031 0.040 21 0.013 0.013 >99.9% 
IFNγ 11 0.100 0.115 26 0.088 0.082 13.1% 
TNFα 19 0.103 0.086 49 0.175 0.103 >99.9% 
IL-4 11 0.242 0.261 10 0.125 0.211 43.6% 
IL-5 18 0.298 0.094 48 0.300 0.129 5.7% 
IL-10 19 0.770 0.325 49 0.666 0.303 31% 
IL-13 9 0.049 0.051 14 0.350 0.030 18.7% 
All cytokines measured in pg ml-1 
The amino acids and cytokines are not normally distributed (Appendix 12 and Appendix 14). 
The median and interquartile range of each amino acid and cytokine in the OA and control 
groups, and the PAR and 0PAR groups is given in Table 6.13 and Table 6.14) 
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Table 6.13: Median values of amino acids (OA/control and PAR/0PAR) 
 Median (IQR) 
 
 Control OA 
 
0PAR PAR 
Glutamate
a 
0.688 
(0.310) 
0.744 
(0.238) 
0.766 
(0.225) 
0.713 
(0.246) 
Aspartate
a 
0.337 
(0.072) 
0.331 
(0.901) 
0.379 
(0.109) 
0.308 
(0.074) 
Arginine
a 
18.388 
(7.617) 
17.789 
(4.898) 
17.615 
(4.218) 
18.232 
(15.150) 
Citrulline
a 
2.474 
(1.149) 
2.549 
(1.085) 
2.630 
(1.191) 
2.516 
(0.903) 
Serine
a 
16.394 
(7.093) 
22.601 
(7.454) 
20.982 
(7.135) 
22.058 
(7.344) 
Glutamine
a 
383.680 
(190.271) 
469.002 
(133.492) 
472.467 
(112.085) 
462.756 
(146.226) 
GABA
b 
99.368 
(49.890) 
102.922 
(46.597) 
104.353 
(60.314) 
100.119 
(43.688) 
Glycine
a 
8.167 
(7.352) 
9.976 
(3.857) 
9.648 
(4.394) 
10.322 
(3.623) 
Tryptophan
a 
1.026 
(0.527) 
0.936 
(0.392) 
0.945 
(0.496) 
0.936 
(0.391) 
Leucine
a 
12.240 
(4.598) 
11.972 
(5.681) 
12.437 
(4.986) 
11.688 
(5.300) 
Isoleucine
a 
4.560 
(1.591) 
4.388 
(1.665) 
4.539 
(1.384) 
4.254 
(1.887) 
Phenylalanine
a 
8.060 
(1.502) 
8.127 
(2.475) 
8.510 
(2.985) 
8.118 
(1.930) 
Tyrosine
a 
7.420 
(1.457) 
7.857 
(2.112) 
8.034 
(2.327) 
7.817 
(1.939) 
Valine
a 
14.169 
(5.253) 
15.294 
(5.136) 
16.242 
(3.739) 
14.585 
(5.163) 
a
 micromol l
-1 (μmol l-1); bpicomole ml-1 (pmol ml-1) 
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Table 6.14: Median values of cytokines (OA/control and PAR/0PAR) 
 Median (IQR) 
 Control OA 0PAR PAR 
IL-6 
3.040 
 (2.880) 
3.355  
(2.790) 
3.140  
(3.210) 
3.555  
(2.570) 
IL-7 
0.170  
(0.140) 
0.130  
(0.120) 
0.125  
(0.150) 
0.140  
(0.110) 
IL-8 
22.960  
(13.950) 
22.850  
(9.030) 
23.350  
(8.880) 
24.520  
(9.380) 
IL-12 
0.015  
(0.040) 
0.010  
(0.010) 
0.010  
(0.030) 
0.010  
(0.010) 
IFNγ 
0.050  
(0.160) 
0.070  
(0.100) 
0.090  
(0.070) 
0.030  
(0.090) 
TNFα 
0.060 
 (0.150) 
0.168  
(0.140) 
0.185  
(0.150) 
0.140  
(0.150) 
IL-4 
0.100  
(0.400) 
0.030  
(0.150) 
0.045  
(0.070) 
0.025  
(0.430) 
IL-5 
0.285  
(0.120) 
0.275  
(0.130) 
0.270  
(0.220) 
0.285  
(0.120) 
IL-10 
0.850  
(0.520) 
0.590  
(0.410) 
0.545  
(0.450) 
0.630 
 (0.370) 
IL-13 
0.030  
(0.050) 
0.025  
(0.060) 
0.020  
(0.080) 
0.030  
(0.040) 
All cytokines measured in pg ml-1 
 
 
 
 
139 
 
6.2.3 Univariate analysis of amino acids and cytokines in control and 
OA groups 
ANCOVA on the amino acids and cytokines adjusting for age, gender and HADS-T identify a 
significant difference for serine, valine, leucine (Table 6.15) and IL-12 and TNFα (Table 
6.16).   
Table 6.15: ANCOVA OA/control amino acids adjusted for age, gender and HADS-T 
  ANCOVA
a 
 Kolmogorov-Smirnov
b 
 F statistic Fdf p Statistic df p 
Glutamate
 0.406 1,70 0.526 0.103 75 0.349 
Aspartate 0.291 1,68 0.591 0.065 73 0.892 
Arginine 0.177 1,70 0.675 0.085 75 0.597 
Citrulline
 0.152 1,71 0.698 0.143 76 0.070 
Serine
c 11.303 1,71 0.001 0.079 76 0.670 
Glutamine
 2.149 1,70 0.124 0.116 75 0.220 
GABA 0.621 1,71 0.433 0.073 75 0.773 
Glycine 0.473 1,70 0.494 0.091 75 0.510 
Tryptophan 0.007 1,710 0.935 0.055 76 0.964 
Leucine
c,d 5.143 1,71 0.026 0.161 76 0.029 
Isoleucine
 1.555 1,71 0.216 0.109 76 0.274 
Phenylalanine 1.467 1,70 0.230 0.055 75 0.965 
Tyrosine 1.767 1,69 0.188 0.102 74 0.366 
Valine
c 6.274 1,71 0.015 0.138 76 0.087 
a
 ANCOVA data generated by SPSS; b Residuals generated by STATA 
c
 Significant difference, p<0.05; 
d
 Residuals not normally distributed, p<0.05 
These results have been generated excluding all cases that were missing or below the limit of detection. 
 
The residuals for leucine were not normally distributed and therefore differences in this amino 
acid in the OA and control group were explored using a boot-strap technique. 1000 
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replications were carried out and the p value calculated for the F statistic was 0.001, 
confirming the significant difference for this amino acid between the OA and control groups. 
Table 6.16: ANCOVA cytokines control/OA group adjusted for age, gender and HADS-T 
  ANCOVA
a 
 Kolmogorov-Smirnov
b 
 F statistic df p Statistic df p 
IL-2
 0.000 1,44 0.997 0.184 49 0.052 
IL-6 1.462 1,58 0.232 0.122 63 0.254 
IL-7
 1.404 1,54 0.241 0.121 59 0.298 
IL-8 0.882 1,59 0.351 0.086 64 0.674 
IL-12
c 4.887 1,24 0.037 0.227 29 0.067 
IFNγ 0.001 1,30 0.981 0.199 35 0.089 
TNFα
c 5.326 1,59 0.025 0.076 64 0.810 
IL-4 0.065 1,14 0.803 0.148 19 0.717 
IL-5 0.196 1,57 0.660 0.111 62 0.370 
IL-10 0.095 1,59 0.759 0.112 64 0.342 
IL-13 0.793 1,17 0.386 0.140 22 0.706 
a
 ANCOVA data generated by SPSS; b Residuals generated by STATA 
c
 Significant difference, p<0.05; 
d
 Residuals not normally distributed, p<0.05 
These results have been generated excluding all cases that were missing or below the limit of detection. 
 
 
 
Inspection of median values for the amino acids and cytokines found to be significantly 
different in the OA and control groups shows that serine, leucine, valine and TNFα are higher 
in the OA group while IL-12 is lower (Table 6.13 and Table 6.14). 
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6.2.4 Univariate analysis of amino acids and cytokines in 0PAR and 
PAR groups 
ANCOVA comparison of amino acids and cytokines in the PAR and 0PAR groups adjusting 
for age, gender and HADS-T reveals a significant difference in aspartate and IFNγ between 
the two groups (Table 6.17 and Table 6.18). 
Table 6.17: ANCOVA for amino acids PAR 0PAR adjusting for age, gender and HADS-T 
  ANCOVA
a 
 Kolmogorov-Smirnov
b 
 F statistic df p Statistic df p 
Glutamate
 0.735 1,52 0.395 0.127 57 0.258 
Aspartate
c 10.057 1,49 0.003 0.094 54 0.672 
Arginine 0.746 1,51 0.392 0.094 56 0.642 
Citrulline
 0.014 1,52 0.905 0.144 56 0.145 
Serine
 0.023 1,52 0.881 0.067 57 0.943 
Glutamine
 0.560 1,52 0.457 0.137 57 0.187 
GABA 1.306 1,52 0.258 0.069 57 0.931 
Glycine 0.492 1,51 0.486 0.087 56 0.740 
Tryptophan
 0.007 1,52 0.934 0.069 57 0.927 
Leucine
 0.009 1,52 0.924 0.138 57 0.182 
Isoleucine
 0.001 1,52 0.978 0.132 57 0.226 
Phenylalanine 0.147 1,51 0.703 0.080 56 0.828 
Tyrosine 0.638 1,51 0.428 0.097 57 0.612 
Valine
 0.047 1,52 0.829 0.160 57 0.080 
a
 ANCOVA data generated by SPSS; b Residuals generated by STATA 
c
 Significant difference, p<0.05; 
d
 Residuals not normally distributed, p<0.05 
These results have been generated excluding all cases that were missing or below the limit of detection. 
 
Inspection of the medians for aspartate and IFNγ reveals that both are present in lower 
concentration in the PAR group than the 0PAR group (Table 6.13 and Table 6.14). 
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Table 6.18: ANCOVA for cytokines PAR and 0PAR adjusting for age, gender and HADS-T 
  ANCOVA
a 
 Kolmogorov-Smirnov
b
  
 F statistic df p Statistic df p 
IL-2
 0.000 1,30 0.993 0.164 35 0.233 
IL-6 0.055 1,41 0.816 0.137 46 0.288 
IL-7
 0.013 1,38 0.908 0.123 43 0.460 
IL-8 0.439 1,42 0.511 0.087 47 0.829 
IL-12
 4.142 1,15 0.060 0.099 20 0.979 
IFNγ
c 4.561 1,20 0.045 0.187 25 0.265 
TNFα
 0.616 1,42 0.437 0.061 47 0.992 
IL-4 0.514 1,5 0.505 0.147 10 0.961 
IL-5 0.776 1,41 0.383 0.087 46 0.838 
IL-10 0.150 1,42 0.701 0.114 47 0.503 
IL-13
 0.066 1,9 0.803 0.196 14 0.542 
a
 ANCOVA data generated by SPSS; b Residuals generated by STATA 
c
 Significant difference, p<0.05; 
d
 Residuals not normally distributed, p<0.05 
These results have been generated excluding all cases that were missing or below the limit of detection. 
 
6.3 Regression analyses 
Logistic regression analyses will be performed to explore the predictor variables that 
contribute most to membership of the OA group, the PAR group and psychological distress.  
Variables predicting HADS-T score will be evaluated using linear regression. 
6.3.1 Selection of predictor variables. 
One of the first considerations in this step of the process is to maximise the number of cases 
that can be entered into the regression analysis without losing representation of important 
facets of the pain signaling process.  There are high percentages of missing values for IL-2, 
IL-4, IL-12, IL-13 and IFNγ.  These variables will be omitted from the analysis and this will 
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be considered while selecting other predictor variables so that representation from the 
appropriate groups of analytes will be included. 
Table 6.19 and Table 6.20  show all correlations between the independent variables.  Colour 
coding helps to identify the strongest significant relationships (those above r=0.7 and r=0.8).  
These correlations can also be viewed diagrammatically (Figure 6-6 and Figure 6-7) and 
demonstrate correlations within and between each group of analytes.  
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Table 6.19: Control group correlations between amino acids and cytokines 
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Table 6.20: OA group correlations between amino acids and cytokines 
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Figure 6-6: Diagrammatic representation of correlations in control group 
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Figure 6-7: Diagrammatic representation of correlations in OA group 
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The diagrammatic representations of the correlations help to visualize the relationships within 
and between groups of analytes in this data set (for groups see Table 5.3).  Within group 
relationships are denoted by connectors drawn across the group or around the outside of the 
group; between group connectors cross the central portion of the diagram. For example, in the 
control group it can be seen that there are more significant correlations within the excitatory 
amino acid group than there are in the OA group.  Similarly it can be seen that some group 
members have a number of relationships with analytes within their own group (e.g. IL-4 in 
the control group) and that these relationships do not necessarily occur in the OA group.  
Other analytes have few relationships within their own group e.g. IL-12.  
The members of the excitatory amino acid group have many significant associations both 
within and between groups.  Serine and glutamine are selected from this group because they 
have already demonstrated a significant difference in concentration between the OA group 
and the control group.  In addition citrulline will be selected from this group to represent the 
result of NMDAR activation and because it has a high number of associations between 
different groups.  
TNFα will be selected from the pro-inflammatory cytokine group because it is significantly 
higher in the OA group and because it has a number of relationships with the excitatory amino 
acids.  
The diagrammatic representations of the linear relationships illustrate relatively high number 
of correlations between the members of the large neutral amino acid group (leucine, 
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isoleucine, phenylalanine, tyrosine and valine). Valine and leucine will be selected as 
representatives for this group because they both differ significantly between the OA and 
control group and they both have strong associations with other members of their group. 
IL-10 will be selected from the anti-inflammatory group and GABA from the inhibitory 
amino acid group due to their high number of associations with other variables and known 
involvement in the pain modulation. This process has led to the selection of a set of predictor 
variables  
Box 6-1:Predictor variables for binary logistic regression OA/control 
HADS-T, age, gender, serine, glutamine, citrulline, valine, leucine, TNFα, IL-10, GABA 
 
6.3.2 Binary logistic regression: OA/control 
HADS-T, age and gender were included in the initial model for the binary logistic regression 
of OA/control. All other variables were included from the second step onwards using a 
forward likelihood ratio stepwise method.   
The model containing HADS-T, age, gender, serine, leucine and GABA (Table 6.21) 
correctly classified 94% of the OA cases and 56% of the control cases; overall the 
classification was correct in 84% of the cases.  
The goodness of fit test suggests that this model performs better than the initial model that 
contained only the constant ( = 24.910, p<0.00). Hosmer and Lemeshow poorness of fit test 
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also supports this model ( =5.406, p=0.713).  The model accounted for 56% (Nagelkerke 
R
2
) of the variance.  
Table 6.21: Binary logistic regression OA/control (n=62) 
 
B S.E. Wald df p 
Odds 
ratio 
95% C.I. for odds ratio 
Lower Upper 
S
te
p
 1
 
age 0.040 0.037 1.150 1 0.283 1.040 0.968 1.119 
gender 0.800 0.842 0.903 1 0.342 2.226 0.427 11.598 
HADS-T 0.244 0.086 8.071 1 0.004 1.277 1.079 1.511 
Serine 0.198 0.078 6.522 1 0.011 1.219 1.047 1.420 
Constant -8.675 3.575 5.889 1 0.015 0.000   
S
te
p
 2
 
age 0.048 0.040 1.385 1 0.239 1.049 0.969 1.135 
gender 1.449 1.001 2.094 1 0.148 4.259 0.598 30.311 
HADS-T 0.294 0.098 8.945 1 0.003 1.342 1.107 1.627 
Serine 0.158 0.082 3.709 1 0.054 1.172 0.997 1.376 
Leucine 0.297 0.177 2.838 1 0.092 1.346 0.953 1.903 
Constant -12.834 4.819 7.093 1 0.008 0.000   
S
te
p
 3
 
age 0.047 0.044 1.157 1 0.282 1.048 0.962 1.142 
gender 1.498 1.024 2.141 1 0.143 4.472 0.601 33.252 
HADS-T 0.315 0.101 9.649 1 0.002 1.371 1.123 1.672 
Serine 0.199 0.091 4.824 1 0.028 1.220 1.022 1.458 
Leucine 0.366 0.193 3.609 1 0.057 1.442 0.988 2.104 
GABA -0.022 0.014 2.708 1 0.100 0.978 0.952 1.004 
Constant -12.469 5.102 5.971 1 0.015 0.000   
 
This model suggests that being male, higher HADS-T, higher serine, higher leucine and lower 
GABA are predictive of belonging to the OA group at the level of p<0.15. HADS-T and 
serine are both significant contributors to the model at the level of p<0.05. 
6.3.2.1 Assumption checks for binary logistic regression OA/control 
There are no suggestions of multicollinearity within this data set (Table 6.22). 
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The case-wise listing produced in this regression analysis shows 4 cases are outliers with 
standardised residuals being > 2.58, which makes them significant at the 0.1 level (Table 
6.23).  
 
Table 6.22: Multicollinearity for regression analysis OA/control model 1 
 Tolerance VIF 
Serine 0.623 1.605 
Glutamine 0.752 1.330 
Leucine 0.119 8.381 
Valine 0.147 6.807 
Citrulline  0.555 1.802 
TNF alpha 0.407 2.454 
IL-10  0.478 2.092 
Age 0.763 1.310 
HADS-T 0.652 1.533 
GABA 0.993 1.007 
a
 Multicollinearity = Tolerance <0.1 and VIF>10 
 
 
Table 6.23: Outlying cases for logistic regression OA/Control 
Case 
Number 
Residual Standardised residual 
31 -0.919 -3.364 
50 0.907 3.131 
56 -0.878 -2.688 
76 -0.939 -9.914 
 
Examination of Cook’s Distance suggests case number 56 may have undue influence over the 
model (Table 6.24).  The average leverage for the regression is 0.079 (  =   ) and none of 
the outlying cases exceed the suggested cut-off point (0.238 to 0.395) (Table 6.24).   
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Table 6.24: Cook's Distance and leverage values for binary logistic regression OA/control 
Case Number  Cooks Distance Leverage value 
31  0.931 0.076 
50  0.742 0.070 
56  1.714 0.192 
76  0.906 0.056 
 
DFBeta values for each of the outlying cases is below the value for concern of 1 (Table 6.25) 
Table 6.25: DFBeta values binary logistic regression OA/control 
Case Number constant age gender HADS-T Serine 
31 2.408 -0.006 -0.007 -0.029 -0.067 
50 3.499 -0.018 -0.327 -0.077 -0.031 
56 -1.601 0.029 -0.517 -0.051 0.025 
76 3.587 -0.032 -0.001 -0.064 -0.025 
 
6.3.3 Binary logistic regression: PAR/0PAR 
A similar process to that undertaken for prediction of membership of the OA group was 
followed to determine which variables were most strongly associated with PAR in the OA 
group. 
Age, HADS-T, and gender were entered into the regression as an initial model.  Due the high 
numbers of missing values IL-2, IL-4, IL-12, and IL-13 were omitted from the model.  
Aspartate, and IFNγ were selected because they differ significantly in the 0PAR/PAR groups, 
however, IFNγ has a large number of missing values and this may create difficulties with the 
model due to the small number of cases.  Serine, citrulline, TNFα, IL-10 and POM were 
selected because of their theoretical importance to the development of PAR.  As in the 
previous model valine and leucine were chosen to represent the large neutral amino acids.   
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Box 6-2: Predictor variables for binary logistic regression PAR/0PAR 
HADS-T, age, gender, aspartate, serine, glutamine, citrulline, valine, leucine, TNFα, IL-10, IFNγ, 
POM 
 
In this model IFNγ was the first independent variable entered in the step-wise process but the 
large standard error, and the odds ratio/confidence intervals approaching zero suggest 
difficulty with convergence (Table 6.26).  
Table 6.26: Binary logistic regression PAR/0PAR (n=24) 
 
B S.E. Wald df Sig. Odds ratio 95% C.I. for odds ratio 
Lower Upper 
 age -0.164 0.079 4.286 1 0.038 0.849 0.727 0.991 
gender 2.037 1.392 2.141 1 0.143 7.666 0.501 117.348 
HADS-T 0.114 0.109 1.096 1 0.295 1.121 0.905 1.387 
IFNγ -25.440 12.636 4.054 1 0.044 0.000
a 
0.000
a 
0.509 
Constant 10.949 5.600 3.822 1 0.051 56885.398   
a 
Approaching zero 
 
The model was repeated without IFNγ (Box 6-3).  
Box 6-3: Variables in the equation logistic regression PAR/0PAR version 2 
HADS-T, age, gender, aspartate, serine, glutamine, citrulline, valine, leucine, TNFα, IL-10, POM 
 
The model produced in version 2 of the binary logistic regression for membership of the PAR 
group correctly classified 46% of the PAR group and 71% of the 0PAR group, the overall 
classification was 60%.  Step 2 of this model reveals that there may be a failure to converge 
(indicated by the large confidence intervals and standard error relating to aspartate) (Table 
6.27).  
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Table 6.27: Binary logistic regression PAR/0PAR version 2 (n=61) 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
S
te
p
 1
 
age -0.012 0.038 0.103 1 0.748 0.988 0.918 1.064 
gender 0.991 0.769 1.660 1 0.198 2.694 0.597 12.163 
HADS-T -0.005 0.068 0.005 1 0.945 0.995 0.871 1.138 
POM 0.730 0.210 12.119 1 0.000 2.074 1.375 3.128 
Constant -3.539 3.157 1.257 1 0.262 0.029   
S
te
p
 2
 
age -0.001 0.041 0.000 1 0.985 0.999 0.922 1.083 
gender 0.819 0.833 0.966 1 0.326 2.268 0.443 11.604 
HADS-T 0.014 0.073 0.039 1 0.843 1.015 0.879 1.171 
POM 0.773 0.223 12.036 1 0.001 2.166 1.400 3.352 
Aspartate -13.611 6.212 4.801 1 0.028 0.000
a 
0.000
a 
0.238 
Constant -0.212 3.715 0.003 1 0.954 0.809   
a 
approaching zero 
 
The model (HADS-T, age, gender, aspartate, and POM) performs better than the constant-
only model (Goodness of fit ( = 19.622, p=0.001). Hosmer and Lemeshow poorness of fit 
test also supports this model ( =4.681, p=0.699). The model accounted for 66% (Nagelkerke 
R
2
) of the variance between the two groups.  
This model suggests that increasing levels of aspartate and POM are associated with an 
increased likelihood of a person with OA having PAR.  
6.3.3.1 Assumption checks for binary logistic regression PAR/0PAR 
There is no sign of multicollinearity within the predictor variable group used in this model 
(Table 6.28). 
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Case-wise listing of outliers reveals two cases with standardised residuals greater than 2.58, 
making them significant at the 0.1 level (Table 6.29). 
Table 6.28: Multicollinearity testing logistic regression PAR/0PAR 
 Tolerance VIF 
Serine  0.720 1.388 
Valine  0.156 6.402 
Citrulline   0.555 1.803 
TNFα  0.495 2.022 
IL-10  0.464 2.155 
Age 0.748 1.338 
HADS-T 0.689 1.451 
IFNγ 0.707 1.414 
Aspartate   0.738 1.355 
Leucine  0.112 8.926 
POM 0.738 1.346 
Multicollinearity =Tolerance <0.1 and VIF>10 
 
Table 6.29: Outlying cases in logistic regression PAR/0PAR model 
Case 
Number 
Residual Standardised residual 
12 0.888 2.819 
27 0.724 1.620 
50 0.959 4.867 
64 -0.843 -2.319 
 
Examination of Cook’s Distance suggests cases 27, 50 and 64 may have undue influence over 
the model (Table 6.30).  The average leverage for the regression is 0.098 (  =   ) and 
cases 12 and 27 exceed the suggested cut-off point (0.196 to 0.294) (Table 6.30).   
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Table 6.30: Cook's Distance and leverage values for binary logistic regression PAR/0PAR 
Case Number  Cooks Distance Leverage value 
12  0.811 0.654 
27  1.518 0.268 
50  1.777 0.043 
64  1.099 0.185 
Influential cases: Cook’s Di >1, Leverage > 2-3 times average leverage (  
DFBeta values for each of the outlying cases are acceptable for all variables except aspartate 
(Table 6.31). This suggests that these four cases are influential outliers with regard to this 
model. 
Table 6.31: DFBeta values binary logistic regression PAR/0PAR 
Case 
Number constant age gender HADS-T POM 
 
Aspartate 
12 1.807 -0.017 -0.252 0.001 -0.149 1.546 
27 4.922 -0.043 -0.094 -0.030 -0.151 -0.958 
50 2.238 -0.017 0.0294 -0.057 -0.200 3.421 
64 -3.149 0.030 -0.513 -0.013 0.001 3.744 
 
6.3.3.2 Repetition of binary logistic regression PAR/0PAR after removal of influential 
cases 
Repeating the logistic regression (using the enter method; Table 6.32) after the deletion of 
these four cases improves the classification of PAR from 46% to 88%, and classification of 
the 0PAR from 71% to 88%.  The amount of variance the model accounts for increases from 
66% to 76% (Nagelkerke R
2
).   
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Table 6.32: Logistic regression PAR/0PAR after removal of influential cases 
 
B S.E. Wald df p 
Odds ratio 95% C.I. for Odds 
ratio 
Lower Upper 
S
te
p
 1
 
age -0.019 0.044 0.192 1 0.661 0.981 0.901 1.069 
gender 1.581 0.903 3.063 1 0.080 4.858 0.827 28.522 
HADS-T -0.007 0.072 0.008 1 0.927 0.993 0.862 1.145 
POM 0.873 0.271 10.346 1 0.001 2.393 1.406 4.072 
Constant -4.154 3.740 1.234 1 0.267 0.016   
S
te
p
 2
 
age -0.017 0.048 0.130 1 0.718 0.983 0.895 1.080 
gender 1.904 1.121 2.886 1 0.089 6.715 0.746 60.427 
HADS-T 0.035 .083 0.177 1 0.674 1.035 0.880 1.218 
POM 1.024 .319 10.275 1 0.001 2.783 1.488 5.204 
Aspartate -21.274 8.500 6.264 1 0.012 0.000
a 
0.000
a 
0.010 
Constant 1.342 4.521 0.088 1 0.767 3.827   
 
This model suggests higher levels of POM and aspartate are associated with being a member 
of the PAR group.  
 
6.3.4 Binary logistic regression whole group: presence or absence of 
psychological distress (total cohort)  
Psychological distress was defined as a HADS-T score of 12 or greater.  High numbers of 
missing values IL-2, IL-4, IL-12, and IL-13 led to these predictor variables not being entered 
into the model.  HADS-T did not correlate with many of the amino acid and cytokine 
variables and so guidance for inclusion from examination of correlation coefficients was not 
helpful.  Tryptophan and the large neutral amino acids have a strong theoretical relationship 
with depression and so the variable ΣLNAA was created by summation of leucine, isoleucine, 
phenylalanine, tyrosine and valine.   POM, glutamate and GABA have been shown in other 
studies to vary with stress and depression and so both are included in the model. The 
hypothesised relationship between pain/central sensitisation and depression mediated by 
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cytokines led to the selection of TNFα and IL-10 as representatives of pro and anti-
inflammatory processes in the dorsal horn being included in the model.  The potential 
involvement of the NMDAR in depression and pain led to the selection of serine (Box 6-4).   
 
Box 6-4: Predictor variables for binary logistic regression psychological distress 
Age, gender, glutamate, GABA, TNFα, IL-10, serine, tryptophan, ΣLNAA, POM 
 
Age and gender were made part of the basic model and then the other predictor variables were 
entered using a forward step-wise process.  Serine and POM made a significant contribution 
to the model (Table 6.33). 
 
Table 6.33: Logistic regression Psychological Distress (HADS-T ≥12)(n=63) 
 
B S.E. Wald df Sig. 
Odds 
ratio 
95% C.I. for Odds 
ratio 
Lower Upper 
S
te
p
 1
a
 
age -0.014 0.025 .295 1 0.587 0.986 0.939 1.037 
gender 0.670 0.557 1.446 1 0.229 1.954 0.656 5.826 
POM 0.155 0.087 3.154 1 0.076 1.168 0.984 1.386 
Constant 0.053 1.797 .001 1 0.976 1.055   
S
te
p
 2
b
 
age -0.006 0.026 .054 1 0.816 0.994 0.944 1.047 
gender 0.666 0.579 1.323 1 0.250 1.946 0.626 6.051 
Serine -0.129 0.061 4.452 1 0.035 0.879 0.779 0.991 
POM 0.237 0.104 5.166 1 0.023 1.267 1.033 1.554 
Constant 1.982 2.078 .910 1 0.340 7.256   
 
 
The model (age, gender, POM and serine) performs better than the constant-only model 
(Goodness of fit = 11.624, p<0.020). Hosmer and Lemeshow poorness of fit test also 
supports this model ( =10.617, p=0.224). The model correctly predicted 70% of the 
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psychological distress cases and accounted for 23% (Nagelkerke r
2
) of the variance between 
the two groups. 
This model suggests decreasing levels of serine and increasing POM are associated with an 
increased likelihood of a person having a HADS-T score ≥12. 
6.3.4.1 Assumption checks for binary logistic regression whole group: psychological 
distress 
There is no sign of multicollinearity within the predictor variable group used in this model 
(Table 6.34). 
Table 6.34: Multicollinearity testing logistic regression psychological distress 
 Tolerance VIF 
Age 0.840 1.190 
Gender 0.691 1.447 
Glutamate 0.648 1.544 
GABA 0.592 1.689 
Serine 0.680 1.471 
POM 0.668 1.498 
TNFα 0.451 2.215 
IL-10 0.416 2.404 
Tryptophan 0.662 1.511 
ΣLNAA 0.730 1.371 
Multicollinearity =Tolerance <0.1 and VIF>10 
 
Case-wise listing of outliers reveals two cases with standardised residuals approaching or 
greater than 2.58, making case 67 significant at the 0.1 level (Table 6.35). 
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Table 6.35: Outlying cases in logistic regression psychological distress model 
Case 
Number 
Residual Standardised residual 
55 -0.867 -2.551 
67 -0.930 -3.643 
 
Examination of Cook’s Distance suggests neither case has undue influence over the model 
(Table 6.36).  The average leverage for the regression is 0.079 (  =   ) and neither case 
exceeds the suggested cut-off point (0.238 to 0.396) (Table 6.36).   
Table 6.36: Cook's Distance and leverage values for binary logistic regression psychological distress 
Case Number  Cooks Distance Leverage value 
55  0.358 0.052 
67  0.991 0.069 
Influential cases: Cook’s Di >1, Leverage > 2-3 times average leverage (  
DFBeta values for each of the outlying cases is below the value for concern of 1 (Table 6.37).   
Table 6.37: DFBeta values binary logistic regression psychological distress 
Case 
Number constant age gender serine POM 
55 -0.520 0.002 -0.153 0.024 -0.041 
67 -0.196 -0.009 -0.138 0.053 -0.066 
 
There are no concerns raised by examination of the assumptions for the binary logistic 
regression of psychological distress in the whole group. 
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6.3.4.2 Assumption checks for binary logistic regression OA group: psychological 
distress 
There is no sign of multicollinearity within the predictor variable group used in this model 
(Table 6.38). 
Table 6.38: Multicollinearity testing logistic regression OA group psychological distress 
 Tolerance VIF 
Age 0.671 1.489 
Gender 0.708 1.413 
Glutamate 0.590 1.696 
GABA 0.515 1.943 
Serine 0.697 1.435 
POM 0.562 1.781 
TNFα 0.212 4.712 
IL-10 0.258 3.878 
Tryptophan 0.637 1.571 
ΣLNAA 0.548 1.826 
Multicollinearity =Tolerance <0.1 and VIF>10 
 
There were no outlying cases. 
6.3.5 Multiple linear regression: HADS-T 
HADS-T is a continuous variable, which can be dichotomised to indicate presence of absence 
of psychological distress.  However, the cut-off point for psychological distress may differ 
from population to population and therefore a linear regression will be undertaken using this 
variable in its continuous form. 
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The independent variables entered into the linear regression were glutamate, GABA, TNFα, 
IL-10, serine, ΣLNAA, POM, gender and age: the same used in the logistic regression 
predicting presence of psychological distress (Box 6-4). 
The model is able to predict HADS-T (F5, 57=5.723, p<0.001) and accounts for 33% of the 
variance of HADS-T (R
2
).  Being female, younger, increasing pain, TNFα and decreasing 
serine are associated with an increasing HADS-T (Table 6.39).  
Table 6.39: Linear regression HADS-T (n=60) 
 B SE t p 
95% confidence interval 
for B 
Age -0.118 0.061 -1.948 0.056 -0.0240 0.003 
Gender -2.885 1.339 -2.154 0.035 -5.567 -0.203 
POM 0.640 0.213 3.009 0.004 0.214 1.065 
Serine -0.330 0.128 -2.575 0.013 -0.587 -0.073 
TNFα 14.720 6.741 2.184 0.033 1.221 28.219 
 
6.3.5.1 Assumption checks for linear regression HADS-T 
There was no multicollinearity within the predictor variables (Table 6.40).  The Durbin-
Watson statistic was 2.275; with 5 predictor variables and n=60 bounds for the Dubin-Watson 
statistic are 1.41 to 1.77.  The observed d is greater than this value and therefore there is no 
serial correlation between residuals.   
There were no outlying cases with a standardised residual >2.5. Cook’s Distance was below 1 
for all cases (minimum <0.001 to maximum 0.120).  
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Table 6.40: Multicollinearity statistics for linear regression HADS-T 
 Tolerance VIF 
Age 0.896 1.116 
Gender 0.870 1.149 
POM 0.822 1.216 
Serine 0.844 1.185 
TNFα 0.814 1.229 
Multicollinearity =Tolerance <0.1 and VIF>10 
 
6.4 Summary of results 
A total of 59 cases and 21 controls were entered into the analysis.  The age and gender of the 
OA group is similar to the national profile for hip and knee arthroplasty.  The groups were 
similar in terms of age but the OA group contained a higher proportion of men than the 
control group.  There was no gender or age difference when the PAR group was compared 
with the 0PAR group.  The proportion of primary OA sites (hip: knee) was similar in the PAR 
and the 0PAR groups. 
The median POM in the OA group was 6, and POM was higher in those participants who had 
PAR. The median PAR was 2 and 59% of the OA group had PAR.  
The total HADS score and the proportion of participants with psychological distress (HADS-
T ≥12) is significantly higher in the OA group than the control group.  The proportion of 
participants with psychological distress in the PAR and 0PAR groups was similar.  
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There were a high number of cases with variables below the level of detection in the cytokine 
data and the study was underpowered for most of the amino acids and cytokines with the 
exception of serine and TNFα.  The data was not normally distributed. 
Comparison of concentrations of amino acids and cytokines in the OA and control groups 
identified significantly higher levels of serine, valine, leucine and TNFα in the OA group.  IL-
12 was significantly lower in the OA group than the control group.  These differences were 
significant after adjustments were made for age, gender and HADS-T. 
When amino acids and cytokines were compared in the PAR and 0PAR group aspartate and 
IFNγ were found to be significantly higher in the 0PAR group. These differences were 
significant after adjustments were made for age, gender and HADS-T. 
Binary logistic regression analyses revealed that membership of the OA group was predicted 
by a model containing age, gender, HADS-T, serine, leucine and GABA.  The model suggests 
that being male, higher HADS-T, higher serine, higher leucine and lower GABA are 
predictive of belonging to the OA group.  
Membership of 0PAR/PAR groups was predicted by a model containing age, gender, HADS-
T, POM, aspartate and IFNγ but IFNγ had a very low odds ratio and large confidence interval 
for the odds ratio.  IFNγ was withdrawn from the model as it was felt that small numbers of 
cases with a value for this variable affected the convergence.  The second version of the 
model containing age, gender, POM, HADS-T, and aspartate was also able to predict 
membership of the PAR group and increases in aspartate and POM made a significant 
contribution to the model.  
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Serine and POM were associated with an increased likelihood of membership of the 
psychological distress (HADS-T≥12) group.  Increases in serine and POM made a significant 
contribution to this model.  A multiple linear regression exploring HADS-T score identified 
being female, increasing POM, decreasing serine, and increasing TNFα as significant 
predictors of increasing HADS scores.   
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Chapter 7 Discussion 
This study is first to report a concurrent exploration of amino acids, cytokines and mood in 
the CSF of people with OA.  The study has identified a significant increase in serine and TNF 
in CSF and this can be interpreted to support the presence of central sensitisation in OA pain.  
This enables the null hypothesis, that there was no difference in amino acids and cytokines 
between the OA and control groups, to be rejected. 
 
This study is one of the first to report the concentrations of a large number of amino acids and 
cytokines in human CSF and the first to do this in people with osteoarthritis.  The findings are 
interesting both for the support they offer to the case for central sensitization in OA pain and 
also because there are differences between OA and control groups that are unexpected, such 
as the significantly lower level of IL-12 in the 0PAR group when compared with the PAR 
group.  IL-12 has been regarded in neuropathic pain studies to have a pro-inflammatory role.  
It is possible that this reflects an anti-inflammatory role for this cytokine in central OA pain 
signaling and thus this reduced level represents and imbalance between pro- and anti-
inflammatory activities in OA pain.  An anti-inflammatory role has been attributed to this 
cytokine in an inflammatory model of the dorsal root ganglion (Xie et al. 2006a) but there are 
no reports of IL-12 in the CSF of clinical pain studies at present.  
 
Increased levels of TNFα in the CSF in OA indicate glial activation, an important requirement 
for central sensitisation.  This is supported by the observation of increased serine, a co-agonist 
of the NMDA receptor whose activation is also a requirement for central sensitisation. This 
study is one of very few to report on levels of serine in the CSF and as such adds important 
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information to our understanding of the role of this amino acid, so far only reported in animal 
studies.  
 
As well as being elevated in the OA group when compared with the control group, increased 
serine was also a significant contributor to a regression model for membership of the OA 
group, and decreasing serine was a significant predictor for membership of the psychological 
distress group (HADS-T≥12).   
 
There were minimal differences between the 0PAR and PAR groups in this study and the 
differences that were significant were not those expected. This means that the null hypothesis 
in respect of these groups cannot be rejected.  Lower levels of IFNγ in the PAR group suggest 
increased anti-inflammatory activity in this sub-group.  This does not fit in with the reports 
from other studies identifying pain at rest as a risk factor for persistent post-operative pain in 
arthroplasty patients (Wylde et al. 2011a; Lundblad et al. 2008).  Those reports lead to the 
expectation that that pro-inflammatory cytokine levels would be elevated in the CSF of the 
PAR sub-group. It is interesting finding therefore that a group suggested by other research to 
have higher levels of central sensitisation should have lower levels of molecules that explain 
the sensitisation process.  Equally anomalous is the finding in this study that there was no 
difference in the levels of HADS between the PAR and 0PAR groups.  This finding is 
unexpected as one might expect a group troubled by spontaneous pain and rest pain to be 
more distressed by that experience than those whose pain tends to be stimulus-evoked. These 
findings call into question the meaning of pain at rest in OA. 
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Psychological distress was defined as having a HADS-T score greater than 12 and this was 
more prevalent in the OA group than the control group than the OA group.  HADS score was 
also significantly higher in the OA group.  This is an important finding which supports 
previous work demonstrating that OA is co-morbid with depression in many people and adds 
to this body of evidence.  
 
The finding that increased TNFα is a predictor of psychological distress is in agreement with 
current neurobiological models of depression and pain, which identify raised CNS cytokine 
levels as part of the process. However, the regression model in the current study also 
identified that decreasing levels of serine and increasing levels of pain on movement were 
associated with also predictive of psychological distress and increasing HADS-T.  This is an 
unexpected result as the most likely role for serine to play in the mediation of pain is as an 
NMDA receptor activator. Thus, in situations where increased pain, and increased 
psychological distress are present one might also expect increased serine.  The anomaly is 
further underlined by the absence of linear correlation between serine and POM, PAR or 
TNFα. 
 
The role of tryptophan metabolism and 5-HT are equally important in the development of 
depression and the OA group in the present study has elevated leucine and valine levels, two 
of the large neutral amino acids that compete with tryptophan for active transport across the 
blood brain barrier.  This might represent a relative imbalance in tryptophan in depression in 
OA.  
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This chapter will present the evidence from the present study in support of the presence of 
central sensitisation in OA pain.  A brief over-view of central sensitisation will provide 
background for the discussion of the findings of this study.  Throughout the discussion the 
current findings, both positive and negative, will be explored in the context of clinical 
research.  The findings will be related both to pain and to psychological distress or mood 
where this is relevant.  
 
This chapter will begin by exploring the evidence for central sensitisation from the findings 
related to the pro-inflammatory cytokines with a focus on TNFα.  Following on from this the 
role of the anti-inflammatory cytokines in OA will be discussed, including a novel proposed 
role for IL-12 as an anti-inflammatory agent in this study.  At the end of the section 
discussing the role of cytokines the relationship between peripheral and central cytokine 
levels will be explored.  This will be followed by a discussion of the role of excitatory and 
inhibitory amino acids with a focus on the role of serine, and the combined roles of glutamate, 
glutamine and GABA.  
 
The notion of rest pain will then be explored with a particular focus on the role of IFNγ and 
HADS-T.  Finally the discussion section will end with a review of what the results relating to 
tryptophan and the large neutral amino acids suggest about psychological distress in this 
cohort.  
 
The chapter will end by discussing the implications of the findings for people who have OA 
pain, describing the limitations of the present study and addressing these in a plan for further 
work to continue to explore OA pain.    
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7.1 Support for central sensitisation in OA from the present study 
Increased concentration of TNFα and serine in the OA group in comparison to the pain free 
control group can be interpreted to support central sensitisation as a mechanism involved in 
the pain experience in OA.  This study also offers correlational support of central sensitisation 
from other cytokine and amino acid analytes.  This result has implications for the accumulated 
knowledge to date on central sensitisation.  
Central sensitisation is defined as ‘increased responsiveness of nociceptive neurons in the 
central nervous system to their normal or subthreshold afferent input’ (Merskey and Bogduk 
2011).  Most synaptic input to neurons is sub-threshold and has little or no effect on the post-
synaptic cell either because the signal strength is too weak or because the inhibitory inputs to 
the membrane are sufficient to overcome the signal.  These sub-threshold signals can cause 
action potentials however if there is an increase in pre-synaptic excitatory transmitter release, 
if the inhibitory processes are themselves inhibited (disinhibition) or if the excitability of the 
post-synaptic membrane is increased (Woolf 2011). These processes together contribute to the 
state of central sensitisation. 
Central sensitisation features altered sensation in the form of hyperalgesia and allodynia.    
Following injury there is an increase in afferent signaling that leads to neurochemical 
changes.  These changes create a heightened sensitivity in the dorsal horn such that 
subthreshold stimuli can evoke pain (hyperalgesia) as can innocuous stimuli (allodynia).   
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This is highly relevant as it is thought that these changes account for some of the discrepancy 
between radiographic findings and the severity of pain experienced by people with OA 
(Graven-Nielsen et al. 2012).  In other words, people with OA experience disproportionate 
pain in comparison with the level of joint damage and inflammation that can be observed 
radiographically (see 1.2.1.1).    
Movement in the normal range is painful in OA because of peripheral and central 
sensitisation.  This lowers the threshold of nociceptive fibres in the joint so that normal range 
of movement and relatively innocuous mechanical stimulation can trigger action potentials.  
This is hyperalgesia and it has been demonstrated in OA by a reduction in pressure pain 
thresholds (Farrell et al. 2000; Graven-Nielsen et al. 2012; Imamura et al. 2008) and a 
heightened response to noxious muscle stimulation in the form of saline injection (Bajaj et al. 
2001).  Hyperalgesia of the joint can be explained partly by local sensitisation (primary 
sensitisation) but OA is also associated with alterations in sensitivity at sites distant to the 
diseased joint.  
Centrally driven sensitisation also accounts for alterations in sensitivity and pain threshold 
that are found at sites distant to the affected joint (Bradley et al. 2004; Lundblad et al. 2008; 
Wylde et al. 2012).  Lundblad et al (2008) assessed sensation and pain threshold in 69 pre-
operative knee arthroplasty participants using electrical stimulation via electrodes grasped 
between the thumb and index finger.  The OA participants had significantly higher sensation 
thresholds and significantly lower pain thresholds than an age and gender matched control 
group.  The fact that these alterations in threshold were distant to the primary pain site 
demonstrates that the changes are centrally mediated. 
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Wylde et al (2012) performed quantitative sensory testing on 107 people with knee OA and 
50 healthy controls and found that 71% of the OA participants had at least one somatosensory 
abnormality including reduced thermal and tactile thresholds as well as pressure hyperalgesia.  
Again, the sensory changes were distant to the primary pain site demonstrating that changes to 
sensitivity were central and had a widespread effect.  These findings are felt to provide direct 
evidence that central sensitisation is an integral part of OA pain but until recently there has 
been no evidence from within the CNS to support these findings or explain how these changes 
are mediated in clinical OA pain.  
Information about the processes and substrates involved in central sensitization originates 
mainly from in vitro and in vivo animal work and has been confirmed in humans mainly 
through studies of neuropathic pain conditions.  Up until this point there has been little 
evidence of the central sensitization process in OA from a neurochemical perspective. The 
present study addresses this and provides support for the notion that central sensitization is an 
integral part of the OA pain experience.  
7.1.1 Cytokine activity in the dorsal horn in OA pain 
One of the main findings of the present study was that TNFα was significantly higher in the 
OA group than the control group and that IL-12 was lower.  The production of TNFα is a key 
component of the central sensitisation process and indicates glial activation is part of the pain 
mechanism in this condition.  There have been very few reports of IL-12 in pain-related 
studies prior to this one, and its role is less well defined than TNFα, but this study supports an 
anti-inflammatory role that together with the finding of increased TNFα  in the OA group 
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suggests an imbalance between pro-inflammatory and anti-inflammatory activity in favour of 
pro-inflammation.  
 
7.1.2 Pro-inflammatory cytokines in the CSF in OA pain 
7.1.2.1 The role of CSF TNFα as a pro-inflammatory cytokine in OA pain 
There are relatively few clinical studies of cytokines in the CSF and the present study is one 
of the few pain-related clinical studies to report TNFα levels (Table 7.1).  This pro-
inflammatory cytokine is reported variously as being undetectable, unchanged and higher in 
pain groups in comparison to pain-free controls in published studies.  As a key molecule 
involved in the genesis of central sensitisation one might expect to find more consistent 
evidence of increased levels of TNFα in these studies, many of which involve pains where 
central sensitisation is a known mechanism.    
TNFα was undetectable in participants with neuropathic pain (Backonja et al. 2008), migraine 
and headache (Bo et al. 2009) and post-operative OA patients who had been given anti-
inflammatory medication (Buvanendran et al. 2005).  It was no different to the control 
participants in studies investigating pre-operative OA (Lundborg et al. 2010), Complex 
Regional Pain Syndrome (CRPS) (Alexander et al. 2005), sciatica (Brisby et al. 2002), painful 
polyneuropathy (Ludwig et al. 2008) and post-herpetic neuralgia (Kikuchi et al. 1999).  The 
only published clinical study demonstrating an increased level of TNFα found that it was 
elevated in people with persistent daily headache when compared with those who had chronic 
migraine (Rozen and Swidan 2007).  This latter finding was explained by the research team as 
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resulting from the likely infective pathogenesis of new persistent daily headache, which thus 
was associated with central nervous system inflammation.    
 
Backonja  et al (2008) studied people with  CRPS and diabetic neuropathy and hypothesised 
that pro-inflammatory cytokines would be found in higher levels in the CSF of the 
participants with pain than the pain-free controls but levels of TNFα were undetectable.  They 
found instead that soluble TNF receptor (sTNFr) was significantly higher in participants with 
CRPS and diabetic neuropathy than in their healthy volunteers.  Soluble TNF receptors are 
shed from membranes and compete with membrane bound receptors for TNFα and therefore 
block the activity of TNFα.  TNFα and sTNFr levels are thought to closely reflect one another 
because the induction process is the same (Aderka 1996); the shedding of the sTNFr is 
stimulated by TNFα itself as well as other cytokines such as IL-1β, IL-2, IL-6 and IFNγ 
(Aderka 1996).  Backonja et al ( 2008) suggested that elevated levels of sTNFr in the CSF 
indicate that TNFα was being locally produced despite it not being present in detectable 
levels.  Thus other studies that fail to detect elevated levels of TNFα might find elevated 
levels of sTNFr.      
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Table 7.1: Clinical pain studies exploring cytokines in CSF of people with painful conditions 
Author Focus Control groups Molecules of interest Summary of changes observed 
Maier et al (2005) Healthy volunteers 
(n=113) 
 IL-6, IL-8, IL-10  
Alexander et al (2005) CRPS (n=24) Mixed (pain and pain 
free) (n=16) 
IL-1β, IL-6, TNFα IL-6 
=IL-1β,  TNFα 
Alexander  et al (2007) CRPS (n=22) Mixed (pain and pain 
free) (n=31) 
IL-4, IL-10, IL-6, IL-8, 
MCP-1, GFAP, nitrate, 
nitrite, glutamat3 
IL-6 
IL-4, IL-10 
Backonja  et al ( 2008) Post-traumatic neuralgia + 
CRPS (8),  painful 
diabetic neuropathy (6) 
Healthy volunteers (n=6) IL-1β, IL-6, TNFα, 
sTNFr, IL-1ra, IL-8, IL-
10, SP 
sTNFr and IL-10 in pain group 
TNFα undetectable 
 
Bo  et al (2009) Migraine, headache 
(n=107) 
Neurological diagnosis 
normal and no pain 
(n=20) 
IL-1β, IL-1ra, IL-4, IL-
10, TNFα, MCP1, TGFb1 
IL-1β, TNFα undetectable in most 
samples 
Brisby et al (2002) Disc herniation + sciatica 
(n=39) 
 IL-1β, IL-6, IL-8, IFNγ, 
TNFα,  
= IL-1β, IL-6, IFNγ, TNFα  
IL-8 in 12 out of 39.   
Buvanendran  et al 
(2005) 
OA: elective joint 
replacement (n=20)  
Placebo (n=10) PGE2, IL-1β, IL-6, IL-8, 
TNFα 
IL-1β, TNFα were undetectable.  
Pre-operative Rofecoxib reduced 
CSF PGE2 and IL-6.   
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Author Focus Control groups Molecules of interest Summary of changes observed 
Kadetoff et al  (2012) Fibromyalgia (n=15) Non-inflammatory neurological 
symptoms (n=11) 
IL-1β, IL-8 IL-8  
=IL-1β 
Kikuchi  et al (1999) Post-herpetic neuralgia 
(n=25) 
 IL-1β, IL-8, IL-6, 
TNFα 
IL-8 decreased after intrathecal steroid.  
Other cytokines ‘normal’. 
Kotani et al (2004) Post-herpetic neuralgia 
(n=277) 
 IL-8 IL-8 decreased with duration of pain 
Ludwig  et al (2008) Painful polyneuropathy 
(n=18) 
Painless polyneuropathy (n=18) TNFα, IL-6 =IL-6, TNFα   
Lundborg et al (2010) Osteoarthritis (n=20) Gynaecological or urological 
surgery (n=20) 
GDNF, IL-1β, IL-6, 
TNFα, IL-8, IL-10 
GDNF, IL-8, IL-1β.   
=TNFα, IL-6 
Munts  et al (2008) CRPS with dystonia - 
women only (n=20) 
TURP, knee replacement, general 
surgery  (n=29)  
IL-1β, IL-6,  =IL-1β, IL-6 and NO  
Rozen & Swidan (2007) Daily persistent headache 
(n=20) 
Chronic migraine (n=16) TNFα TNFα  
Sarchielli et al (2001) Chronic migraine,   
Fibromyalgia (n=20) 
Age and sex matched (n=20) NGF, BDNF, 
glutamate 
glutamate 
Yeager et al (1999) Post joint replacement 
surgery (n=19) 
Healthy volunteers (n=6) IL-6, IL-10  IL6,  
= IL10 
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Backonja et al. speculate that rapid metabolism of TNFα makes it difficult to detect this 
cytokine but this does not explain why it is detected in other studies that explore similarly 
persistent pains including other CRPS studies (Alexander et al. 2005).  It is also possible 
that TNFα was below the level of detection in a number of the clinical studies and yet it 
might still be present in sufficient concentration to have an effect.   It is likely that a 
combination of these factors has led to a failure to detect increased levels of TNFα in the 
CSF of people with pain conditions where glial activation is known to be involved.   
Lundborg et al (2010) is a particularly interesting study as it involves the same patient 
group as the present study.   Their aim was to explore the concentrations of pro-
inflammatory cytokines (IL-1β, IL-6, IL-8 and TNFα) as well as IL-10 and glial derived 
neurotrophic factor (GDNF) in the blood and the CSF.  The main focus of the study was 
GDNF and they found that this was elevated in the CSF and reduced in the blood in the 
pain cases. GDNF has pro-algesic effects in inflammatory conditions (Fang et al. 2003) 
and analgesic effects in neuropathic (Leffler et al. 2002; Boucher et al. 2000).  Lundborg et 
al (2010) conclude that the GDNF increase they observed was as a result of its production 
within the CNS and that is was acting in a pro-algesic fashion.  They found that TNFα was 
present in similar levels in pain cases and controls while IL-1β and IL-8 were elevated in 
the CSF of the OA group.  The lack of difference in TNFα in the Lundborg et al. study 
may be explained, as hypothesised by Backonja et al (2008) by an actual but unmeasured 
difference in sTNFr.  Their finding of increased IL-1β and IL-8 supports a pro-
inflammatory process in their OA sample.   
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7.1.2.2 The role of CSF IL-1β in OA pain 
IL-1β was largely undetectable in the samples in the present study despite the high 
sensitivity of the assay.  However, it is not unusual to fail to detect this cytokine.  A 
number of clinical studies in which IL-1β was included for assay have similarly failed to 
detect it (Table 7.1) including in post-operative OA (Buvanendran et al. 2006), post-
herpetic neuralgia (Kikuchi et al. 1999), spinal stenosis and disc degeneration (Scuderi et 
al. 2006), and chronic fatigue syndrome (Natelson et al. 2005).  In studies where IL-1β has 
been detected no significant difference has been observed in its concentration when 
compared to the pain free control group, including CRPS (Munts et al. 2008; Alexander et 
al. 2005), sciatica (Brisby et al. 2002) and fibromyalgia (Lundborg et al. 2010).  No studies 
have at present reported IL-1β to be increased in people with painful conditions.  
The role of IL-1β in OA pain has been demonstrated in animal studies.  Inhibition of IL-1β 
leads to an improvement in the condition of the osteoarthritic animal joint (Fiorentino et al. 
2008) and Rheumatoid joint (Guo et al. 2007; Boyle et al. 2002).   
The role of IL-1β in pain transmission may need to be inferred indirectly.  IL-1β often 
correlates with IL-6 and TNFα because activation of glia results in the production of all the 
pro-inflammatory cytokines as a cascade (Milligan and Watkins 2009).  This correlation 
has been reported in animal models of inflammatory arthritis (Bao et al. 2001; Sweitzer et 
al. 1999).   Thus activity of IL-1β may be inferred from observing activity of other pro-
inflammatory cytokines.  
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IL-1β also plays an important role in the induction of cox-2 and thus amplification of pain 
via centrally produced prostaglandins (Narita et al. 2008).  Thus it may be possible to infer 
the involvement of IL-1β in a pain signaling cascade from observation of increased 
prostaglandin E2.  Although it has been observed that PGE2 is evoked in measurable 
quantities in an animal model of arthritis (Ebersberger et al. 1999; Sorkin and Moore 1996) 
there are no published clinical studies at present exploring PGE2 in OA.  
7.1.2.3 The role of CSF IL-6 and IL-8 in OA pain 
In the present study there was no difference between IL-6 or IL-8 concentration in the OA 
group and the control group.  Retrospective power calculation revealed that the study was 
underpowered for detecting a difference in either between the groups.  There were 
moderate positive correlations between TNFα, IL-6 and IL-8 in the OA group although IL-
6 and TNFα did not correlate in the control group.  This is not unexpected given the usual 
pattern of release of pro-inflammatory cytokines and this suggests that with a better 
powered study an increase in IL-6 and/or IL-8 may have been seen.  
The majority of clinical studies that have set out to explore CSF IL-6 levels have likewise 
not been able to detect a difference between their pain cases and the pain-free controls 
(Table 7.1). These studies include investigations of CRPS (Munts et al. 2008), 
polyneuropathy (Ludwig et al. 2008), and osteoarthritis (Lundborg et al. 2010).  However, 
increased levels of IL-6 have been observed in the CSF of patients with CRPS (Alexander 
et al. 2007; Alexander et al. 2005).  Increases in IL-8 have been observed in osteoarthritis 
(Lundborg et al. 2010), fibromyalgia (Kadetoff et al. 2012) and some patients with sciatica 
(Brisby et al. 2002).   
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All of these studies had similarly low numbers of participants (<30) and so it is unlikely 
that differences in power explain the lack of agreement in their results but given the 
variance of many cytokines and their involvement in multiple processes it is also quite 
likely that many of these clinical studies were underpowered.   
It is interesting that in the Lundborg et al (2010) study there was a difference seen in IL-8 
and IL-1  but not TNFα or IL-6.  A pattern is emerging from this study and others that one 
or two key substrates are found to be significantly different between groups while other 
related molecules are not.  
7.1.3 Anti-inflammatory cytokines in the CSF in OA pain 
7.1.3.1 The role of CSF IL-12 as an anti-inflammatory cytokine in OA pain 
A lower concentration of IL-12 was seen in the OA group in this study when compared 
with the control group.  This seems an anomalous finding given that IL-12 is thought to 
have a pro-inflammatory role.  Much of the work exploring IL-12 has a focus on CNS 
infection and there is very little published about this cytokine in relation to pain and what 
has been published suggests the role of IL-12 may differ dependent on the stimulus for its 
production.   
IL-12 production is increased in the spinal cord following nerve injury in mice (Cao et al. 
2009) and also from microglia in vitro stimulated simultaneously with lipopolysaccharides 
(LPS) and IFNγ (Aloisi et al. 1997).  This latter study also demonstrated that IL-12 
secretion could be down-regulated effectively by IL-10.  However, in a model of dorsal 
root ganglion (DRG) inflammation  (zymosan injection to the DRG)– designed to explore 
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how inflammation affects the DRG in the absence of nerve damage, Xie  et al ( 2006b) 
categorise IL-12 as an anti-inflammatory cytokine along with IL-2 and report that it was 
significantly lower in the inflammation group.   
The lower concentration of IL-12 in the OA group present study might therefore represent 
a reduction in anti-inflammatory activity.  This is a novel interpretation for the function of 
this cytokine prompted by animal work in which both an anti-inflammatory (Xie et al. 
2006a) and pro-inflammatory role (Cao et al. 2009; Aloisi et al. 1997).  Dual effects of 
cytokines have been described in contexts other than pain, for example the pro-
inflammatory and immunosuppressant activities of TNFα in animal models of Multiple 
Sclerosis (Kassiotis and Kollias 2001).  There are two different explanations for the dual 
role observed in some cytokines.  Activity can be dependent on other local factors (i.e. the 
presence of other cytokines) as illustrated by the lack of effect on beta-cells by IFNγ until 
in the presence of TNFα and IL-1β when IFNγ induces apoptosis (Gysemans et al. 2008).  
Activity may be dose dependent, as illustrated by the changing role of IL-1β in memory 
function in the hippocampus.  At low and high doses IL-1β has a detrimental effect but 
there is a range within which increasing the level of IL-β above baseline levels improves 
memory in a water-maze task (Goshen et al. 2009).   
The cytokines do work together as a network and the exploration of potential 
interdependences is not possible in the current data set but it worth exploring in the future.  
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7.1.3.2 The role of CSF IL-4, IL-5 and IL-10 in OA pain 
There was no difference in the concentrations of anti-inflammatory cytokines between the 
OA group and the control group.  However, IL-10 has a number of strong correlations with 
other anti-inflammatory and pro-inflammatory cytokines in the control and OA groups.  
This supports the idea that increasing pro-inflammatory activity causes an increase in anti-
inflammatory activity designed to modulate the level of excitation.   
Rather less has been published about the concentrations of anti-inflammatory cytokines in 
pain conditions in comparison with what has been written about the pro-inflammatory 
cytokines (Milligan et al. 2005) although their analgesic effect is an accepted fact (Uceyler 
and Sommer 2007; Milligan et al. 2005; Vale et al. 2003; Kanaan et al. 1998).  IL-10 is a 
key modulator known to suppress the release of pro-inflammatory cytokines (Ding et al. 
2003).  This has led to interest in using IL-10 therapeutically for neuropathic pain 
(Soderquist et al. 2010) and to promote neuronal survival after spinal trauma (Zhou et al. 
2009).   
Clinical studies of people with CRPS (Alexander et al. 2007), diabetic and post-traumatic 
neuropathy (Backonja et al. 2008) and recovering from arthroplasty (Yeager et al. 1999) 
have reported low or unchanged levels of CSF IL-10.  IL-4 and IL-10 mRNA and protein 
levels have been observed to be reduced in the blood of people with chronic widespread 
pain, many of whom had fibromyalgia (Uceyler et al. 2006).  These findings suggest that 
lower levels of anti-inflammatory cytokines can contribute to pathological pain, perhaps 
not as an absolute but relative to the change in balance between excitation and inhibition.  
It would be interesting to follow up this idea in a post-hoc analysis, exploring the ratio of 
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pro and anti-inflammatory levels in the different groups identified in this study.  It would 
be necessary to construct hypotheses that allowed for a potential dual role for certain 
cytokines such as IL-12.  
7.1.4 Peripheral stimulation of cytokine activity in the dorsal horn 
The increase in CSF TNFα seen in the present study can be attributed to increased activity 
in the primary afferent fibres as has already been outlined.  However, increased CNS pro-
inflammatory activity is also a response to communication from the periphery to the CNS 
via the blood stream and vagus nerve.  Signaling pathways from the immune system to the 
CNS were identified following observation of the sick response: that peripheral immune 
activation causes activation of central nervous system responses mediating symptoms such 
as fatigue, fever, anorexia and sleepiness.  The proof that the sick response is centrally 
mediated triggered by peripheral immune activation has been demonstrated by blocking 
the activity of peripheral cytokines, and by peripheral administration of cytokines (Maier et 
al. 1998; Kent et al. 1992).   
Communication of peripheral immune activation to the CNS involves neural pathways (the 
vagus afferent and the glossopharyngeal nerve) and blood borne communication via 
interaction with, and active transport across the blood brain barrier (Dantzer 2001; Watkins 
et al. 1995).  Thus the increased levels of pro-inflammatory cytokines observed in the 
periphery as a result of an inflammatory process will directly influence the levels of 
cytokines measured in the CNS.   
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There are increased levels of pro-inflammatory cytokines in the synovial fluid (SF) of 
people with OA (Kokebie et al. 2011; Goldring 2000;Sipe 1995).  These changes in the 
levels of pro-inflammatory cytokines local to the site of the disease processes of OA are 
reflected in the serum where levels of acute phase proteins (C-reactive protein and serum 
amyloid A) (Sturmer et al. 2004) and pro-inflammatory cytokines (Petrovic-Rackov 2005) 
are also observed to be higher than in age matched controls.  This demonstrates that there 
is a systemic pro-inflammatory cytokine stimulus in OA, which has the potential to initiate 
the immune-CNS communication discussed above.  Thus, increased levels of TNFα 
observed in the present study are a consequence of direct pain signaling via primary 
afferent fibres but also may be related to increased peripheral levels of pro-inflammatory 
cytokines resulting from the inflammatory processes within the joint and also increased 
levels relating to depression in some of the group. This suggests that complete 
understanding of CSF levels of cytokines requires concurrent measurement of their levels 
in the synovial fluid and blood. 
The sick response shares common symptoms with depression and it has been shown that 
TNFα and IL-6 are consistently elevated in the periphery of people with major depression 
(Dowlati et al. 2010).  The sick response/peripheral immune activation also heightens pain 
sensitivity (Wiertelak et al. 1994; Watkins et al. 1994a; Watkins et al. 1994b).  Thus there 
is an inter-relationship between pain, depression and the levels of peripheral and central 
cytokines.  This is supported in the findings of the present study, which identify the 
predictive value of HADS for OA group membership and of TNFα for HAD score.  These 
findings together with the increased prevalence of psychological distress in the OA group 
are in agreement with the inter-relationship between pain, cytokines and depression.  
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These findings support a combined role of peripheral afferent activity and an activation of 
the CNS by elevated peripheral cytokines as a result of OA or depression or both.   
7.1.5 Amino acid activity in the dorsal horn in OA pain 
The finding in this study that serine is elevated in the OA group provides considerable 
support for central sensitisation being a part of OA pain signaling.  As well as the 
increased concentration of serine in the OA group of the present study there were a number 
of significant correlations between serine and glutamine and between glutamate, GABA 
and glutamine. These amino acids are all related to the process of pain signaling and 
recycling of glutamate (Struzynska and Sulkowski 2004).   
7.1.5.1 The role of CSF serine as an excitatory amino acid in OA pain 
Serine is released from activated glia as result of AMPA receptor activation (Mothet et al. 
2005).  It then acts as a co-agonist of the NMDA receptor, the activation of which is an 
integral part of the amplification processes in central sensitisation (Wolosker 2007).    No 
published reports of CSF serine in clinical studies could be found: it has received more 
attention in animal studies.  Serine has been found in elevated levels in the CSF following 
plantar incision in rats (Zahn et al. 2002), and acetic-acid induced visceral pain (Feng et al. 
2003) but not in an animal model of neuropathic pain (intrathecal pertussis-toxin) (Wen et 
al. 2003).   
 
The finding in the present study that TNFα and serine are higher in the OA group indicates 
NMDA receptor activation.   
  
186 
One of the effects of serine activity observed in animal studies is the development of 
dynamic allodynia.  Usually light brushing of the skin or mucosa does not evoke pain.  The 
fibres that transmit these sensations synapse deep within the dorsal horn with wide 
dynamic range cells.  However, there are circumstances in which light brushing does evoke 
pain and this involves disinhibition of glycine receptors.  This disinhibition is an outcome 
of prostaglandin activity, the production of which is stimulated by pro-inflammatory 
cytokines.   The process of disinhibition and the development of allodynia are NMDA 
receptor and serine dependent (Miraucourt et al. 2011); degrading serine prior the 
experiment prevents the development of allodynia.   
Thus, the finding that serine is elevated in OA pain might increase the risk of allodynia in 
this pain.  Evidence of allodynia in OA has been seen in rats following intra-articular 
injection of monosodium iodoacetate (MIA) (Sagar et al. 2011; Stevenson et al. 2011), and 
partial medial meniscectomy in mice (Knights et al. 2012).   
Quantitative sensory testing is a technique for the assessment of cutaneous sensory nerve 
function (Courtney et al. 2010), and is often used as a diagnostic tool (Geber et al. 2011).  
Standardised processes have been developed to reduce inter-rater reliability problems with 
this technique, and the standard test battery takes approximately one hour to administer per 
participant.  The  standard set of tests comprises assessment of normal thermal perception 
and pain thresholds, touch and vibration detection thresholds and mechanical pain 
sensitivity including thresholds for pin-prick and blunt pressure, stimulus-response 
functions for pin-prick sensitivity and dynamic mechanical allodynia and pain summation 
to repetitive pin-prick (Rolke et al. 2006a; Rolke et al. 2006b).  
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Clinical studies using quantitative sensory testing have not yet reported any evidence of 
allodynia in OA.  However, most reports focus on pressure pain thresholds and 
hyperalgesia (Wylde et al. 2011a; Wylde et al. 2011b; Gwilym et al. 2009; Kosek and 
Ordeberg 2000a; Kosek and Ordeberg 2000b) and only one published report has 
documented specifically looking for allodynia in OA.  Westermann et al (2011), provide 
the only published report where allodynia was specified as an outcome and they found no 
evidence of it in the hands of 20 people with OA pain.    
This suggests that the presence of serine and TNFα in the CSF in OA is not sufficient of 
itself to trigger allodynia and that other factors (not present in this study) are also required. 
The higher level of serine in the OA group in comparison to the control group can be 
interpreted as seen above by the known mechanism of central sensitisation.  However, this 
study also identifies an unexpectedly inverse relationship between serine levels and 
HADS-T.     
7.1.6 The role of CSF glutamate, GABA and glutamine in OA pain 
One might expect that raised serine and TNFα in this study would be accompanied by a 
simultaneous increase in glutamate levels, and decrease in glutamine and GABA. This is 
because glutamate, glutamine and GABA are all affected by NMDA R activation and 
linked by a cycle of production and regulation (Struzynska and Sulkowski 2004; 
Schousboe et al. 1997). Although direct comparisons between groups of the concentrations 
of these amino acids did not reveal a statistically significant difference at the 0.05 level 
GABA does contribute to the regression model for membership of the OA group with 
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decreased levels of GABA being associated with an increased likelihood of belonging to 
the OA group.   
Glutamate is cleared from the synaptic cleft by active transport into glia where it is 
transformed into glutamine in a process driven by glutamine synthetase (Arriza et al. 
1994).  Glutamine is then released into the synaptic cleft from the glia and is taken up by 
neuronal cells where it is converted to glutamate (in the primary afferent fibres) or GABA 
(in the GABAergic interneurons) (Liang et al. 2006).  NMDA activation leads to the 
formation of  peroxynitrite (produced in a reaction between superoxide and nitric oxide), 
which inactivates both the glial glutamate transporter and glutamine synthetase (Chen et al. 
2010).  Therefore synaptic glutamate levels rise because of inhibition of the transport 
systems and glutamine levels fall due to the decreased availability of glial glutamate and 
the inhibition of glutamine synthetase, which then affects the production of GABA (Chen 
et al. 2010).  This outcome of this process is increased excitation due to increased levels of 
glutamate and also disinhibition due to decreased amount of GABA.  The contribution of 
reduction in GABA to the membership of the OA group may be an indication that reduced 
inhibition plays a part in the pain mechanism in this pain.    
Correlations between glutamate, glutamine and GABA in the present study can be 
explained by this mechanism but there was no change in levels of these amino acids in the 
OA group.  Increased levels of glutamate have been reported in other clinical studies 
involving severe pain or presumed central sensitisation including headache or migraine 
(Sarchielli et al. 2007a; Peres et al. 2004; Castillo et al. 1995; Martinez et al. 1993b), 
fibromyalgia (Sarchielli et al. 2007a), CRPS (Alexander et al. 2007) and labour pain (Hsu 
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et al. 2001; Olofsson et al. 1997).   Equally, some studies report no difference when a pain-
free control group is compared with active labour (Sethuraman et al. 2006) and 
fibromyalgia (Larson et al. 2000).   
One of the reasons offered for finding no significant difference in glutamate levels is 
provided by Larson et al ( 2000) who suggest that efficient reuptake of glutamate and 
subsequent transformation of this to glutamine masked increases in glutamate.  However, 
they did find an increased level of glutamine and this they state demonstrates an increase in 
excitatory amino acid activity.  In this study direct comparison of glutamine in the OA and 
control groups and the PAR/0PAR groups does not reveal a statistically significant 
difference.  However the median levels of glutamine are higher in the OA group than the 
control group and in the 0PAR group than the PAR group.  This non-significant difference 
is interesting as it matches Larson et al’s explanation for lack of observable difference in 
the glutamate levels. Further, the observation that there is a non-significant reduction of 
glutamine in the PAR group in comparison to the 0PAR group matches with the 
unexpected finding in this study that other pro-inflammatory/excitatory mediators, IFNγ 
and aspartate are also reduced.  
Fibromyalgia has been associated with increased CSF IL-8 (Kadetoff et al. 2012), a pro-
inflammatory cytokine the presence of which indicates glial activation.  Glial activation 
suggests NMDAR activation and that in turn increases the likelihood that the glutamate-
glutamine cycle would be disrupted by peroxynitrite inhibition of glutamate transport and 
glutamine synthesis.  Thus it could be expected that fibromyalgia would be accompanied 
by increased glutamate and decreased glutamine.  Fibromyalgia is likewise associated with 
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a dysfunction of the inhibitory descending pathways (Mense 2000) and this also is likely to 
create elevated levels of glutamate.  
In this study there was no significant difference observed in the concentration of GABA 
between the groups.   There is very little that can be compared this finding.  GABA is 
known to be upregulated in animal models of inflammatory pain (Castro-Lopes et al. 
1995).  GABA is produced in the dorsal horn by glial cells and interneurons.  Glia 
continuously synthesise GABA and maintain a gradient between intracellular and 
extracellular concentrations by active transport (Lee et al. 2011).  An increased release of 
GABA from the glia can be stimulated by glial uptake of synaptic glutamate (Heja et al. 
2009) and by receptor agonism by glutamate, glycine and serine (Lee et al. 2011).  GABA 
release from inhibitory interneurons is similarly triggered by glutamate (Kerchner et al. 
2001) or 5-HT receptor agonism (Kawamata et al. 2003).  The release of GABA in 
inflammatory pain has been associated with activation of presynaptic (primary afferent 
fibre) GABAA receptors, which create an action potential resulting in an antidromic signal 
to the peripheral terminals causing the release of Substance P and calcitonin gene related 
peptide (CGRP) which contribute to peripheral sensitisation, vasodilation and plasma 
extravasation (Kelley et al. 2008; Willis, Jr. 1999).  This suggests that in theory GABA 
levels in the CSF should be increased in response to increased glutamatergic activity and in 
this study the increased level of serine in the CSF also provides a stimulus for GABA 
release.   
There are no published clinical studies exploring GABA levels in clinical pain conditions 
except for one demonstrating that GABA release is increased in migraine with depression 
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but not in migraine alone (Vieira et al. 2006).  GABA levels in the CSF are consistently 
reported to be reduced in depression in clinical studies (Gerner et al. 1984; Kasa et al. 
1982; Gerner and Hare 1981). This suggests that understanding the mood of the 
participants might help in the interpretation of the levels of these amino acids and that 
levels of these amino acids should not be interpreted without that information in clinical 
studies.  
In the present study GABA, glutamate and glutamine were not found to correlate with 
HADS-T, nor did GABA or glutamate remain in the regression model developed to predict 
the presence of psychological distress, nor the model developed to predict the level of 
HADS-T.  HADS-T was higher in the OA group as was pain, which is associated with a 
decrease and an increase in GABA levels respectively. GABA may be one of the analytes 
in this study for which a more sophisticated and better powered analysis is required to 
appreciate the relative influences of each of the potential predictors for this amino acids 
expression.   
7.1.7 Spontaneous pain in OA 
Pain at rest was present in 59% of the participants with OA in this study.  These 
participants did not differ from those who did not have pain at rest in terms of the primary 
joint where they had pain, their HADS, age or gender.  When amino acids and cytokines 
were explored in the 0PAR and PAR groups the only differences were that the 0PAR 
group had higher levels of aspartate and IFNγ.    Logistic regression showed that both these 
substrates contributed to the model predicting membership of the PAR group (lower levels 
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being predictive) but the confidence intervals were very large and that suggests a failure to 
converge.   
7.1.8 The role of CSF IFNγ in spontaneous pain 
Pain at rest is by definition present in the absence of movement or other external stimulus.  
True rest pain may be a form of spontaneous pain.  Lundblad et al. (2008) associated the 
presence of pain at rest in their OA cohort with an increased risk of persistent post-
operative pain.  They explain that rest pain represents an extreme form of central 
sensitisation, which is resistant to extinction following the removal of the noxious input.  
The expectation that arises from this hypothesis is that the present study should detect 
increased levels of pro-inflammatory cytokines or serine in the PAR group, and this was 
not the case.  
IFNγ is found in increased levels in the dorsal horn following nerve injury (Tanga et al. 
2005), induced from microglia by the activity of IL-12 (Aloisi et al. 1997).  The role of 
IFNγ therefore might be expected to relate to sensitisation of the dorsal horn and to play a 
role in spontaneous pain and that would lead to an expectation that this cytokine would be 
elevated in the PAR group.  However, we have seen evidence in respect of IL-12 that the 
behaviour of that cytokine in neuropathic and inflammatory conditions is very different 
and that may provide an explanation for this result.  Aspartate is an excitatory amino acid 
about which little documented except in the context of co-release with glutamate (Zahn et 
al. 2002). The fact that it is elevated alongside IFNγ in the 0PAR group suggests that both 
are acting in a pro-inflammatory role.  That they are elevated in comparison to their 
concentration in the PAR group might be explained by a difference in the pain mechanism 
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of these two groups.  Aspartate and IFNγ may be involved in transmission of stimulus-
evoked pain but not in spontaneous pain.  The fact that the study is under-powered may 
prevent detection of the cytokines that are important in spontaneous pain in the current 
study.  However, there may also be heterogeneity within the PAR group which together 
with the small sample size will mask differences.  The group may contain people with true 
spontaneous pain as well as some who do not.  It would be appropriate to ‘test’ for rest 
pain in future studies to try and improve the reliability of this category so that comparisons 
can be made.  
7.2 Psychological distress and OA pain 
This study found that OA participants had higher HADS-T scores and a higher prevalence 
of psychological distress (HADS-T≥12) than those in the control group.  This is in 
agreement with other studies that identify co-morbidity between OA and depression and 
cite it as one of the factors that contributes to poor quality of life in some people with OA 
(Rosemann et al. 2007b; Dexter and Brandt 1994).    
This study also identified a relationship between the large neutral amino acids OA.   An 
increase in leucine was one of the predictors for membership of the OA group and leucine 
and valine were both found to be significantly higher in that group. These results suggest 
that one of the mechanisms of depression in OA is via the tryptophan-serotonin pathway.  
This is strengthened by the finding of increased TNFα in the OA group because of the role 
that cytokines play in tryptophan metabolism (see below). However, this study did not 
reveal a direct relationship between the large neutral amino acids or tryptophan and 
HADS-T as might have been expected.  Further, the idea that depression is more prevalent 
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because OA sufferers have pain is not supported by the finding that decreased serine is a 
significant predictor of increased HADS-T.  
The neurobiological relationship between pain and depression is complex.  The findings of 
this study are in agreement with current neurobiological models of depression that 
integrate the effects of cytokines, the HPA axis and monoamines.  Increased levels of pro-
inflammatory cytokines in the CNS lead to a switch in tryptophan catabolism from the 
production of 5-HT to the production of quinolinic acid, thus reducing the amount of 5-HT 
available for central signaling and enhancing depression (Laugeray et al. 2010; Muller and 
Schwarz 2007; Raison et al. 2006).  The concurrent effect of this is a reduction of 
descending inhibition via the serotonergic pathways and because of this a decrease in 
inhibition of pain signaling.  This is reinforced by the finding in this study that HAD score 
could be predicted by a combination of pain, and increased TNFα for the cohort when 
explored as a whole.  
This study has demonstrated that OA is associated with increased pain, increased TNFα, 
increased HADS-T and increased serine but the regression analysis suggests that lower 
levels of serine are associated with an increased likelihood of having psychological distress 
or increasing HADS-T.  This suggests a potential disconnect between the pain mechanism 
involving serine and the mechanism of psychological distress associated with OA.  In 
support of this it is notable that another ‘pain-related’ amino acid, GABA is also absent 
from the regression models for HADS-T but is present in the OA model.   OA-
psychological distress seems to be more influenced by cytokine activity than it is related to 
other mediators of the pain process.  The relationship between the disease process, pain 
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and psychological distress is mediated by many factors including stress, fatigue and 
catastrophising.  This and the pleiotropic nature of many of the mediators being 
investigated in this study mean that this interesting finding cannot be fully explored but is 
potentially important in helping to understand the relationship between pain and 
depression. 
The findings relating to HADS-T are therefore in agreement with the pain-related findings 
and generally support the contention at the outset of this study that it is important to take 
anxiety and depression into account in clinical pain studies.  
7.3 Limitations 
7.3.1 Sample size  
There were fewer participants in this study than desirable.  Although a power calculation 
suggests TNFα, serine and serine were adequately powered the remainder of the analytes 
were not.  The lack of difference in some of the transmitters and modulators explored may 
be related to the fact that the true difference between the OA/control group and the 
PAR/0PAR groups of participants was likely to have been small and would therefore 
require a larger sample to demonstrate this.   
7.3.2 Recruitment of sufficient numbers to the pain-free control 
group 
It was difficult to recruit participants for the control group because the experience of pain 
was an exclusion criterion and this is a common feature of the lives of many people aged 
over 50 years.   The present study is not alone in struggling to recruit large numbers of 
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pain-free control participants.  Clinical pain studies that do include normal healthy controls 
generally obtain only low numbers (Backonja et al. 2008 (8); Steensberg et al. 2006 (24); 
Scuderi et al. 2006 (3); Natelson et al. 2005 (13); Stenlof et al. 2003 (10); Yeager et al. 
1999 (6)).  A favoured method of creating a larger control group is to recruit people who 
are being tested for possible neurological disorders, who subsequently were declared to 
have no detectable abnormality (Gallai et al. 2003 (20); Garseth et al. 2002 (31); Garseth et 
al. 2001 (31)).  Other control groups are comprised of people with known pathology 
including painful neuropathy (Alexander et al. 2007 (16); Alexander et al. 2005 (31)), and 
general surgery patients without pain (Munts et al. 2008 (20); Kotani et al. 2004 (50)).  The 
difficulties encountered necessitate the collection of samples over a much longer period of 
time. 
A further limitation of this study relating to the eventual size of the control group was that 
the study involved a number of simultaneous processes (recruitment, data collection, 
sample collection, sample processing, assay work, and liaison with surgeons, anaesthetists, 
ward staff and participants).  In this study these processes were all conducted by one 
person and this limited recruitment at times.  
7.3.3 Recruitment issues relating to anaesthetic technique 
Recruitment to this study was dependent on the participants being willing to have a spinal 
anaesthetic as part of their operative process.  The choice of anaesthetic technique was 
entirely independent from the study; however, potential participants who were approached 
about the study prior to seeing an anaesthetist expressed worries not about the study but 
about spinal anaesthesia.  Experience during the recruitment process suggests that it is 
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important to have an anaesthetist available to assess the patient prior to any discussion 
about participation in the study.   
Resolution of this problem during the course of the study required the recruitment to be 
moved from a pre-admission clinic visit 7-10 days before surgery, to the day of surgery.  
This raises ethical concerns as it does not provide the participants with a sufficient ‘cooling 
off’ period, nor time to digest the written information given in support of the study.  A 
better solution would be for the anaesthetic assessment to take place in the pre-admission 
clinic where it could be followed up where appropriate with an invitation to discuss the 
study with the research nurse.  
The rate of use of spinal anaesthesia varied among anaesthetic staff and was generally low. 
This was entirely unanticipated and was exacerbated by the change of role of one of the 
most enthusiastic anaesthetists such that she no longer delivered anaesthetics at all.  Future 
studies will need to ensure adequate support from anaesthetists and a more thorough 
feasibility study to calculate the expected number of spinal anaesthetics per week.   
The surgeons were approached prior to ethical approval being sought and were generally 
supportive of the study but during the course of the study it became clear that some had 
concerns about the time it would take to take a CSF sample and give a spinal anaesthetic – 
this was particularly an issue for the participants in the control group who were generally 
in the operating theatre for a very short time thus increasing the ‘turn-over’ in the 
anaesthetic room.   This may have had an influence on the likelihood of the anaesthetist to 
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offer a spinal anaesthetic as part of the procedure and this affected recruitment 
significantly.   
7.3.4 Pain intensity in the OA group 
It is probable that the lack of large numbers of people with moderate to severe pain in this 
study influenced the findings.  Pain is a key indicator of the need for surgery and yet one 
fifth of the OA group were offered surgery with pain on movement scores of three or less 
on a scale of 0-10 with 0 being no pain and 10 being the worst the participant could 
imagine.   
It will be important in future studies to collect samples over a longer period of time, to aim 
to recruit participants with a range of pre-operative pain intensities and to be able to 
analyse the data in pain subgroups.   
7.3.5 Pain at rest 
In this study pain at rest was assessed by asking the participant to score his or her pain 
following a period of inactivity and without moving.  It was made clear to the participant 
that the pain score being sought was the amount of pain present without movement or other 
stimulus.  It is possible that pain at rest scores may include score related to residual activity 
pain despite efforts to prevent this.  It would be appropriate in future studies to explore 
pain scores in a more sophisticated way, and to consider quantitative sensory testing to 
enable distinctions to be drawn between different groups of OA sufferers. 
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7.3.6 Supporting information about impact of OA 
Interpretation of the data in this study would be enhanced by a more detailed understanding 
of the impact that OA had on the recruits.  The information that would be useful would 
come from more detailed diagnostic information about the degree of OA changes as well 
as greater information about pain interference and function.    Many studies exploring 
osteoarthritis use the Western Ontario and McMaster’s Universities Osteoarthritis Index 
(WOMAC) scale (Bellamy et al. 1988) to measure pain, stiffness and function and this 
would have been an appropriate tool to include in this study so that comparisons could be 
made with other OA studies and so that functional restriction could be examined as one of 
the covariates.  It is quite likely that this would have affected some of the modulators as 
well as the level of depression and anxiety.  The use of tools in this study was restricted by 
the limited amount of time for data collection prior to the participant being taken to theatre 
and therefore recruitment at pre-assessment where more time could be taken would be an 
advantage. 
7.3.7 The incidence and degree of anxiety and depression 
There were relatively few participants in this study with significant levels of psychological 
distress and this limited the ability to consider fully the effect that these affective disorders 
may have on the spinal transmission of pain signals.  Anxiety and depression have a strong 
reciprocal relationship with pain and this exploration could have a significant impact on 
future management strategies.  It is possible that self-selection for regional anaesthesia 
skewed the research population artificially in favour of normal anxiety and depression.  
Future studies may be able to rectify this.   
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7.3.7.1 Hospital Anxiety and Depression Scale 
The HADS was used in this study because it has been validated, and in the clinical setting 
where time is at a premium it is quick and reliable to administer.  However, it became 
apparent in the interpretation of the data that more sophisticated tools would have assisted 
greater insight and have been more informative.  
7.3.8 Quantification of inflammation 
One of the clearest limitations that emerged during data analysis was that there was no 
objective marker of inflammation for each participant.  The lack of data regarding the 
presence or absence of ongoing active inflammation makes much of the interpretation of 
the data speculative.  This study should be repeated on a larger scale in the future and 
identifying and collecting information about reliable inflammatory biomarkers will be 
essential.  These should include a general measure of inflammation such as C-reactive 
protein in both the OA and the control group in addition to measures of pro and anti-
inflammatory cytokines in the synovial fluid and plasma.   This would have enabled the 
characterisation of the control group to be more detailed and exclusion from this group of 
those who had undeclared or unknown inflammatory processes that may have confounded 
the results.  It would also have been very useful to be able to identify the OA participants 
who had a higher degree of peripheral inflammation in order to interpret the dorsal horn 
data. 
  
201 
7.3.9 The selection of amino acids and cytokines 
The range of amino acids and cytokines assayed in this study was extensive by comparison 
with other human studies, in part made possible by the development of multiplex bead 
arrays.  The early adoption of this technology had limitations in as much as the cytokine 
profile was ‘off the shelf’ and further work would benefit from a bespoke selection of 
cytokines that could more fully explore some of the questions left by this study.  However, 
the complexity of relationships between the different substrates in this study, the influence 
of mood, the suggestion that there are different subtypes of OA pain, and the desire to have 
contributing information from some that weren’t assayed (see below) means that future 
studies need greater numbers of participants to be able to properly characterise this pain. 
It has become apparent by data analysis and interpretation in this study that 5-HT, NA and 
NO metabolites are important to the interpretation of the data.  In addition it would have 
been useful to have data about Substance P, CGRP, cox-1, cox-2 and PGE2.   This study 
provides a basis for a better informed choice of analytes to consider in the future. 
7.3.10 Confounding factors 
7.3.10.1 Participant’s weight 
There are some other factors that also influence cytokine and amino acid levels that would 
be useful to take into consideration.  CSF IL-6 correlates negatively with body weight in 
obese people (Stenlof et al. 2003) and therefore this is a variable that needs to be taken into 
account.   
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7.3.10.2 Medication use and analgesia 
The use of anti-depressant and analgesic drugs by a small number of participants may have 
had a limited impact on the results of the study and more rigorous method for the 
collection and integration of this data needs to be built into any future study. It may be 
appropriate to use antidepressant medication as an exclusion criteria.  In this study the 
majority of OA participants who used analgesic medication did so on an ad hoc basis and 
the led to difficulty in generating precise data.  Future studies may take advantage of the 
natural pause between pre admission and admission by asking patients to keep a pain and 
medication diary. 
7.3.10.3 Effect of lumbar puncture on CSF constituents. 
CSF is obtained from humans by the use of a lumbar puncture.  It is anecdotally reported 
that anticipation of lumbar puncture is anxiety-provoking and produces a physiological 
stress response in terms of elevation of adrenocorticotrophic hormone (ACTH) and cortisol 
in the plasma of subjects who have undergone a lumbar puncture (Lerner et al. 2000; 
Geracioti, Jr. et al. 1999; Petrie et al. 1999; Hill et al. 1999b; Geracioti, Jr. et al. 1997c; 
Chappell et al. 1994; Breier et al. 1988).  The main feature of the stress response is the 
hypothalamic-pituitary-adrenal axis (HPA axis).  One of the results of HPA axis activation 
is an increase in NA release into the dorsal horn, leading to an increase in GABA and 
glycine (Baba et al. 2000).  Thus it is possible that the activity of performing a lumbar 
puncture will lead to increased GABA and glycine in the samples taken.  
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7.3.11 Missing data and cytokine concentrations below the level of 
detection 
This study contains bias introduced by the method used to deal with concentrations of 
cytokines that were below the level of detection (non-detects).  Concentrations lower than 
the level of detection that are not reported by the assay software tend to fall within the 
same range as the background ‘noise’ of the assay and are considered to be inaccurate.   
However, if these are omitted from the data analysis the resulting outcomes will only 
include complete cases. This can reduce the data set to unmanageable levels and this is 
seen in logistic regression in the current study where numbers of cases that can be entered 
into the analysis are dramatically reduced because so many cases do not have complete 
data sets for the predictor variables of interest. 
Leaving non-detect variables out of the analysis on a variable by variable basis will lead to 
the data set being unrepresentative of the expected range of concentrations of cytokines, 
which can be present in very small but still biologically active concentrations.  Thus, 
omission of non-detectable values can lead to bias in interpretation of the results.   
One of the methods of dealing with non-detects is to use a symbolic ‘non-detect’ term to 
exclude these data from the analysis, which is how the very low concentrations were dealt 
with in the current study (achieved by assigning a value tag in SPSS).  This censoring of 
the data will have an effect on the analysis that is performed by skewing the findings of the 
study because only the higher values of the analytes will be included in the statistical 
analysis. An alternative method for dealing with non-detects is to replace them with a 
nominal constant value.  This is a popular method which involves replacing the non-detects 
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with one half or  times the detection limit but Helsel (2009) describes this as a dangerous 
procedure. The reason, he explains, is that ‘substituted values possess a pattern that is alien 
to the pattern of the original data’ (p. 258).  
When the non-detects are missing at random, determined by Little’s MCAR (missing 
completely at random) test then a multiple imputation method can be used (White and 
Carlin 2010) using a maximum value of the limit of detection as given by the assay 
manufacturer. Prior to publication of the findings of this study the bias introduced by 
leaving the non-detect cases out of the analysis will be corrected by using multiple 
imputation to substitute non-detects with values below the limit of detection and then re-
analysis to determine any changes to the outcome of the statistical tests. 
7.4 Implications of this study for the management of OA pain  
7.4.1 The potential for persistent pain after surgery 
The findings of the present study support a process of central sensitisation in OA pain and 
have also identified a difference between people with OA rest pain and those who no pain 
at rest.   
 
Wylde et al ( 2011a) speculate that depression and rest pain are suggestive of an 
underlying vulnerability to pain and are both factors that increase the risk of persistent 
post-operative pain.  This study identifies psychological distress in the form of HADS-T as 
one of the predictors of pain at rest and therefore offers some support of Wylde et al.’s 
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findings.  The implication for practice is that close attention needs to be paid to the 
psychological comorbidities associated with OA, more-so in those who have pain at rest.  
 
Lundblad et al ( 2008) offer evidence to support the hypothesis that persistent post-
operative pain can be predicted by the presence of higher levels of pain at rest before 
surgery.  This idea of pain vulnerability is supported by work into the cortical processing 
of pain (Apkarian et al. 2009).  There are differences in cortical processing for stimulus-
evoked pain and spontaneous pain.  Spontaneous pain has a higher emotional salience 
whereas stimulus evoked pain creates a greater levels of activity in regions associated with 
the sensory-discriminative aspect of pain.  The present study does not provide direct and 
rigorous support for this hypothesis, possibly because of the small sample size. However, 
the findings suggest a tentative support because of the finding that there are difference 
between the PAR and 0PAR groups in terms of IFNγ and aspartate. Together with the 
support for Wylde et al.’s findings this suggests that closer attention needs to be paid to the 
PAR group in terms of research and perhaps in terms of ensuring effective pre-operative 
pain and mood management.   
 
7.4.2 Pharmaceutical management of OA pain 
 
 Current management strategies for pain relief in OA are capable of ameliorating this type 
of pain in many cases.  Combinations of capsaicin, NSAIDs, Paracetamol and opioids 
target appropriate parts of this pain pathway at the periphery, in the brain and in the dorsal 
horn.  There were no findings in the present study that suggested that these measures are 
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not the most appropriate, indeed the findings tell a story of pain signalling that suggests 
that OA pain, very often, will be very responsive to these drugs. 
 
The findings of the present study also support the use of anti-depressant medication for the 
management of OA pain.  The rationale for this is that 5-HT driven inhibition of OA pain 
is likely to be diminished by the activity of pro-inflammatory cytokines in the CNS.  A 
number of studies have been exploring the use of duloxetine, a selective serotonin and 
noradrenaline reuptake inhibitor approved for use for chronic musculoskeletal pain in OA 
pain, and have found this drug to be helpful in the relief of pain and improvement of 
function (Hochberg et al. 2012).  
 
7.5 Future work 
The findings from this study suggest that future exploration into the role of amino acid and 
cytokines in OA pain would be highly beneficial.  Whilst there are some limitations, this 
work has added to the discussion about the underlying pain mechanisms of people with OA 
and contributed to our understanding of its central processing.   It is important that this 
work is followed up by an adequately powered study exploring a range of amino acids and 
cytokines designed to confirm the present results and facilitate interpretation by the 
inclusion of other substrates such as PGE2, cox-2, 5-HT and its metabolites, nitrites and 
nitrates, the metabolites of noradrenaline, and soluble receptors of IL-β and TNFα.  
Furthermore these analytes should be assessed in the synovial fluid, plasma and CSF to 
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enable a more complete understanding of peripheral inflammation to be taken into 
consideration when CNS data is interpreted.  
The same groups will be of interest in future studies (OA/control, PAR/0PAR) and need to 
be recruited in sufficient numbers to ensure the study is adequately powered to detect 
differences in the key independent variables.  Using mean data from the present study it 
was calculated that detecting a significant difference (p<0.05) between two groups for IL-
6, with a power of 80%, would require a sample of 173 in each group and for IL-8 the 
sample size required increases to 1039 in each group. Detecting a significant difference in 
IFNγ in a comparison of 0PAR and PAR would require a sample size of  88 in each group 
while a TNFα  between the same groups would require a sample size of 5157 (SISA 2012). 
These are fairly crude calculations based on the observed mean and standard deviation in 
the present study and have not taken into consideration the skew of the data.   
Recruitment of control participants for studies such as this are always difficult and there 
are two ways that this can be addressed in future studies.  In the first instance the 
population from which the control sample is drawn can be enlarged to include participants 
undergoing lumbar puncture for neurological diagnostic purposes.  Many of those who 
have these procedures have no abnormality detected either at the time or following 
subsequent tests.  Providing sufficient follow up via medical records was conducted this 
group offers a further pool from which control participants can be drawn.  The second 
consideration for sample collection is the use of a tissue bio-repository approach.  This 
involves the consent of individuals for their tissues to be used in a number of studies.  The 
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tissues are collected in standardized ways by hospital staff and stored in a University bio-
repository where they can be accessed by a number of different research teams.    
Measurement tools in a future study of this nature should include the WOMAC scale and 
more sophisticated measures of anxiety and depression such as the Beck Depression 
Inventory and the State-Trait Anxiety Inventory. Data interpretation in the present study 
would also have enhanced by additional information about the participant’s weight (and in 
particular whether they were overweight) as well as information regarding hyperalgesia 
and allodynia that would be collected by quantitative sensory testing.  In addition it allow 
more complete data interpretation if more complete data were available on general 
inflammatory conditions the participants and controls were experiencing and to this end a 
C-reactive protein assay should be incorporated into the data set. 
It is probable that anti-depressant, anti-inflammatory and analgesic use will affect central 
and peripheral levels of amino acids and cytokines and therefore a future study will ensure 
a more rigorous collection of data about the participant’s medication use.  This could be 
collected using a diary and enable simultaneous collection of contemporaneous pain data. 
A greater amount of time with the participant for discussion about the study and informed 
consent is necessary for future work.  This would enable a more ethical approach to 
consent, and a greater amount of time for preliminary data collection.  A future study will 
aim to recruit participants before admission for their surgery, and ensure an anaesthetic 
assessment takes place at the time of the pre-admission visit.  This would also enable the 
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participant to be approached for recruitment in a more timely fashion and facilitate the 
collection of a more sophisticated data set. 
One of the requirements for a future study to be successful would be an increased number 
of research staff.  Recruitment, data collection, CSF processing and assay work need to be 
conducted simultaneously and therefore require a team of research staff.  
One of the unanswered questions at the end of this study was whether any of the 
participants went on to experience persistent post-operative pain.  It is theorectically 
possible to contact participants who took part in this study to determine whether they had 
residual pain and if so how long it lasted for.  However, the value of doing this must be 
weighed against the ethics of returning to a participant who was assured at the time of the 
research that the study was a one-off and did not involve follow up.  In this case, the small 
sample size of the present study, the amount of missing data, and the amount of time that 
has passed since samples were collected makes the potential benefit of tracing the 
individuals minimal.  It is important that a future study includes patient follow up of 2 
years to include quantitative sensory testing, and thorough examination of residual joint 
pain to allow full interpretation of the collected data.   
This small sample size of this study is not unusual in clinical CSF work and it is suspected 
that other studies have similar challenges in recruiting sufficient numbers of participants to 
enable detection of relatively small differences in highly variable substances, the nature of 
which is involvement in myriad biological processes.  The data itself is therefore precious 
and deserves closer scrutiny.  One of the questions that were not addressed in this study 
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was whether OA pain is affected in anyway by the ratio of pro- to anti-inflammatory 
cytokines.  This would be interesting to pursue in a post-hoc analysis.  Similarly there are 
bidirectional influences on the levels of some of the analytes in this study e.g. GABA is 
under stimulatory and inhibitory conditions, and it would be interesting to investigate these 
influences using linear regression techniques. 
Large sample sizes are necessary to investigate statistically the idea of interdependence 
between the cytokines.  Some of the findings in the present study suggest that cytokines 
like IFNγ and IL-12 may have different roles depending on the local conditions, perhaps 
dependent on the levels of other cytokines.  It is therefore proposed that following the 
conclusion of this study the idea of further statistical analysis will be discussed with expert 
colleagues.  Although the heterogeneity of study populations suggests it might be difficult, 
it is proposed that the feasibility of a meta-analysis is discussed.  
7.6 Conclusions 
This study has added important new information to the knowledge we have of the spinal 
transmission of OA pain.  Up until this point this knowledge has been accumulated, in the 
main, from animal studies using various models to represent inflammatory conditions 
including osteoarthritis. Very few clinical studies have reported amino acid or cytokine 
data for OA pain, and none has reported both in the same study.  Despite the very likely 
relationships between pain, inflammation and depression, no clinical studies until the 
present study have sought to control for mood as a confounding variable. 
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The findings of this study support the involvement of central sensitisation in OA pain.  
However, while increased levels of TNFα and serine fit in with what is currently known 
about sensitized pain transmission in the dorsal horn other results from this study do not, 
and suggest that there is further work to be done.  The role of IL-12 is interesting as it may 
be functioning in an anti-inflammatory capacity in OA pain.  The potential for this and 
other modulators to have dual roles, and the known redundancy within the cytokine 
network suggests closer investigation of single and groups of pain-related mediators is 
appropriate.  
The data generated in the study was not able to detect a clear and clinically relevant 
difference between those OA participants who suffer from pain at rest and those who do 
not.  There is some interest in this group of people because of the increased risk they have 
of developing persistent pain following arthroplasty.  This risk is very likely to relate to 
changes in the central mediation of pain and although some work to date has demonstrated 
these changes in relation to sensory thresholds there has been very limited exploration of 
changes in the dorsal horn that might provide explanation and potentially modifiable 
targets for novel therapies.   
This study also supports previous findings that pain and depression are co-morbid for a 
number of people with OA.  The findings of this study are in agreement with the current 
understanding of the relationships between peripheral inflammation, pain and depression in 
as much as the findings provide support for the role of pro-inflammatory cytokines and the 
serotonin pathway.  However, there are anomalies in this data too; if pain has a direct 
influence over the development of depression irrespective of inflammation, one might 
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expect that serine would be one of the amino acids to demonstrate an association with 
depression or psychological distress.  The fact that this amino acid does not have a linear 
relationship with HADS-T in this study but does have an association with OA, stimulates 
questions about the relationship between the mediation of pain and depression.  
Psychological distress was identified in this study as a key variable that has an association 
with the pain of OA and is likely to influence changes in the concentrations of some of the 
amino acid and cytokine variables of interest. 
The finding that OA pain involves central sensitisation is supported by the data in this 
study but some results are anomalous with this.  Other results are more tentative and need 
to be treated with some caution, but they nevertheless contribute importantly to our 
knowledge of OA pain and contribute to the development of future studies. The study of 
OA is important; it affects a great many people and carries a significant personal and 
economic cost which is likely to increase as the demographic of the population continues 
to change.  The work in this study provides important information about OA pain and 
provides a template and foundation for future work. 
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Appendix 3 Patient Information 
 
Title of Project:  Neurotransmitters in the Spinal Cord 
EXPLANATION 
We would like to invite you to take part in a research study. This study is being 
funded by an academic grant from Pfizer.  Before you decide if you would like to be 
involved it is important to understand why the research is being done and what it will 
involve.  Please take as much time as you need to read the following information 
carefully and discuss it with friends, relatives and your doctor if you wish.  We will 
write to your GP to explain the study should you decide to take part.  Please ask us if 
there is anything that is not clear or if you would like more information.  We 
appreciate you thinking about being in our study. 
What is the purpose of the study? 
Pain is a common experience but it is not well understood.  The study is designed to 
help us understand what happens inside the body when a person experiences pain.  
Neurotransmitters are chemicals that are involved in the transmission of pain signals.  
There are lots of different neurotransmitters involved in this process.  The amounts of 
neurotransmitters are altered by pain and pain relieving drugs.  In this study we will 
examine the amounts of neurotransmitters in the spinal cord fluid and relate it to your 
pain.  We hope to find out if the amount of each neurotransmitter is affected by the 
type of pain you are experiencing. 
Why have I been chosen? 
You are being asked because you are experiencing one of the types of pain we are 
interested in studying and because you are having an operation that often involves the 
use of a spinal anaesthetic. 
The neurotransmitters we are interested in are found in the spinal fluid.  The 
operation you have come into hospital for is being performed under spinal 
anaesthetic.  The decision for a spinal anaesthetic will be made by the anaesthetist 
after discussion with you.  A spinal anaesthetic involves placing a needle into your 
back and injecting local anaesthetic into the cerebrospinal fluid (CSF).  Correct 
placement of the needle is important.  To ensure the needle is placed correctly the 
anaesthetist will check that spinal fluid flows freely from the needle.  We would like 
to take this opportunity to collect a 2 ml volume of that spinal fluid.  The collection of 
such a small volume does not harm you in any way.  The anaesthetist will then inject 
the local anaesthetic as normal and this will provide the anaesthetic for your 
operation. 
There is no difference in the way the anaesthetic procedure will be performed 
whether you take part in the study or not.  
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Collection of CSF from many selected patients will enable us to identify how 
neurotransmitter levels vary with differing types of pain. 
Do I have to take part? 
No, it is up to you to decide whether or not to take part.  If you do decide to take part 
you will be asked to sign a consent form and we will ask you to keep this information 
sheet to refer to.  If you decide to take part you are still free to withdraw from the 
study at any time without giving a reason.  This will not affect your medical care. 
What will happen to me if I take part? 
You will have an opportunity to discuss the study with the research nurse.  If you 
decide to take part she will ask you to sign a consent form.  This form is used to show 
that you have been given information about the study and that you have understood 
that information and agree to take part. 
The research nurse will then gather some information about your medical history 
from your notes.  She will then visit you at a convenient time before your intervention 
to ask about your pain.  If the pain you have is due to a type of neuropathy the 
research nurse will perform two tests on you in addition to asking you the questions.  
The tests are performed on an area of skin where you have the pain and on an area of 
skin from the opposite side of the body where you do not have any pain.  The tests do 
not take long to do. 
You will be visited by the anaesthetist before your intervention and will be asked to 
consent to the intervention and to the use of a spinal anaesthetic. 
The anaesthetist will explain the procedure as it progresses.  When he or she has 
entered the appropriate space with the spinal needle a 2 ml specimen of spinal fluid 
will be collected, the local anaesthetic will then be given.  The research nurse will 
take the sample away to prepare and analyse.   
What do I have to do? 
This study will require you to give a sample of CSF and answer a few straightforward 
questions about your pain and about how you feel. 
If I decide not to take part will my treatment be affected? 
No.  If you decide not to take part this will not affect your medical care.  There are no 
penalties for deciding not to take part. 
What are the risks of taking part? 
There are risks associated with having a spinal anaesthetic.  These are explained 
below.  You can discuss these with the anaesthetist before the intervention takes 
place.  The anaesthetic staff are trained to prevent or minimise the risks associated 
with providing anaesthesia using a spinal technique.  
Risks: temporary fall in blood pressure, temporary headache, temporary change in 
heart rate or rhythm, urine retention, nausea or vomiting. 
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The total volume of cerebrospinal fluid in your head and bathing the spinal cord is 
approximately 130 millilitres.  You produce 500 millilitres of this fluid each day.  We 
will take a sample of 2 millilitres.   
You are covered by the normal arrangements in the Trust whereby you are entitled to 
complain about any aspect of your care.  There is no specific indemnity identified for 
the collection of the CSF. 
What are the benefits of taking part? 
You will receive no payment for taking part in this study.  We hope the study will 
help in our understanding of pain and this may lead to developments of better pain 
control techniques in the future. 
What will happen to the sample of cerebrospinal fluid (CSF)? 
The sample of fluid will be analysed to determine the levels of neurotransmitters.  
The fluid (CSF) will not be used for any other purpose and will be destroyed at the 
end of the analysis.   
Will my taking part in this study be kept confidential? 
Records obtained while you take part in this study will be kept confidential.  These 
records will need to be seen by the research team at Heartlands and Solihull Hospital 
as well as the research team at the University of Birmingham and their collaborators.  
By signing the consent form you agree to the information that is collected related to 
the study being used by this group of people. 
What will happen to the results of the study? 
The research will be reported in medical, nursing and scientific journals.  It will also 
be discussed at conferences. You will not be identified in any discussions or 
publications related to the research. 
Data protection act: What use will be made of data collected from this study? 
Personal data: e.g. date of birth.  This data will be collected and processed.  This data 
may be shared within the research team but not in a form that would lead to your 
identification. 
The research team will take steps to ensure that your personal data is protected. 
By agreeing to take part in this study you agree to the transfer of your personal data to 
the research team. 
Contact for further information. 
Research Nurse: Amelia Williamson 
0121 424 4329 
If you have any problems with the conduct of this study you can telephone the 
secretary of the ethics committee who has considered this application, on 0121 424 
0594, who will arrange for your worries to be investigated. 
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Appendix 4 Consent form 
 
Title of study: Neurotransmitters in spinal cord study. 
Patient name   ____________________________________________ 
Address   ____________________________________________ 
Date of Birth   ____________________________________________ 
Hospital number  ___________________________________________ 
 
Please read each statement carefully.  If you agree with the statement please initial the 
appropriate line. 
 
I have read the patient information sheet about this study  ______________ 
I have had an opportunity to discuss the study   ______________ 
I agree to take part in the study     ______________ 
I understand that I am free to withdraw at any time without penalty ______________ 
I agree to a 2 ml sample of CSF being taken     ______________ 
I agree to the sample of CSF being analysed 
to determine the levels of neurotransmitters    ______________ 
I agree to my GP being told about my participation   ______________ 
 
 
 
Name of patient   Signature of patient   Date 
__________________  ____________________ _________ 
Name of research nurse  Signature of research nurse Date 
__________________  _____________________  _____ 
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Appendix 5 Data collection tool 
Patient Label Patient code 
Site 
Date 
Exclusion criteria 
Pain other than OA pain. 
Neurodegenerative disorder  
Anorexia  
Psychiatric disorder  
Head trauma or CVA 
Inflammatory disorder  
Active cancer within past 6 months 
Pregnancy 
Current neuro investigations  
Immunosuppressants. 
Steroids  
Inclusion criteria 
Age > 18 years 
Able to consent 
English language speaker 
Procedure (tick) 
 
Joint replacement or revision 
TURP/TURB 
Other surgical procedure (given name 
below) 
Lumbar puncture (diagnostic) 
Lumbar puncture (therapeutic) 
Other 
 
_______________________________ 
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Pain Group 
Neuropathic 
Osteoarthritis 
Trauma 
Mixed OA and neuropathic 
Mixed trauma and OA 
Control (no pain) 
Other (please state) 
Ethnic group 
A White 
A1 British  
A2 Irish  
A3 Any other white 
B Mixed 
B1 Mixed white/black Caribbean  
B2 Mixed white/black African  
B3 Mixed white/Asian 
B4 Any other mixed 
C Asian/Asian British 
C1 Indian  
C2 Pakistani  
C3 Bangladeshi  
C4 Any other Asian 
D Black/black British 
D1 Caribbean D2 African D3 Other 
E Chinese/other ethnic group 
E1 Chinese 
E2 Any other ethnic group 
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Medication 
Daily 
dose 
Start 
date 
Stop 
date 
Changes to dose in last 6 months 
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
Past Medical History 
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Pain Rating Scales 
Pain at REST 
 
 
0 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Pain on MOVEMENT 
 
 
0 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Average daily pain in last 3 months 
 
 
0 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Average daily pain in last 12 months 
 
 
0 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Primary pain Duration (trauma pain first) 
 
 
days 
 
 
months 
 
years 
 
Chronic pain duration 
 
 
days 
 
 
months 
 
years 
 
Site of pain 
 
 
1 
 
 
2 
 
 
3 
 
AWS Amino acids and cytokines in OA pain 296 
Hospital Anxiety and Depression Score 
Clinicians know that emotions play an important part in most illnesses.  This questionnaire is designed to help us 
measure feelings.  Read each item and tick to box next to the response that comes closest to how you have been 
feeling in the last week.  Don’t take too long over your replies, your immediate reaction to each item will probably 
be more accurate that a long thought-out response. 
 
I feel tense or ‘wound-up’   I feel as if I am slowed down   
Most of the time 3  Nearly all the time 3  
A  lot of the time 2  Very often 2  
From time to time, occasionally 1  Sometimes 1  
Not at all 0  Not at all 0  
      
I still enjoy the things I used to enjoy   I get a sort of frightened feeling like ‘butterflies’ 
in the stomach 
  
Definitely as much 0  Not at all 0  
Not quite so much 1  Only occasionally 1  
Only a little 2  Quite often 2  
Hardly at all 3  Very often 3  
      
I get a sort of frightened feeling as if 
something awful is about to happen 
  I have lost interest in my appearance   
Very definitely and quite badly 3  Definitely 3  
Yes, but not too badly 2  I don’t take as much care as I should 2  
A little but it doesn’t worry me 1  I may not take quite so much care 1  
Not at all 0  I take just as much care as ever 0  
      
I can laugh and see the funny side of things   I feel restless as if I have to be on the move   
As much as I always could 0  Very much indeed 3  
Not quite so much now 1  Quite a lot 2  
Definitely not so much now 2  Not very much 1  
Not at all 3  Not at all 0  
      
Worrying thoughts go through my mind   I look forward with enjoyment to things   
A great deal of the time 3  As much as I ever did 0  
A lot of the time 2  Rather less than I used to 1  
From time to time but not too often 1  Definitely less than  I used to  2  
Only occasionally 0  Hardly at all 3  
      
I feel cheerful   I get sudden feelings of panic   
Not at all 3  Very often indeed 3  
Not often 2  Quite often 2  
Sometimes 1  Not very often 1  
Most of the time 0  Not at all 0  
      
I can sit at ease and feel relaxed   I can enjoy a good book or radio or TV 
programme 
  
Definitely 0  Often 0  
Usually 1  Sometimes 1  
Not often 2  Not often 2  
Not at all 3  Seldom 3  
      
Score A (1+3+5+7+9+11+13)     
Score D (2+4+6+8+10+12+14)     
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Michigan Neuropathy Screening Instrument Instructions 
 
Instructions for all physical assessments: For all assessments, the foot should be warm 
(>30
o
C) 
 
Foot inspection 
The feet are inspected for evidence of excessively dry skin, callous formation, fissures, frank 
ulceration or deformities.  Deformities include flat feet, hammer toes, overlapping toes, halux 
valgus, joint subluxation, prominent metatarsal heads, medial convexity (Charcot foot) and 
amputation. 
Vibration sense 
 
Vibration sense should be performed with the great toe supported.  Vibration sense will be 
tested bilaterally using a 128Hz tuning fork placed over the dorsum of the great toe on the 
bony prominence of the DIP joint.  Patients, whose eyes are closed, will be asked to indicate 
when they can no longer sense the vibration from the vibrating tuning fork. 
 
In general, the examiner should be able to feel vibration from the hand-held tuning fork for 5 
seconds longer on his distal forefinger than the normal subject can at the great toe (e.g. the 
examiners DIP joint of the first finger versus the patient's toe).  If the examiner feels vibration 
for 10 or more seconds on his or her finger, then vibration is considered decreased.  A trial 
should be given when the tuning fork is not vibrating to be certain that the patient is 
responding to vibration and not pressure or some other clue.  Vibration is scored as: 
Present if the examiner senses the vibration on his or her finger for <10 seconds 
Reduced if sensed for >10 seconds 
Absent (no vibration detected) 
 
Muscle stretch reflexes 
 
The ankle reflexes will be examined using an appropriate reflex hammer (e.g. Trommer or 
Queen Square).  The ankle reflexes should be elicited in the sitting position with the foot 
dependent and the patient relaxed.  For the reflex, the foot should be passively positioned and 
the foot dorsiflexed slightly to obtain optimal stretch of the muscle.  The Achilles tendon 
should be percussed directly.  If the reflex is obtained it is graded as present.  If the reflex is 
absent, the patient is asked to perform the Jendrassic manoeuvre (i.e. hooked fingers together 
pulling).  Reflexes elicited with the Jendrassic manoeuvre alone are designated 'present with 
reinforcement'.  If the reflex is absent, even in the face of the Jendrassic manoeuvre, the 
reflex is considered absent. 
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Michigan Neuropathy Screening Instrument 
 
Appearance of feet LEFT 
 
RIGHT 
Normal 
 
YES 0 NO 1 YES 0 NO 1 
If not check all that apply 
 
 Deformities 
 
  
 Dry skin, callus 
 
  
 Infection 
 
  
 Fissure 
 
  
 Other (specify) 
 
  
 
Ulceration 
 
Absent 0 
 
 
Present 1 Absent 0 Present 1 
 
Ankle reflexes 
 
RIGHT 
 
LEFT 
Present 0 Present/ 
reinforcement  
0.5 
 
Absent 1 Present 0 Present/ 
reinforcement 
0.5 
Absent 1 
 
Vibration perception at great toe (128Hz) 
 
Present 0 
 
 
Decreased 0.5 Absent 1 Present 0 Decreased 0.5 Absent 1 
 
 
 
 
Score _________________________/8 
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Appendix 6 Studies used in literature review for inclusion/exclusion criteria 
Author Year Focus Control groups Molecules of interest 
Abbot 1982 Parkinson’s 
Diagnostic lumbar 
puncture normal GABA 
Alexander  2005 CRPS 
Pain from 
spondylolisthesis, 
radiculopathy, 
peripheral 
neuropathy, also 
some with no pain IL1B, IL6, TNFa 
Alexander  2007 CRPS 
Radiculopathy (13), 
ALS (9), peripheral 
neuropathy (3), 
spondylolisthesis (4), 
normal pressure 
hydrocephalus with 
shunt (2) 
IL4, IL10, IL6, IL8, 
MCP1, GFAP, nitrate, 
nitrite, glutamate 
Altemus 2004 Pregnancy Control (normal) 
MHPG, HVA, 5HIAA, 
GABA, Glu 
Araki 1986 Parkinson’s 
  Araki 1988 Epilepsy Headache 
 
Asahara 1996 
Lumbar 
spondylosis 
 
nitrate,. Nitrite 
Backonja 2008 
Post-traumatic 
neuralgia with 
features of CRPS 
(8) or painful 
diabetic 
neuropathy (6) Healthy volunteers 
IL1B, IL6, TNFa, 
sTNFr, IL1ra, IL8, 
IL10, SP 
Basun 1990 Alzheimer’s Healthy volunteers 
 
Belleroche 1984 
Motor neurone 
disease 
Diagnostic 
myelography 
 
Ben 
Menarchem 1989 Healthy volunteers 
 
GABA, 
homocarnosine, HVA, 
5-HIAA,  
Berretini 1986 Manic depression 
  
Berretini 1982 
Bipolar affective 
disorder Healthy controls 
 
Berretini 1983 
Unipolar and 
biploar disorder 
  Bertislsson 1982 Depressed Healthy controls 
 
Blennow 1993 
Neuropsychiatric 
patients Healthy controls 
 
Blin 1994 ALS 
Neurological 
disorders but not 
degenerative 
 
Blin 1994 ALS 
Neurological 
disorders (not 
neurodegenerative) 
asp, asgn, glu, ser, 
gln, tau, ala, tryp, val, 
phe, iso, leu 
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Bo 2009 
Migraine, 
cervicogenic and 
tension headache 
Neurological 
diagnosis normal 
and no pain 
IL1b, IL1ra, IL4, IL10, 
TNFa, MCP1, TGFb1 
Bowers 1980 Psychosis Neurological controls 
 
Bridges 1976 
Depression and 
anxiety 
  
Brisby 2002 
Disc herniation 
and sciatica 
 
IL1b, IL6, IL8, IFNg, 
TNFa,  
Buvanendran 2006 
OA for elective 
joint replacement, 
either cox inhibitor 
on day of surgery 
(10), or cox 
inhibitor on 4 days 
leading up to 
surgery (10) Placebo 
PGE2, IL1b, IL6, IL8, 
TNFa 
Carrieri 1998 Multiple Sclerosis 
Non inflammatory 
neurological 
diseases 
 
Castillo 1995 
Acute CVA 
headache 
Acute CVA no 
headache Glu 
Castillo 1995 CVA 
  
Crawford 1987 
Newly diagnosed 
Untreated 
Epilepsy, chronic 
drug resistant 
epilepsy control 
 Csernansky 1996 Alzheimers Control 
 
de Jong 1984 
Untreated 
Parkinsons Treated Parkinsons 
 Degrell 1989 Dementia Young neurotics 
 Devinsky 1993 Epilepsy 
  
Enna 1977 
Huntingtons or 
Parkinsons Control 
 Espey 2002 HIV dementia 
  
Frye 2006 
Refractory 
affective disorder 
Recruited from the 
community controls 
 
Gallai 2003 
Chronic daily 
headache 
diagnostic lumbar 
puncture - no CNS 
disease, no 
neurodegenerative 
disease 
Glutamate, nitrate, 
cGMP, SP, CGRP, 
NKA 
Garseth 2001 
Polyradiculopathy 
(Guillain Barre) or 
active MS Normal controls 
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Garseth  2002 
Low back pain or 
sciatica 
Neurological 
diagnosis with NAD 
(18), elective 
orthopaedic surgery 
(13) - no pain 
Glucose, lactate, 
pyruvate, citrate, 
glutamine, alanine, 
creatine, creatinine, 
inositol, formate, 
acetate 
gattaz 1986 
Schizophrenia 
before Haloperidol 
Schizo after 
haloperidol 
 Geracioti 1997 Depression 
  
Gerner 1981 
Depression, 
anorexia, mania Normal 
 
Gerner 1984 
Depression, 
mania, 
schiziphrenia Normal 
 
Gjerris 1987 
Depression, 
dementia controls 
 
Gjessing 1972 
Neurological 
investigation and 
disorders 
 
tau, asp, thre, ser, 
aspn, glu, gln, gly, ala, 
cit, val, leu, emth, iso, 
tyr, phe, tryp, orn, lys, 
his, homo, arg, etc. 
Gold 1980 
Depression, 
psychosis Neurologic controls 
 Hagenfeldt 1988 Healthy twins 
  
Hagenfeldt 1984 
Healthy twins 
comparison with 
plasma 
  Hashimoto 2005 Schizophrenia Normal control  D and L Serine 
Heyes 1991 HIV 
  
Honig 1988 Depression 
 
Tau, aspn, thre, ser, 
glu, gln, gly. Ala, val, 
meth, iso, leu, tyr, phe, 
his, lys, arg, GABA 
Hsu 2001 
Labour pain 
Csection No pain Csection 
 Kalviainen 1993 Epilepsy Treated epilepsy 
 
Kasa 1982 
Depressive 
disorders controls 
 
Kikuchi 1999 
Post-herpetic 
neuralgia 
 
IL1B, IL8, IL6, TNFa 
Kimura 1999 
Degenerative 
lumbar disease, 
fracture, 
appendicitis 
Healthy volunteers 
(6), inguinal 
herniation (10), 
removal of pins/plate 
(5), prolapsed uterus 
(1), hallux valgus (1) 
, soft tissue tumour 
to leg (1) but all were 
pain-free 
neurologically 
healthy. nitrate, nitrite 
Klivenyi 1997 MS Low back pain 
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Kotani 2008 
Post-herpetic 
neuralgia 
 
IL-8 
Kuroda 1982 
Psychiatric and 
neurological 
diseases 
  
Lakke 1986 
Head injury (41), 
various 
neurodegenerative 
disorders (22), 
Parkinsons (31) 
disc herniation (38), 
caudography (8), 
spondylolisthesis (1), 
RhA (2) 
Alanine, glycine, Abu, 
valine, leucine, Ile, 
Phenylalanine, 
Tyrosine, Serine, 
Histidine, Threonine, 
Methionine, Arginine, 
Ornithine, Lysine, 
Citrulline, Taurine, 
Cystine 
Larson 2000 
Fibromyalgia 
(primary (16), 
secondary = with 
another disorder 
such as RhA (9)) 
or musculoskeletal 
pain (10) Healthy volunteers 
arginine, asparagine, 
aspartate, citrulline, 
glutamine, glutamate, 
glycine, taurine 
Levine 1999 Acute depression 
  
Levine 2000 Acute depression 
Neurological 
diagnosis NAD given as mole percent 
Ludwig 2008 
Painful 
polyneuropathy 
Painless 
polyneuropathy TNFa, IL6 
Ludwig 2008 
Painful 
polyneuropathy 
Painless 
polyneuropathy 
 
Maier 2005 Healthy volunteers 
 
IL6, IL8, IL10, sICAM, 
sTNFr, sE-selectin 
Manyam 1988 
Parkinson’s 
untreated or 
untreated Controls 
 
Martinez 1993 Migraine Stress Glutamate, aspartate. 
Martinez 1993 Alzheimer’s 
  
McGale 1977 
Headache or back 
pain 
 
Serine, taurine, 
Threonine, 
asparagine, glutamine, 
valine, glutamate, 
glycine, leucine, 
tyrosine, 
phenylalanine, lysine, 
histidine, arginine 
Meier 1988 ALS 
  
Mertens 2000 Neuropathic pain Spasticity 
asparate, glutamate, 
GABA, glycine, 
alanine, threonine,  
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Molina 1997 Parkinson’s controls 
 
Molina 2005 Dementia 
Healthy normal 
controls 
 
Munts 2008 
CRPS with 
dystonia - women 
only 
Controls (13 women, 
16 men), spinal 
anaesthesia for 
TURP, total knee 
replacement, 
femeropopliteal 
bypass, vulvectomy 
and general surgery 
e.g. lipoma excision 
IL1b, IL6, IP10, 
RANTES, C3, Clq, 
MBL, sICAM1, ET1, 
NO, Lactoferrin 
Nisijima 1995 
Neuroleptic 
malignant 
syndrome 
normal age matched 
controls 
 
Olofsson 1997 
Labour pain (16); 
Elective C Section 
(20); Post-
menopausal 
Healthy volunteers 
or post-menopausal 
gynae surgery (not 
combined for 
analysis) 
nitrate, nitrite, 
aspartate, glutamate,  
Peres 2004 
Migraine with 
fibromyalgia (12) 
or without (8) 
diagnostic lumbar 
puncture - no CNS 
disease, no 
neurodegenerative 
disease Glutamate 
Perry 1982 Huntington’s 
Neurological 
diagnosis NAD but 
some disc problems 
 
Perry  1990 ALS 
Neurological and 
psychiatric disorders 
taurine, aspartate, 
threonine, serine, 
glutamate, citrulline, 
isoleucine, leucine, 
tyrosine, arginine, 
glycine etc. 
Pomara 1989 
Spouses (F) of 
Alzheimer’s 
patients 
Spouses of normal 
men 
 Roy 1988 Depression controls 
 
Roy 1990 
Abstinent 
Alcoholics controls 
 Roy 1991 Depression controls 
 
Rozen 2007 
Daily persistent 
headache  Chronic migraine TNFa 
Sarchielli 2007 
Chronic migraine.  
Fibromyalgia 
Age and sex 
matched 
NGF, BDNF, 
glutamate 
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Shaw 1995 
Motor neurone 
disease 
disc herniation (11), 
cervical spondylosis 
(10) stenosis (2) 
radiculopathy (1) 
back pain (3) spastic 
paraparesis (1) 
tumours (1) 
syringomyelia (1) 
unstable bladder (1) 
ischaemic cord 
disorder (3) 
asparate, threonine, 
serine, asparagine, 
glutamate, glutamine, 
glycine, citrulline, 
alanine, valine, 
methionine, AABA, 
isoleucine, leucine, 
tyrosine, 
phenylalanine, 
histidine, ornithine, 
lysine, arginine, 
cystine, tryptophan 
Stahel 1998 Head trauma 
  Stoeck 2006 CJD 
  Stover 1999 Brain injury Back pain 
 Van Sande 1970 
   
Van Sande 1970 
Neurological 
disorders  Normal 
tau, asp, thre, ser, glu, 
leu, tyr, phe, orn,, lys, 
his, homo, arg, cit, gly. 
Ala, val, cys, met, ile 
Viera 2006 
Migraine with 
depression 
Migraine without 
depression GABA 
Welch 1975 Migraine Tension headache GABA, Leu, val, gly 
Yao 2003 Schizophrenia 
  
Yeager 1999 
Post joint 
replacement 
surgery Healthy volunteers IL6, IL10 
Zimmer 1980 
Psychiatric 
patients before 
treatment 
After medication 
treatment 
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Appendix 7 Healthy normal control CSF amino acid concentrations from human studies 
 
Substrate Study 
Number of 
control 
participants 
Mean or median 
pg mL-1   ± SD 
Glutamate Frye  et al  2006 16 0.59 ± 0.16  
 Gallai  et al 2003 20 0.31 ± 0.17  
 Garseth et al 2000 25 0.55 ± 0.11  
 Larson  et al 2000 18 0.85 ± 0.25  
 Mertens  et al 2000 5 0.18 ±0.13  
 Van Sande  et al 1976 13 2.16 ± 1.96  
Aspartate Frye  et al  2006 16 0.21 ± 0.19  
 Larson  et al 2000 18 3.71 ± 0.55  
 Mertens  et al 2000 5 0.05 ± 0.04  
 Van Sande  et al 1976 13 0.38 ± 0.36  
Glutamine Garseth  et al 2001 25 68.3 ± 8  
 Larson  et al 2000 18 72.1 ± 23.8  
 Van Sande  et al  1976 13 66.2 ± 17.5  
Citrulline Larson et al 2000 18 0.26 ± 0.19  
 Van Sande  et al 1976  13 0.06 ± 0.02  
Serine Garseth  et al  2001 25 2.49 ± 0.5  
GABA Abbott  et al 1982 15 0.027 ± 0.012  
 Altemus  et al 2004 22 0.005 ± 0.0005  
 Berretini  et al 1982 41 0.018 ± 0.005  
 Mertens  et al 2000 5 0.021 ± 0.01  
Glycine Frye et al 2006 16 2.0 ± 1.07  
 Garseth  et al 2001 25 0.77 ± 0.17  
 Larson  et al 2000 18 0.77 ± 0.38  
 Mertens  et al 2000 5 0.19 ± 0.04  
 Van Sande  et al 1976 13 0.64 ± 0.14  
Isoleucine Garseth  et al 2001 25 0.62 ± 0.21  
 Van Sande  et al 1976 13 0.66 ± 0.12  
Leucine Garseth  et al 2001 25 1.52 ± 0.45  
 Van Sande  et al 1976 13 1.52 ± 0.31  
Valine Garseth et al 2001 25 1.67 ± 0.06  
 Van Sande et al 1976 13 1.67 ± 0.47  
Tyrosine Garseth  et al 2001 25 1.9 ± 0.71  
 Van Sande  et al 1976 13 1.43 ± 0.42  
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Appendix 8 Healthy normal control CSF cytokine concentrations from human studies 
 
Substrate Study 
Number of 
control 
participants 
Mean or 
median 
pg mL
-1
   ± SD 
Range 
IL-1β Alexander  et al 2005 16 0.02 ± 0.01  
 Backonja  et al 2008 8 0.85 ± 0.28  
 Levine  et al 1999 10 0.14 ± 0.7  
 Tarkowski  et al 1999 59 0.2 ± 0.5  
IL-6 Alexander  et al 2005 16 1.32 ± 0.53  
 Backonja  et al 2008 8 0.67 ±1.1   
 Levine  et al 1999 10 2.36 ± 1.3  
 Maier et al 2005 113 6 1 to 34 
 Stoeck et al 2006 111 1.6 0.1 to 18 
 Tarkowski  et al 1999 59 2 ± 7  
IL-8 Backonja  et al 2008 8 10.44 ± 8.17  
 Kotani  et al 2004 50 18 17 to 24 
 Maier  et al 2005 113 6 1 to 23 
 Stoeck  et al 2006 111 12.6 4.2 to 19.9 
IL-10 Backonja  et al 2008 8 4.97 ± 1.1  
 Maier  et al  2005 113 0.9 0 to 39 
IL-12 Backonja  et al  2008 8 1.68 ± 0.39  
 Stahel  et al 1998 15 0.57 ±0.37  
TNFα Alexander  et al 2005 16 0.11 ± 0.04  
 Backonja  et al 2008 8 < 0.1 ± 0.28  
 Levine  et al 1999 10 0.47 ±0.62  
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Appendix 9 Box plots showing outliers in control and OA groups for amino acids 
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Outliers 
 Control OA 
Arginine 75,  55 
Aspartate 75, 25, 105 60,45 
Citrulline 74 48 
GABA  54,42 
Glutamate 107 12*, 48*, 56, 59, 60 
Glutamine 107 54, 63, 43, 40, 31, 21, 12, 11 
Isoleucine  17, 59 
Lycine  38, 12, 22, 32 
Phenylalanine 44  
Tryptophan  91 
Tyrosine 2 60, 80, 49 
Valine  20, 17, 12, 19 
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Appendix 10  Boxplots showing outliers of cytokines in control and OA groups. 
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AWS Amino acids and cytokines in OA pain 312 
Outliers for cytokine assay 
 Control OA 
IL2 52 23 
IL4  78*, 21* 
IL5  31 
IL6 2 3, 101 
IL8  3 
IL12 107, 52 101*, 86, 60, 82*, 6*, 3*, 
43*, 58* 
IL13 44  
IFNg 2 62 
TNFa  3 
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Appendix 11 Histograms and normal curves for amino acids and in the control and OA 
groups 
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Appendix 12 : Normality testing (Kolmorgorov-Smirnov) amino acid data OA and control 
groups 
 
Control 
 
OA 
  Statistic df Sig. Statistic df Sig. 
Glutamate   0.177 20 0.101 0.108 59 0.084 
Aspartate  0.121 21 0.200 0.076 56 0.200 
Arginine  0.182 21 0.067 0.108 58 0.092 
Citrulline  0.134 21 0.200 0.123 59 0.026
a 
Serine  0.220 21 0.009
a 
0.118 59 0.041
a 
Glutamine  0.174 20 0.113 0.149 58 0.003
a 
GABA  0.111 21 0.200 0.093 59 0.200 
Glycine   0.144 21 0.200 0.065 58 0.200 
Tryptophan  0.168 21 0.124 0.086 59 0.200 
Leucine  0.107 21 0.200 0.132 59 0.013
a 
Isoleucine  0.104 21 0.200 0.080 59 0.200 
Phenylalanine  0.139 21 0.200 0.087 58 0.200 
Tyrosine  0.196 20 0.200 0.081 58 0.200 
Valine  0.085 21 0.200 0.098 59 0.200 
IL- 2  0.247 16 0.010
a 
0.193 36 0.002
a 
IL-6  0.163 19 0.200 0.128 48 0.047
a 
IL-7  0.133 18 0.200 0.146 45 0.017
a 
IL-8  0.133 19 0.200 0.106 49 0.200 
IL-12  0.310 10 0.007
a 
0.362 21 <0.001
a 
IFNγ  0.304 11 0.005
a 
0.183 26 0.025
a 
TNFα 0.229 19 0.010
a 
0.123 49 0.063 
IL-4  0.252 11 0.050
a 
0.366 10 <0.001
a 
IL-5  0.118 18 0.200 0.157 48 0.005
a 
IL-10  0.151 19 0.200 0.130 49 0.039
a 
IL-13 0.228 9 0.196 0.191 14 0.177 
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Appendix 13 Histograms of cytokines in control and OA groups 
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Appendix 14  Normality testing (Kolmogorov-Smirnov) cytokines OA and control groups 
 0PAR PAR 
 Statistic n p Statistic n p 
Glutamate  0.138 24 0.200 0.132 35 0.128 
Aspartate  0.082 24 0.200 0.106 32 0.200 
Arginine  0.143 23 0.200 0.092 35 0.200 
Citrulline  0.127 24 0.200 0.150 35 0.046
a 
Serine 0.184 24 0.035
a 
0.079 35 0.200 
Glutamine  0.206 23 0.012
a 
0.128 35 0.160 
GABA  0.130 24 0.200 0.093 35 0.200 
Glycine   0.090 23 0.200 0.083 35 0.200 
Tryptophan  0.102 24 0.200 0.125 35 0.186 
Leucine  0.142 24 0.200 0.152 24 0.039
a 
Isoleucine  0.108 24 0.200 0.108 24 0.200 
Tyrosine   0.127 23 0.200 0.081 35 0.200 
Phenylalanine  0.108 23 0.200 0.107 35 0.200 
Valine  0.142 24 0.200 0.142 35 0.056 
IL- 2 0.172 14 0.200 0.258 22 0.001
a 
IL-6  0.169 20 0.137 0.152 28 0.096 
IL-7  0.183 18 0.113 0.155 27 0.093 
IL-8  0.129 20 0.200 0.124 29 0.200 
IL-12  0.353 12 <0.001
a 
0.353 9 0.021
a 
IFNγ 0.292 13 0.003
a 
0.232 13 0.054 
TNFα  0.102 20 0.200 0.151 29 0.089 
IL-4
b
  0.151 4  0.377 6 0.008
a 
IL-5  0.221 20 0.012
a 
0.145 28 0.140 
IL-10  0.233 20 0.006
a 
0.083 29 0.200 
IL-13  0.257 7 0.179 0.236 7 0.200 
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